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Abstract
Thyroid and adrenocortical function are altered during
critical illness. Some of the mechanisms responsible for the
changes in thyroid function have been elucidated, and the
majority of patients are considered to be euthyroid. Hence,
the Sick Euthyroid Syndrome. However, despite normal or
raised free thyroxine levels in many patients, some authors
have recommended thyroxine replacement. Two small clinical
trials of replacement therapy were inconclusive. Similarly,
although total Cortisol concentrations usually increase
during critical illness and there is no evidence of reduced
availability of free hormone, there are anecdotal reports of
relative adrenocortical insufficiency in some critically ill
patients, and a number of ICU clinicians regularly give low
dose steroid replacement.
The extent of changes in concentration of thyroid hormones
or Cortisol have not been determined in sufficiently large
numbers of critically ill patients not receiving confounding
medications. It is unclear how the changes relate to type
and severity of illness. In particular, neither the expected
range of baseline hormone concentrations nor the expected
responses to dynamic tests of adrenocortical or thyroid
function have been defined at different levels of illness
severity. Moreover, the nature of the relationship between
the changes in thyroid and adrenocortical function and
mortality is unclear.
Aims
The main aims of the thesis were as follows: (1) To deter¬
mine the ranges of total thyroxine, triiodothyrone, TSH and
Cortisol concentrations at different levels of illness sever-
ity, and to relate these to mortality; (2) To determine the
range of responses to standard dynamic tests of adrenocorti¬
cal and thyroid function, and relate them to severity of
illness and mortality; (3) To determine the relationship
between the extent of the changes in total thyroid hormone
concentrations during illness and metabolic rate; (4) To
accurately determine the prognostic value of measurement of
thyroxine, triiodothyrone, TSH and Cortisol on admission to
an ICU.
The guestion of whether or not thyroxine or Cortisol are
deficient during critical illness was not addressed. The
main aim was to determine whether or not patients with low
total hormone concentrations or impaired responses to dyna¬
mic tests had an increased mortality when severity of ill¬
ness was taken into account.
Summary of Main Findings
Adrenocortical Function: The majority of critically ill pa¬
tients had plasma Cortisol concentrations above the upper
limit of normal in health. In keeping with Seyle's General
Adaption Theory, plasma Cortisol concentration correlated
with severity of illness. The normal ranges of plasma Corti¬
sol concentration, defined as population mean +/- 2 standard
deviations, differed according to the severity of illness. A
plasma Cortisol concentration above 200 nmol/L would be
within the 95% range for a moderately ill patient (APACHE II
score <16) whereas a concentration of under 400 nmol/L would
be below the expected range in a severely ill patient
(APACHE II score >24).
There was evidence of impairment of adrenocortical function
in patients suffering from septic shock. Basal Cortisol
concentrations and Cortisol responses to standard and low
dose ACTH stimulation tests were lower than in critically
ill controls and the Cortisol response to depot ACTH was not
maintained.
The overall relationship between mortality and plasma Corti¬
sol concentration was linear. However, after taking severity
of illness into account, a J-shaped relationship was found.
In other words, mortality increased as Cortisol concentra¬
tion increased above normal, but low normal concentrations
were also associated with a high mortality. The Cortisol
response to a standard ACTH stimulation test varied between
-100 and 1000 nmol/L. In general, the Cortisol response was
maintained despite very high basal Cortisol concentrations.
There was an inverse correlation between the Cortisol re¬
sponse and severity of illness. Mortality among patients
with Cortisol responses of less than 250 nmol/L was 76%
[95% CI, 55-91] compared with 31% (95% CI, 19-45) among the
remainder. A reduced Cortisol response to ACTH might be due
to adrenocortical impairment in the context of widespread
organ failure. The high mortality reflecting the associated
organ failure rather than any insufficiency of Cortisol. The
higher than expected mortality among patients with low
admission Cortisol concentrations reguires further study.
Thyroid Function: In patients without known preexisting
thyroid disease, not receiving treatment with dopamine or
steroids, the range of TSH concentrations found using a
sensitive assay was broader than that found using similar
assays in health. TSH concentrations were subnormal in 15%
of patients, a third of whom had concentrations of less than
0.1 mU/L. A further 13% of patients had raised TSH concen¬
trations, despite relatively normal total T4 levels. In the
majority of these, TSH concentrations returned to normal on
recovery. TSH concentration correlated inversely with sever¬
ity of illness and plasma Cortisol concentration.
Compared with controls, the TSH response to TRH was reduced
or absent in all patients. The response correlated inversely
with severity of illness and plasma Cortisol concentration.
There was a positive correlation between TSH and total
thyroxine. Patients with low concentrations of both hormones
had small or absent TSH responses to TRH, suggesting that
function of pituitary thyrotrophs was suppressed. The thyr¬
oid hormone response to TSH was normal or increased compared
with healthy controls, suggesting that, despite widespread
organ failure, function of the thyroid gland was not im¬
paired. These findings raise the possibility that reduced
TSH secretion might contribute to the reduced total thyroid
hormone concentrations found during critical illness.
Mortality increased as total thyroxine concentration fell.
However, the mortality among patients with low concentra¬
tions of total thyroxine was no higher than expected on the
basis of their severity of illness, suggesting that the
association was not causal. Indeed, metabolic rate was
highest in patients with the lowest total thyroxine concen¬
trations. These findings do not support the contention that
critically ill patients might benefit from thyroid hormone
replacement.
A prognostic index based on admission measurements of Corti¬
sol, thyroxine and thyrotropin concentrations was developed
using multiple logistic regression analysis. The model
obtained predicted outcome of illness with significantly
greater accuracy than APACHE II scores.
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Statistical Analysis
A consistent approach to statistical analysis has been
attempted. The technique used for a particular analysis will
not be stated, unless it deviates from the protocol set out
below. For comparison of parametric data, the 95% confidence
intervals of the difference between the means are given.
O
Student's t test is used for proportionate data, and X
tests are used for categorical data, unless the numbers are
small, in which case Fisher's exact test is used. The Wil-
coxon Rank Sum test is used for comparisons of non-para-
metric data. Correlation is assessed using Pearson's Product
Moment method, and multiple regression analysis is performed
using Cox's Proportional Hazards method.
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(1) Defining Critical Illness
Throughout the intensive care literature there are a large
number of undefined terms relating to type or severity of
illness. Terms such as sepsis, septicaemia, sepsis syndrome,
septic shock, organ failure and multi-organ system failure
are all frequently used without qualification. Even in
recent multicentre trials (Bone et al, 1987; VASSCSG, 1987;
Ziegler et al, 1991) different definitions of sepsis, shock,
and organ failure were used. This causes confusion, and
limits the generalisability of research findings. There are
historical reasons why firm definitions are lacking. Only in
the past thirty years have septic shock and multiple organ
failure been regularly encountered. Prior to this period it
was not possible to keep severely ill patients alive long
enough for them to develop such syndromes. Early work focus-
sed on patients with Gram-negative bacteraemia. However, we
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now know that the majority of patients with sepsis are not
bacteraemic. The terms sepsis and infection have been used
synonymously, the role of invading organisms being consid¬
ered crucial, but it is now clear that sepsis is related
more to the immunological response of the individual than to
the invading organism itself. Moreover, a clinical syndrome
identical to sepsis occurs as a complication of a number of
conditions in which there is no infection.
Sepsis is a very old medical term which derives from the
Greek "sepsin" meaning "to make putrid". It refers to a
constellation of signs including fever, tachycardia and
tachypnoea, usually accompanied by a characteristic haemody-
namic disturbance involving an elevated cardiac output and a
reduced systemic vascular resistance. This syndrome is
associated with release of a considerable array of medi¬
ators, including tumour necrosis factor [TNF], various
interleukins, platelet activating factor, nitric oxide and
many others. The response to administration of TNF to volun¬
teers is identical to the response following administration
of endotoxin, namely fever, malaise and myalgia, with tachy¬
cardia, increased cardiac output and reduced systemic vascu¬
lar resistance (Michie et al, 1988; Fong and Lowry, 1991).
The release of these same mediators has been demonstrated in
conditions such as pancreatitis (Vincent and Bihari, 1992),
heart failure (Levine et al, 1990) and salicylate poisoning
(Leatherman and Schmitz, 1991). Thus, sepsis is a clinical
manifestation of the host response to various insults, in¬
cluding infection, but also other acute diseases associated
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with inflammation. The presence of bacteria in the blood is
clearly not a requirement for the diagnosis of sepsis. The
term septicaemia should be reserved for the association of
demonstrable bacteraemia and the clinical syndrome of sep¬
sis .
The development of a variably distensible and permeable
vascular bed is one of the major achievements of mammalian
evolution. It allows blood flow to a tissue to be determined
by its oxygen requirement and to vary according to external
conditions. As a result the cardiovascular system can cope
with various demands, such as extremes of temperature and
vigorous exercise. In septic shock this system breaks down.
Septic shock is sepsis with evidence of inadequate tissue
perfusion. Arterial hypotension is an important clinical
sign, but is not always present because the disorder pri¬
marily involves the microcirculation. While shock describes
the clinical syndrome, acute circulatory failure is the
underlying pathophysiological process. The presence of
tissue hypoxia is reflected by an increase in blood lactate
levels. The degree of hypotension, the requirement for vaso¬
pressors, and the severity of the lactic acidosis are dir¬
ectly related to outcome (Bakker et al, 1991; Vincent et
al, 1992).
As defined above, septic shock is characterised by circula¬
tory failure. This usually involves systemic vasodilatation,
pulmonary vasoconstriction, and increased vascular perme¬
ability. This haemodynamic state may be induced by admin¬
istration of endotoxin. Serum from septic patients has been
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shown to dilate catecholamine-precontracted aortic smooth
muscle (Hollenberg et al, 1992), and the haemodynamic re¬
sponse to infused Eschericia coli in baboons is abolished
by pretreatment with anti-TNF antibody (Tracey et al, 1987).
This, and other evidence (Ayres, 1992), implicates cytokines
in the causation of the vasculopathy of septic shock. In¬
deed, progressively severe vascular paralysis may be the
defining characteristic of sepsis, while increasing concen¬
trations of lactate, interleukin-1 [IL-1], TNF, and other
cytokines may define the transition from sepsis to septic
shock and the development of multiple organ failure.
Septic shock is associated with dysfunction of major organs
such as the heart, lungs, liver and kidneys. The extent of
organ dysfunction can vary, and it is difficult to define
the point at which organ failure begins. There are two
distinct pathways by which organ dysfunction may develop. In
primary organ dysfunction, there is a direct insult to the
organ. Examples include aspiration of gastric contents into
the lungs, and the effect of rhabdomyolysis on the kidneys.
This direct insult causes an inflammatory response that is
localised to the affected organ. Secondary organ dysfunc¬
tion, such as adult respiratory distress syndrome [ARDS],
results from a systemic inflammatory response, and commonly
occurs in septic shock. Multiple organ dysfunction in cri¬
tically ill patients is usually secondary, and results from
a complex and generalised disorder of vasomotor tone and
permeability of the vascular bed.
The term "sepsis syndrome" (Bone et al, 1991), indicates the
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association of sepsis due to any cause, and altered organ
perfusion or function. Since sepsis itself is no more than a
clinical syndrome, and no longer presupposes infection,
sepsis syndrome would seem to be redundant. It has been
argued that the term "systemic inflammatory response syn¬
drome" be used instead of sepsis (Bone et al, 1992). Others
have argued that the introduction of further terms will only
lead to more confusion (Vincent and Bihari, 1992).
In conclusion, whilst many terms are still used to describe
the same syndromes, a degree of consensus is developing.
Sepsis is a clinical syndrome, which occurs in response to
various insults, and reflects the systemic immune mediated
response. Septic shock is sepsis associated with evidence of
circulatory failure, indicated by increasing blood lactate
concentration with or without arterial hypotension. Multiple
organ failure indicates failure of more than one organ which
is not due to localised pathology of the organ, but is
mediated by a systemic vasculopathy. These are the terms
which will be used in this thesis. Quantitative definitions
will be given where necessary.
(2) Adrenocortical Function During Critical Illness?
The biochemistry and physiology of adrenocortical function
are discussed in Chapter 3. The background to the study of
adrenocortical function during critical illness is discussed
here. As long ago 1893, Zappert reported that the number of
circulating eosinophils and lymphocytes fell during severe
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infections. Hills (1948) showed that these changes were
dependent on a functioning adrenal cortex. Studies of the
steroid or eosinophil response to surgery demonstrated a
consistent postoperative increase in steroid levels or fall
in eosinophil levels which lasted about 48 hours in uncom¬
plicated cases, (Sandberg et al, 1954; Moore, 1957) and much
longer in patients developing serious complications (Ven¬
ning, 1945). With the advent of reliable Cortisol assays,
similar findings were reported during episodes of severe
illness, (Melby and Spink, 1958; Cornil et al, 1968) and the
possibility that the adrenocortical response may be inade¬
quate in some patients was raised (Swingle et al, 1942;
Sibbald et al, 1976).
It is important to distinguish between impairment of adreno¬
cortical function and insufficiency of adrenocortical hor¬
mones. The former may be common during critical illness
whereas the latter is considered to be rare. For example,
widespread haemorrhage within the adrenal cortex can occur
as a complication of septicaemia due to Neisseria meningiti¬
dis (Melby, 1961; Migeon et al, 1967) and other organisms
(Melby and Spink, 1958). Although the adrenal cortex is
damaged and its function is likely to be impaired to a
degree, absolute adrenocortical insufficiency is unusual
(Xarli et al, 1978).
Impairment
The prevalence of impaired adrenocortical function during
critical illness is unknown. Adrenal ischaemia and necrosis
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are common in pathological studies of experimental shock in
animals (Lopes de Faria et al, 1979; Kajihara et al, 1983),
and post mortem studies following circulatory shock (Mack et
al, 1969) and severe burns (Arai et al, 1976) in man. How¬
ever, the extent to which this is associated with impairment
of adrenocortical function is unclear.
Hypotention and shock associated with severe illness might
impair adrenocortical function. Renal blood flow is main¬
tained with greater efficiency than adrenal blood flow in
animal models of both haemorrhagic and endotoxic shock
(Akiyama et al, 1987). Cortisol secretion is profoundly
influenced by adrenal perfusion (Urquhart, 1965; L'Age et
al, 1970). Studies of haemorrhagic shock in dogs show that
adrenocortical sensitivity to ACTH is not impaired, but that
as blood pressure falls, adrenal blood flow is reduced and
Cortisol secretion diminishes (Mack and Egdahl, 1970).
Reperfusion of the adrenal artery markedly increases Corti¬
sol secretion. Moreover, whilst all dogs increase Cortisol
secretion initially in response to haemorrhagic shock,
increased secretion persists only in those dogs in which
adrenal blood flow is maintained (Hume and Nelson, 1954). In
man, positive pressure ventilation, which is frequently
required during critical illness, has been shown to reduce
adrenal blood flow by 25% (Manny et al, 1979). A number of
drugs commonly used in critical illness, including dopamine
(Morra et al, 1990), benzodiazepines (Nilsson, 1990) and
ketoconazole (Couch et al, 1987; Best et al, 1987) reduce
Cortisol secretion.
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Septic shock due to Gram-negative infection appears to be
most frequently associated with impairment of adrenocortical
function. Plasma Cortisol levels are lower in Gram-negative
infection than in Gram-positive infection [Schein et al,
1990]. Severe toxaemia due to typhoid infection is associa¬
ted with lower Cortisol levels than non-septic critically
ill controls (Khosla et al, 1989), and steroid replacement
may sometimes be indicated (Hoffman et al, 1984). Pathologi¬
cal studies have demonstrated severe destructive changes in
the adrenal cortex following endotoxic shock [Bardiakhchian
and Kirichenko, 1986). Injection of E. Coli lipopolysacchar-
ide (Catalano et al, 1984; Garcia et al, 1990) or Gram-
negative septic shock plasma (Keri at al, 1981) impairs
ACTH-induced steroidogenesis in rats.
There are isolated reports of patients suffering from septic
shock who do not respond to ACTH during their illness but
regain normal function on recovery (Jacobs and Nabarro,
1969; Jurney et al, 1987; Varma et al, 1990). Validation of
ACTH stimulation tests has been carried out in healthy
individuals (Wood et al, 1965; Crowley et al, 1991) or in
out-patient populations (Lindholm and Kellet, 1987; Stewart
et al, 1988). In health, the Cortisol increment following
ACTH stimulation is independent of the basal Cortisol con¬
centration (Kukreja and Williams et al, 1981; May and Carey,
1985; Dickstein et al, 1991), but interpretation of tests
performed in critically ill patients with high baseline
Cortisol concentrations is difficult. However, there are
reports of impaired responses to ACTH in critically ill
8
patients with low Cortisol concentrations. Two patients
investigated by Jurney et al (1981) had stimulated Cortisol
concentrations below 400 nmol/L. Both were suffering from
sepsis, were given Cortisol replacement therapy, and had a
normal response to a repeat ACTH stimulation test on recov¬
ery. Sibbald et al (1977) identified five patients suffering
from septic shock with baseline Cortisol concentrations of
less than 400 nmol/L, and Cortisol increments of less than
100 nmol/L. Interestingly, the only patient to survive was
treated with Cortisol.
In summary, there is good evidence that adrenal haemorrhage,
necrosis and hypoperfusion occur in animal models of endo-
toxic and haemorrhagic shock and to some extent during
critical illness illness in man. However, there is only
anecdotal evidence that this results in impairment of adren-
renocortical function in man.
Insufficiency
Defining adrenal insufficiency during critical illness is
problematic. Increased Cortisol concentrations are required
during illness. Patients with Addison's disease require
increased Cortisol replacement, and animals succumb rapidly
to experimentally induced sepsis following adrenalectomy,
but survive if given steroid replacement (Hinshaw et al,
1985; Bertini et al, 1988). The adrenocortical response to
illness is necessary for survival. Since Cortisol concentra¬
tions increase in response to illness, and the capacity to
increase Cortisol concentration is necessary for survival,
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it follows that the level of adrenocortical function below
which is insufficient must also increase. The criteria used
to define adrenocortical insufficiency in otherwise healthy
patients cannot be applied in critical illness. This was
demonstrated very clearly by observartions made by Finlay
and McKee (1982). In an ICU population, they found a high
prevalence of Cortisol concentrations within the normal
range for health. This observation coincided with a sudden
increase in mortality on their ICU which appeared to be
confined to those patients with low Cortisol concentrations
and a relatively small Cortisol response to ACTH stimulation
tests. It transpired that these patients had been given
etomidate (Watt and Ledingham, 1984), a new anaesthetic
agent which was subseguently shown to impair adrenocortical
function (Fellows et al, 1983). On the basis of their base¬
line Cortisol concentrations and response to ACTH, the
majority of these patients did not have absolute adrenocor¬
tical insufficiency as defined for otherwise healthy indi¬
viduals, but their adrenocortical function was sufficiently
impaired to increase mortality. In other words, their adre¬
nocortical function was insufficient relative to the sever¬
ity of their illness. Indeed, Cortisol replacement in phy¬
siological dosage reduced mortality (McKee and Finlay,
1983) .
Swingle et al (1942) first suggested that refractory shock
might be partly due to adrenal failure. More recently,
similarities between decompensated Addison's disease and
sepsis, namely fever, hypotension, high-output cardiac
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failure, and low systemic vascular resistance, have been
pointed out (Melby et al, 1988, Dorin and Kearns, 1988). It
was suggested some years ago that administration of hydro¬
cortisone in moderate dosage reduced mortality (Swingle et
al, 1944; Knapp and Howard, 1957), although evidence of
adrenocortical failure prior to death could not be demon¬
strated by others. Jennings (1951 and 1952) followed the
circulating eosinophil counts of 50 severely ill patients,
all of whom died. In 47, the eosinophil count fell to zero
or near zero prior to death, suggesting a strong adrenocor¬
tical reaction. Sandberg et al (1956) studied 17-hydroxycor-
ticosteroids in dying patients, and found elevated levels in
the great majority. Done et al (1958) investigated 64 se¬
verely ill adults a few minutes after death. Plasma corti-
costeriods were raised in the majority of cases, although
lower levels were found in 11 cases who had suffered pro¬
longed hypotension or apnoea.
Interest subsequently turned to studies of high dose steroid
therapy. However, high dose steroids did not reduce mortal¬
ity in animal models of septic shock (Hinshaw et al, 1981
and 1982; Ottosson et al, 1987 and 1989) or in clinical
trials in human septic shock (Schumer et al, 1976; Sprung et
al, 1984; VASSCSG, 1987; Luce et al, 1988). Indeed, high
dose steroids may increase mortality, possibly due to sec¬
ondary infection (Bone et al, 1987). High dose steroids were
not used treat potential adrenocortical insufficiency, but
to prevent potentially damaging inflammatory cascades. The
doses of steroid used, usually lg methylprednisolone daily,
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were hugely supraphysiological and were likely to have
impaired adrenocortical responsiveness to ACTH for several
days after administration (Weiskopf et al, 1985; Streck and
Lockwood, 1979).
The realisation that the development of septic shock is
mediated by cytokines, the production of which is suppressed
by steroids, has increased interest in the adrenocortical
response. Uncontrolled production of cytokines is associated
with fatal outcome in critical illness (Waage et al, 1987;
Girardin et al, 1988; Marks et al, 1990; Calandra et al,
1991), there is anecdotal evidence that low dose steroid
replacement may be beneficial in septic shock. Park and
Raggatt (1989) reported haemodynamic and clinical improve¬
ment, following hydrocortisone replacement (20mg tid), in 2
patients suffering from septic shock who had plasma Cortisol
levels of around 400 nmol/L with only small increments
following standard ACTH stimulation tests. There are numer¬
ous similar reports of apparent benefit in small numbers of
patients with relatively low plasma Cortisol concentrations
or poor responses to ACTH stimulation tests, but in whom
there was no absolute adrenocortical insufficiency (Jacobs
and Nabarro, 1969; Hubay et al, 1975; Sibbald et al, 1977;
Jurney et al, 1987; Varma et al, 1990; Voerman et al, 1990).
However, little can be concluded from these anecdotal re¬
ports .
In summary, there is no evidence that absolute adrenocorti¬
cal insufficiency is common during critical illness. How¬
ever, the optimum level of adrenocortical function during
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severe illness is difficult to define. If a certain degree
of apparent impairment of adrenocortical function was shown
to be associated with a higher than expected mortality, then
randomised clinical trials of steroid replacement would be
worthwhile.
3) Thyroid Function During Critical Illness?
The biochemistry and physiology of thyroid function during
health are discussed in Chapter 5. The changes in thyroid
hormone concentrations during illness are well documented,
and have been termed the "Sick Euthyroid Syndrome". The main
diagnostic problem is to distinguish the very ill patient in
whom the low total T4 concentration is due to illness from
the sick patient with hypothyroidism. The Sick Euthyroid
Syndrome is divided into two main subtypes (Chopra et al,
1983) :
The Low T3 Syndrome
The low T3 syndrome is characterised by a subnormal serum
total T3 and a normal serum total T4. This syndrome occurs
in many situations, including liver disease (Hepner and
Chopra, 1979), infection (Wartofsky et al, 1977), renal
failure (Kaptein et al, 1981; Hardy et al, 1989), ischaemic
heart disease (Wiersinga et al, 1981; McAlpine and Cobbe,
1988), burns (Becker et al, 1982), starvation (Portnay et
al, 1974) and following surgery (Chu et al, 1991; Kobayashi
et al, 1991). Low T3 concentrations are found in 70% of
general medical patients in hospital (Kaplan et al, 1982),
and virtually all intensive care patients (Slag et al, 1981;
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Wehman et al, 1985). The syndrome may also occur following
administration of certain drugs, including dexamethasone,
amiodarone and propranolol (Cavalieri and Pitt-Rivers,
1981) .
The concentration of T3 may be very low, and is often below
assay sensitivity. Serum free T4 levels and the FTI are
usually normal, but concentrations of free T3 are low. In
normal subjects 20% of T3 production stems from thyroidal
secretion and 80% from peripheral deiodination of T4. Thyr¬
oidal production of T3 is normal during illness (Lim et al,
1977) and the metabolic clearance rate of T3 is little
changed from normal (Van der Heyden et al, 1988; Kaptein et
al, 1986). Reverse T3 concentrations are markedly increased
during illness. This results from increased production and
diminshed metabolic clearance (Chopra et al, 1976; Kaptein
et al, 1982). Peripheral deiodination of T4 to T3 is reduced
and deiodination to rT3 is increased. The cause of the
altered 5'-deiodinase activity is unknown. Hagenfeldt et al
(1979) and others have observed that increases in plasma
Cortisol precede the alterations in T3 and rT3 concentra¬
tion, suggesting a causal relationship. However, Brandt et
al (1976) showed that the changes in T3 levels following
surgery were identical irrespective of whether the patient
had undergone general, in which case Cortisol concentrations
increase, or epidural anaesthesia, in which case Cortisol
concentrations remain normal. Moreover, the low T3 syndrome
occurs in starvation which is not associated with increased
Cortisol concentrations. Others has suggested that reduced
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availability of cytosolic cofactors for 5'-deiodinase, such
as NADPH or glutathione, might alter the peripheral T4 meta¬
bolism (Kaplan, 1979; Yamada et al, 1982).
The Low T4 Syndrome
The low T4 syndrome is seen in severely ill patients with a
variety of systemic illnesses. The T4 concentration is
reduced, but the TSH concentration is usually normal. T4
production and secretion by the thyroid gland are normal or
only slightly decreased (Kaptein et al, 1982). The concen¬
tration of thyroid-binding globulin (TBG) is normal (Chopra
and Smith, 1975; Slag et al, 1981) or slightly decreased
(Talwar et al, 1976). The concentrations of albumin and
thyroid-binding prealbumin (TBPA) are decreased during
illness (Helenius and Liewendahl, 1979), but even comlete
loss of these binding proteins would only increase the free
T4 fraction by 30% (Silberman et al, 1988). Since the free
T4 fraction is greater than this in many critically ill
patients, other factors must be present (Chopra and Smith,
1975) .
The thyroid hormone binding capacity of TBG is reduced
during illness (Chopra et al, 1979; Woeber and Maddux, 1981)
and may be responsible for much of the change in thyroid
hormone levels. Free T4 levels are high during illness,
whereas the free thyroxine index (FTI) is variable but often
low (Woeber and Maddux, 1981). It is argued that the dispar¬
ate free T4 and FTI results are due to the presence of a
thyroid hormone-binding inhibitor that functions well under
conditions of eguilibrium dialysis, but not under those of
15
T3 resin uptake used in the calculation of FTI (Kaptein et
al. 1981; Vermaak et al, 1983; Surks et al, 1988). The
presence in the serum of severely ill patients of such a
binding inhibitor has been demonstrated (Chopra et al, 1979;
Oppenheimer et al, 1982). The inhibitor is thought to be a
substance released from damaged tissue during illness, but
the exact nature of the substance or substances remains
unclear. There is evidence that certain free fatty acids may
be responsible (Mendel et al, 1986; Chopra et al, 1986) but
this is not universely accepted (Shifferdecker et al, 1990),
and other factors have been suggested (Mendel et al, 1991;
Ramaker and Wood, 1990).
The reduced protein binding of T4 leads to accelerated
degradation (Gregerman and Solomon, 1967) and increased free
hormone concentration. The extent of the fall in T4 concen¬
tration correlates with severity of illness and mortality
(Slag et al, 1981; Werner, 1981; Philips et al, 1984; Song
et al, 1991). Detailed analysis of free T4 levels is diffi¬
cult due to marked discrepancies between different assays in
severe illness (Kaptein et al, 1981; Slag et al, 1981).
There is conflicting evidence regarding TSH concentration in
severe illness. Studies performed using early TSH RIAs
suggested that TSH levels were normal (Mclarty et al, 1975;
Slag et al, 1981; Kaptein et al, 1982; Kaplan et al, 1982),
and occasionally high on recovery (Bacci et al, 1982; Ham-
blin et al, 1986). More recent work with sensitive TSH
assays has shown that a proportion of patients have subnor¬
mal TSH concentrations (Boles et al, 1987). However, most
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studies reporting low TSH levels (Wehman et al, 1985; Arem
and Deppe, 1990) included patients receiving treatment with
steroids and dopamine which inhibit TSH secretion. The
situation is further complicated by the finding that a
significant minority of normal healthy subjects have subnor¬
mal TSH levels measured by sensitive assays (Chosich et al,
1989; Arem et al, 1990;). The nocturnal surge in TSH secre¬
tion is lost in severe illness (Romijn and Wiersinga, 1990),
and raised TSH levels in myxoedema fall to normal during
illness and rise on recovery (Hooper, 1976). The TSH re¬
sponse to TRH is reduced in severely ill patients (Talwar et
al, 1976; Heinen et al, 1981), although the evidence is
again confounded by treatment with steroids and dopamine.
Maturlo et al (1980) induced a fall in T4 concentration by
administration of iodide to a group of ill patients. The
basal or TRH-stimulated TSH levels increased in only half
the cases, suggesting that the TSH response to a hypothyroid
state may be lost in certain patients.
Cytokines may be partly responsible for changes in thyroid
function during illness. Injection of IL-1 beta (Dubuis et
al, 1988) and TNF alpha (Ozawa et al, 1988) to rats leads to
a fall in TSH, T4 and T3 concentrations in rats. The fall in
TSH occurs after the fall in thyroid hormone concentrations,
suggesting a direct effect of the cytokines on the thyroid
gland or hormone metabolism. Treatment of rats with I1-1
impairs the T3 and T4 responses to TSH (Fujii et al, 1989),
and decreases pituitary TSH content (Enomoto et al, 1990).
TNF alpha has similar effects (Pang et al, 1989), and both
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IL-1 and TNF inhibit thyroid cell growth in culture and
thyroid hormone release from cultured cells (Sato et al,
1990; Kraiem et al, 1990).
The combination of reduced serum T3 and T4 concentrations
found during critical illness indicate a poor prognosis
(Heinen et al, 1981; Slag et al, 1981, Vierhapper et al,
1982). However, in general patients are considered to be
euthyroid (Faber et al, 1987) with normal or depressed TSH
concentrations (Arem and Deppe, 1990). There is some evi¬
dence of hypothyroidism at tissue level, estimated using
angiotensin converting enzyme activity (Brent et al, 1984;
Smallridge et al, 1985) or erythrocyte sodium/potassium
adenosine triphosphatase activity (Dasmahapatra et al,
1985). Low tissue concentrations of T3 have also been found
(Reichlin et al, 1973). Some authors suggest treatmenteither
with T3 (Hesch et al, 1981; Becker et al, 1982) or with a
combination of T3 and T4 (DeGroot, 1989), while others
suggest that the low T3 state is metabolically protective
and "an important beneficial adaption to illness in man"
(Utiger, 1980).
Starvation produces changes in thryoid function similar to
those found during illness (Burman et al, 1979; Borst et al,
1983). In calorie-deprived patients, the pulse rate de¬
creases and the QKd interval and systolic time interval are
prolonged (Meyers et al, 1980). Basal metabolic rate de¬
creases (Huang et al, 1981), and can be restored to normal
with T3 replacement (Mince et al, 1980). It has been sug¬
gested that starvation leads to an hypothyroid state inten-
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ded to limit catabolism (Wartofsky and Burman, 1982).
Is there any evidence that thyroid hormone replacement is
beneficial during illness? In a rat model of pneumococcal
septicaemia, thyroxine replacement increased mortality and
shortened survival compared to controls (Little, 1985). A
Japanese study of T3 replacement in a canine model of hae-
morrhagic shock (Shigematsu and Shatney et al, 1988), demon¬
strated dramatic haemodynamic improvements in the treated
group, and an impressive reduction in mortality in treated
animals (1/13 deaths vs 9/10 deaths). However, a study of a
canine model of myocardial infarction by another Japanese
worker (Tanaka et al, 1988) failed to demonstrate any effect
of T3 replacement on haemodynamic parameters or mortality.
An uncontrolled study of T3 replacement in septic shock in
man claimed to show an increase in systolic blood pressure,
reduced vasopressor reguirements, and improvement in renal
function in the treated group (Hesch et al, 1981). There
have been only two controlled trials of thyroid hormone
replacement during severe illness in man. Becker et al
(1982) treated 8 patients with severe burns with 200 meg
nasogastric T3 replacement daily. There was no change in
metabolic rate compared with controls receiving no treat¬
ment, and mortality (50%) was identical in both groups.
Brent et al (1986) treated 11 ICU patients with a daily
injection of 1.5 mcg/kg thyroxine. Serum concentrations of
total T4 and free T3 concentrations were normalised in the
treatment group after 5 days. Mortality (73%) was identical
to the control group. Thyroid hormone replacement is clearly
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not life saving in severe illness, although a more modest
effect on mortality or morbidity cannot be excluded.
The association between low concentrations of thyroid hor¬
mones and an increased mortality in critical illness has not
been studied in detail. This is of particular relevance to
the debate regarding thyroxine replacement during illness.
Although mortality among patients with low thyroid hormone
levels is high, is it higher than would be expected on the
basis of illness severity measured using other parameters?
Are low thyroid hormone concentrations really associated
with an increased mortality when severity of illness is
taken into account? This is one of the main guestions ex¬
amined in this thesis.
(4) Difficulties in The Interpretation of Research in Cri¬
tically ill Patients
Intensive care patients are an extremely heterogeneous
group, with a wide range of underlying pathologies. Manage¬
ment regimes differ for each patient, and seldom remain the
same from day to day. Research is therefore difficult and
findings are not necessarily reproducible. Measurement of
any single parameter is likely to be affected by a number of
confounding factors related to pathology, monitoring or
treatment. Most published research in intensive care medi¬
cine ignores these difficulties. Researchers take the pra¬
gmatic view that it is not necessary to disentangle the
effects of illness from those of intensive care. It is
argued that patients must necessarily be subject to both
20
groups of influences. However, management differs from unit
to unit, and new treatments freguently emerge. If results of
research involving ICU patients are to be generalisable,
then the confounding effect of treatment must be minimised,
although a degree of heterogeneity of patients and condi¬
tions must be accepted if any clinical research is to be
carried out at all.
Endocrine and metabolic changes accompanying critical ill¬
ness are likely to be particularly susceptible to confound¬
ing by external influences. Such influences can be divided
into two groups. There are those which affect the majority
of patients egually, such as continuous noise and twenty
four hour lighting, and those which affect only a propor¬
tion of patients, such as haemodialysis, physiotherapy, and
intravenous nutrition. The effects of the former are diffi¬
cult to measure without elaborate control data. The effects
of the latter can be assessed. One of the aims of this the¬
sis was to define conditions in which some of these influ¬
ences could be minimised.
Research into the endocrine response to critical illness is
also hampered by the difficulty in defining what should be
regarded as normal in critically ill patients. The defini¬
tion of normality of a measurement is often arbitrary, and
will vary depending on purpose for which the measurement is
to be used. For example, a normal response to a standard
ACTH stimulation test has been defined by identifying the
line of demarcation between the response to ACTH in patients
diagnosed by other methods to be suffering from hypoadrenal-
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ism and the response of individuals with apparently normal
adrenocortical function. This approach, frequently used by
endocrinologists to define normality, is quite different
from the two standard deviations about the mean of a popula¬
tion used elsewhere. The line of demarcation between normal
and abnormal or insufficient endocrine function is unclear
in critically ill patients. The dynamic tests of adrenocor¬
tical and thyroid function used in this thesis are not used
to identify abnormality but simply to define the range of
responses expected in a population of severely ill patients.
(5) Ethical Difficulties of Research During Critical illness
It is difficult to draw a line between what is medical prac¬
tice and what is research. As the Belmont Report (1983)
noted, the distinction "is blurred partly because both occur
together ... and partly because departures from standard
practice are often called experimental when the terms ex¬
perimental and research are not carefully defined." The
Royal College of Physicians (1990) defined medical practice
as "an activity undertaken solely with the intention of
benefiting an individual patient, where there is a reason¬
able chance of success." It was further stated that "the
progressive modification of methods of investigation and
treatment in the light of experience is a normal feature of
medical practice and is not to be considered as research."
By contrast, "Where an activity involving a patient is
undertaken with the prime purpose of testing a hypothesis
and permitting conclusions to be drawn in the hope of con-
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tributing to general knowledge, this is research."
Medical research may be divided into therapeutic and non-
therapeutic. Therapeutic research, such as a clinical trial
comparing two established treatments, is relatively easy to
justify. Non-therapeutic research, into which category this
thesis falls, involves no benefit to the patient, but is
simply "a systematic investigation designed to develop or
contribute to generalisable knowledge" (Levine, 1979). The
distinction is important when considering the issue of
informed consent. Informed consent requires that the fol¬
lowing conditions be met: the patient involved in a study is
given sufficient information in order that he is able to
decide whether the proposed research is something in which
he would be willing to participate; consent must be volun¬
tarily given; the patient must have the legal capacity to
consent to the proposed research. Levine (1988) lists 16
separate elements of informed consent.
In intensive care research there are difficulties with
informed consent because patients are frequently uncon¬
scious. For the purposes of acute care in this situation,
the requirement for informed consent is routinely abandoned
under the auspice of beneficence. This practice is justified
on the grounds of the legal concept of implied consent which
assumes that patients needing immediate medical intervention
would want such care in order to avoid death or reduce
morbidity (Buchanan and Brock, 1989). It has been suggested
that this principal should also apply to therapeutic re¬
search in acute care of unconscious patients (Iserson and
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Mahowald, 1992). This may or may not be reasonable, but the
same principal cannot be applied to non-therapeutic re¬
search. The requirement for consent in this situation was
considered by the Royal College of Physicians (1990), where
it was suggested that a near relative should be informed of
the nature of the research and should concur. It was stated
that "the legal status of non-therapeutic research involving
patients who are incompetent through the severity of their
illness is quite uncertain In general, the patient
should be told about participation in research later when he
recovers sufficiently to comprehend."
Consent by a relative or other surrogate is neither legally
nor morally as binding as consent from the patient. It is
not certain that surrogate decision-makers always have the
best wishes of the patient in mind (Boyle, 1990), and there
is a tendency to comply with the wishes of the researchers.
Schaffner et al (1988) found that in more than 700 consecu¬
tive cases of post-resuscitation coma involved in clinical
studies, no relative removed a patient from the research
protocol. In this thesis, a proportion of the research was
performed soon after patients were admitted to the ICU. At
this point in time relatives are frequently extremely dis¬
tressed about the deterioration in the condition, or sudden
onset of illness, in their relative. It seems unnecessarily
cruel to compound their anxiety by requesting the right to
"experiment" on the patient.
In severely ill patients who are conscious, consent is para¬
doxically more problematic than in unconscious patients.
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Whether severely ill patients really have the capacity to
make free and informed decisions has rightly been questioned
(Frost, 1975). Studies of consent prior to elective surgery
show that patients understand little about the procedure,
and cannot remember their informed consent (Robinson and
Merav, 1976). Critically ill patients are often suffering
great distress, and are unlikely to give any decision ade¬
quate consideration, even if they are able to comprehend the
issues. There is a danger that patients may be fearful of
offending the physician who is seeking consent, by declining
to take part in research. They are often aware of their
uncertain prognosis, and may be willing to go to consider¬
able lengths to oblige a physician, whom they perceive to
have a degree of influence over their fate.
In the case of many of the patients included in this work,
the only intervention to which they were subject was the
taking of a single sample of blood. This was almost invari¬
ably obtained at a time when blood was also being sampled
for routine investigations, and accounted for an additional
blood loss of only 10ml. A record of routinely collected
data was kept outwith the medical records for each patient
included in the study. This was securely stored and the
format was anonymous. It was felt that in such cases, bear¬
ing in mind the difficulties with informed consent in ICU
patients outlined above, consent from the patient or rela¬
tive would not be sought. However, on recovery the patient
would be told that some of the results of tests performed
during their illness would be used for the purposes of
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research.
The situation in patients in whom we wished to perform
dynamic tests of endocrine function, requiring the admin¬
istration of drugs, or in whom repeated blood sampling was
necessary, was less clear cut. The tests performed in this
study are standard diagnostic tests of proven safety used in
everyday clinical practice. The Ethical Committee decided
that when a patient was conscious, consent should be ob¬
tained, but in the cases of an unconscious patient, dynamic
tests could be performed without consent of a relative, the
patient being told of the research on recovery.
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Chapter 2
Patients, Setting and Assays
(1) Setting
(2) Patients
(3) The APACHE II Severity of Disease Classification System
(4) Principals of Radioimmunoassay
(5) Cortisol Measurement and Validation of Assay
(6) Thyrotropin Measurement
(7) Thyroid Hormone Measurement
(8) Interpretation of Total Hormone Concentrations during illness.
(1) Setting
All investigations detailed in this thesis were performed on
the Intensive Care Unit at South Cleveland Hospital, Mid¬
dlesbrough. This is an 8 bed ICU, which has the capacity to
care for 8 patients reguiring ventilation and 24 hour nur¬
sing care and up to 6 patients requiring regular haemodia-
lysis. In addition to haemodialysis, the unit has consider¬
able experience of continuous arteriovenous haemofiltration.
Continuous cardiac monitoring, in situ transducer measure¬
ments of central venous and arterial blood pressure, venti¬
lation pressures, end expiratory carbon dioxide, and trans¬
cutaneous oxygen saturation are available at each bed.
The ICU is one of two subregional IUCs serving a population
of 500,000. The second unit at Middlesbrough General Hospi¬
tal is dedicated to the care of trauma, neurosurgery and
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neurology cases. The study ICU is mainly a medical and
general surgical unit. It provides the subregional renal
intensive care service, and is referred patients reguiring
intensive care from five local district general hospitals.
Patients on the unit are under the care of a full-time
consultant in Intensive Care Medicine, with support from two
consultants in Renal Medicine. One senior registrar and two
senior house officers are attached to the unit. There is a
separate neonatal and paediatric intensive care unit.
(2) Patients
The 260 patients investigated formed 90% of all ICU admis¬
sions over a 2 year period. Of the 29 patients excluded, 21
were receiving dopamine on admission, which alters thyroid
and pituitary function, 5 were on longterm steroid therapy,
and 3 were receiving T4 replacement. The principal diagnoses
of patients studied are shown in Table 2.1. The average age
of patients studied was 59.6 years [range 14-86] and there
was a slight excess of males, 137 vs 123 females.
The mean APACHE II score [see below] of patients studied was
19.8 [SD = 8.6] with a range of 7 - 41. Eighty eight pa¬
tients died prior to discharge from the unit, giving an
overall mortality of 31%. The mean duration from ICU admis¬
sion to death was 10 days [range, 2 hours - 69 days]. Ninety
five patients (37%) were admitted within 24 hours of elec¬
tive or emergency general surgery and a further 26 patients
(10%) were admitted with later postoperative complications.
No patient declined consent to any of the tests detailed in
28
this thesis.
Table 2.1. Principal diagnosis in the 260 patients studied
DIAGNOSIS PATIENTS [%]
Septicaemia 59 [23]
Abdominal surgery for benign disease 41 [16]
Abdominal surgery for malignant disease 34 [13]
Pelvic surgery 11 [4]
Abdominal aortic aneurysm surgery 19 [7]
Pneumonia 23 [9]
Asthma 19 [7]
Guillain-Barre Syndrome 9 [3]
Multiple trauma 5 [2]
Acute pancreatitis 8 [3]
Eclampsia 3 [1]
Other diagnosis 29 [11]
Total 260 [100]
(3) The APACHE II Severity of Disease Classification System
The APACHE II system (Knaus et al ,1985) is made up of three
elements: the acute physiology score; the age score; the
chronic health score. The acute physiology score is the sum
of the 12 scores obtained from Table 2.2. In this thesis,
the term APACHE II score has been used to refer to the acute
physiology score alone. The acute physiology score measures
physiological derangement which is usually eguated with
severity of illness.
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Table 2.2. The APACHE II severity of disease classification systea: the scores given to each of the 12
physiological paraaeters which sake up the acute physiology score.
PHYSIOLOGICAL VARIABLE HIGH ABNORMAL RANGE NORMAL LOU ABNORMAL RANGE
+4 +3 +2 +1 0 +1 +2 +3 +4
RECTAL TEMPERATURE (°C) >41 39-41 - 38.5-39 36-38.4 34-36 32-34 30-32 <30
MEAN ARTERIAL PRESSURE (aaHg) <160 130-159 110-129 - 70-109 50-69 - <49
RESPIRATORY RATE
(ventilated or not)
>50 35-49 - 25-34 12-24 10-11 6-9 - <5
OXYGENATION
(if FI02 >0.5 use A-aDO.,)
(if FI02 <0.5 use Pa02)
>500 350-499 200-349 - <200
<70 61-70 55-60 <55
ARTERIAL pH >7.7 7.6-7.7 - 7.5-7.6 7.3-7.5 - 7.2-7.3 7.1-7.2 <7.1
SERUM SODIUM (bboI/L) >180 160-179 155-159 150-154 130-149 - 120-129 111-119 <110
SERUM POTASSIUM (moI/L) >7 6-6.9 - 5.5-6 3.5-5.4 3-3.4 2.5-3 - <2.5
SERUM CREATININE (ag/IOOsl)
(x2 if acute renal failure)
>3.5 2-3.4 1.5-2 - 0.6-1.4 <0.6 - -
HAENATOCRIT (X) >60 - 50-60 46-50 30-46 20-30 - <20
UHITE BLOOD COUNT
(1000s/*3)
>40 - 20-40 15-20 3-15 1-3 - <1
GLASGOW COMA SCORE (GCS) points score equal to 15 ■inus actual GCS
The APACHE II system has two additional elements [Table
2.3]. The age score allocates additional points purely on
the basis of the age of the patient. The chronic health
score allocates additional points on the basis of a past
history of severe chronic illness. This thesis is primarily
concerned with the effects of acute severe illness and so
the age points and chronic health points are not used.
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Table 2.3. The derivation of the age and the chronic health status
elements of the APACHE II Severity of Illness Classification System.
(a) Age Score
AGE (YRS): <45 45 - 54 55 - 64 65 - 74 >75
POINTS: 02 3 56
(b) Chronic Health Score
If the patient has a history of severe organ system insufficiency or is
immuno-compromised assign points as follows:
1) For non-operative or emergency postoperative patients - 5 points;
2) For elective postoperative patients - 2 points
Definitions
Organ insufficiency or immuno-compromised state must have been evident
prior to this hospital admission and conform to the following criteria.
LIVER: Biopsy proven cirrhosis or portal hypertension, episodes of upper
GI bleeding attributed to portal hypertension or prior episodes of
hepatic failure/encephalopathy/coma.
CARDIOVASCULAR: New York Heart Association class IV.
RESPIRATORY: Chronic restrictive, obstructive or vascular disease
resulting in severe exercise restriction, i.e, unable to climb stairs or
perform household duties, or documented chronic hypoxia, hypercapnoea,
secondary polycythaemia, severe pulmonary hypertension (>40mmHg), or
respirator dependency.
RENAL: Receiving chronic dialysis.
IMMUNO-COMPROMISED: Patient receiving immuno-suppressant drugs, chemo¬
therapy, radiation, long term steroids, or had disease which is suffici¬
ently advanced to suppress resistance to infection eg. leukaemia, AIDS.
(4) The Principals of Radioimmunoassay
Radioimmunoassay [RIA] has a high degree of specificity and
relative freedom from interference. The specificity of
Cortisol RIA methods tends to vary with the antiserum that
is used, but when using a specific antiserum, significant
interference is only likely to be encountered in patients
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being treated with prednisone or prednisolone.
The basis of RIA is the competition between radioactively
labelled and unlabelled hormone for a fixed but limiting
number of binding sites on antibody molecules. Radioactively
labelled hormone is added in excess to all assay tubes. In
the absence of any unlabelled hormone, all the antibody
binding sites will be occupied by radioactive hormone. If
unlabelled hormone is present, it will compete with the
radioactive species for the available binding sites, and as
the concentration of unlabelled hormone increases, so more
labelled hormone will be displaced from the bound fraction.
Using standard hormone preparations of known concentration,
the binding of radioactively labelled hormone at each con¬
centration of standard can be determined, and a calibration
curve constructed. Hormone concentrations from biological
test samples are obtained from such a curve by interpola¬
tion. When unlabelled hormone is present in large excess,
only a few binding sites will be occupied by radioactive
hormone making measurement difficult. In this case the assay
is repeated with the biological sample diluted with standard
containing no hormone.
The procedure for RIA involves several steps. First, antibo¬
dies specific for a hormone have to be obtained. A supply
of radioactive hormone is reguired. All tubes in the assay
contain the same mass of antibody and the same excess of
labelled hormone, that is the number of binding sites is
fixed and sufficient label is present to fill all of them.
Some tubes contain known amounts of unlabelled hormone
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arranged incrementally to give a standard curve.
The biological test sample is added to the tube and left to
incubate under specified conditions for a fixed period. At
the end of the incubation period labelled hormone bound to
antibody must be separated from that remaining free in
solution. This separation is the major technical problem
because antibody is generally so dilute that no precipita¬
tion occurs when the hormone-anti-hormone complex forms.
Production of antisera is the first stage in the development
of an RIA. This can be achieved by animal immunisation or by
monoclonal antibody technigues. For steroids, a major pro¬
blem is that the molecule itself is not antigenic. It must
be coupled to a larger antigenic molecule to form a struc¬
ture [hapten] which will be recognised by the animal which
is to produce antibodies. Antibodies which react with the
hapten will exhibit some cross-reactivity with the steroid.
Proteins to which steroids are freguently coupled are bovine
serum albumin, ovalbumin, and keyhole limpet haemocyanin.
In animal immunisation techniques, rabbits and sheep are
most often used. The hormone is injected in an oil-in-water
emulsion with Freund's adjuvant [a mineral oil containing
dead tubercular bacilli, which sensitises the immune system
in a non-specific way to the presenting antigen]. The anti¬
body is then extracted from blood taken from the animal some
weeks or months after injection of antigen.
To produce monoclonal antibodies, specific strains of mice
or rat are injected with hormone immunogen. Lymphocytes from
the spleens of these animals, which are likely to be produ-
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cing antibodies, are fused with appropriate myeloma cells
and then grown in culture. The hybrid cells which retain the
capacity for antibody secretion from the lymphocytes, and
the ability to grow well in culture from the myeloma cells,
are selected out and propagated. Anti-hormone can be harves¬
ted from the cell culture medium.
Steroid RIAs use either tritium [H3] or radioactive iodine
IOC
[I ] as tracers. Tritium has the advantage of a longer
half-life, and the fact that it can be bonded directly to
the steroid ring structure. Radioactive iodine cannot be
bonded directly to the steroid ring structure without sig¬
nificantly changing its conformation. This problem is cir¬
cumvented by binding i125 to a bridging molecule such as
histamine or tyramine. In this way the i^25 produces minimal
interference in the hormone-antibody reaction. Despite these
problems i^25 j_s more popular in steroid RIAs than H3 be¬
cause it has a higher specific activity and yields assays
that are much cheaper and more robust. Gamma particles are
emitted by I"*-^3, and these are more easily counted than the
beta particles emitted by H3.
Separation of antibody-bound and free radioactive label is a
limiting factor in the accuracy of many RIAs. Briefly,
separation is most commonly achieved using charcoal adsorp¬
tion, precipitating antibody, or solid-phase antibody tech¬
niques. In the charcoal technique, free hormone is adsorbed
onto the charcoal leaving antibody-bound hormone in solu¬
tion. Solid phase techniques utilise anti-IgG antibody bound
to microspheres such as sepharose beads, or some other solid
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material. Most assays now use some variation of the solid
phase antibody technique.
Assay Validation
In the early days of immunoassay, each laboratory had to
produce and evaluate all its own reagents, and validate
assays based on those reagents. Most hospital clinical
chemistry laboratories now use commercial radioimmunoassay
kits, of which there are a considerable number. Criteria for
the acceptability of kits have been published (Fraser and
Wilde, 1986). Kits used in clinical laboratories in the
United Kingdom are evaluated by the National External Qual¬
ity Assessment Scheme [NEQAS]. However, it is recommended
that each laboratory validates its own use of a particular
assay kit. It is necessary to know the accuracy and preci¬
sion of an assay if it is to be used in clinical research in
relatively small numbers of patients in order that signif¬
icant changes in hormone concentration can be differentiated
from assay variability.
Accuracy is defined as closeness to the "true" value. It can
be assessed by analysing a standard for which the concentra¬
tion of analyte has been determined by a reference method,
such as gas chromatography / mass spectroscopy. Standards in
human serum are available from NEQAS. Precision is defined
as the spread of replicate observations about the mean. It
is expressed as a standard deviation [SD] or as the coeffi¬
cient of variation [CV]. This is defined as 100*SD/mean.
The precision of immunoassays varies as a function of dose.
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It is recommended that an assay is optimised with reference
to its "precision profile" (Ekins and Edwards, 1983). This
is a plot of the CV against dose which facilitates the
selection of maximum precision in the region of the dose-
response curve that is of principal interest to the analyst.
In a good steroid RIA the CV at the nadir of this curve
should be less than 5%, and should be below 10% throughout
the working range of the curve.
The precision between assay batches [inter-assay] will not
be as good as that within a single batch [intra-assay]. For
sequential studies over a period of time it will be neces¬
sary to determine the inter-assay CV. While a precision
profile approach can be used for this purpose, it is more
common to estimate the CV obtained for a number of quality
control samples that are analysed by every assay. At least
three quality controls should be used and they should con¬
tain hormone concentrations at different points within the
working range of the standard curve. Ideally, the mean
inter-assay CV should always be below 15%, and should aim to
be below 10% (Jeffcoate, 1981).
Sensitivity and detection limit of an assay are often quo¬
ted. Although the two terms are used interchangeably, they
describe different parameters. The sensitivity of an assay
is a feature of the precision at zero analyte concentration,
whereas the detection limit refers to the lowest concentra¬
tion of an analyte that may be distinguished statistically
from zero.
36
(5) Cortisol Measurement and Validation of Assay
Blood sampling and storage
All investigations of adrenocortical function in this thesis
rely on accurate measurement of Cortisol concentration. The
conditions required for accurate sampling of plasma Cortisol
are detailed below:
1] It is recommended that stress to the patient should be
avoided. Increases in plasma Cortisol concentration occur
very rapidly after even mild stress [Ismail, 1981]. Vene¬
puncture may increase plasma Cortisol levels, and so samp¬
ling from an indwelling venous catheter is recommended.
2] Venous stasis increases the concentration of plasma
proteins in blood. Stasis is likely to occur while searching
for a vein, following the application of a tourniquet. Since
Cortisol is mainly protein bound, venous stasis may produce
misleadingly high concentrations.
4] Haemolysis should be avoided as this interferes with
radioimmunoassay techniques which assay Cortisol in plasma
without extraction into an organic phase (Cook and Beastall,
1987). In such direct assays, the standards are commonly
made up in serum which will contain none of the proteins
from red blood cells.
5] Time of sampling is vital to interpretation of results
because of the marked circadian rhythm of Cortisol secre¬
tion .
Storage of blood for Cortisol assay is also important. After
collection, blood is transferred to a lithium heparin tube
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and centrifuged in order to separate the plasma. Plasma can
then be stored at 4®C [a standard refrigerator] for up to 72
hours (Ismail, 1981). Storage for longer periods reguires
the sample to be frozen at - 20°C.
In this study, venous blood was used for all Cortisol mea¬
surements. As far as possible study blood samples were
taken at the same time as samples for routine non-study
investigations. In those patients with central venous lines
in place (80%), study samples were taken from the line. All
infusions via the central line were stopped for 30 seconds
prior to sampling and the first 5 ml of blood drawn from the
central line was discarded. In the remaining patients sam¬
ples were taken immediately following insertion of a 20
French gauge "Butterfly" canulla in an antecubital fossa
vein. A tourniquet was used. Blood was drawn into a plastic
syringe and 5 ml transferred immediately to a 10 ml plastic
lithium-heparin tube for Cortisol measurement. Samples were
stored at 4°C until transfer to the Clinical Chemistry
Laboratory, Middlesbrough General Hospital, where the Corti¬
sol assay was performed. All assays were performed within 72
hours of sampling.
Cortisol Assay
Cortisol was measured using a commercial radioimmunoassay
kit ("CORT-CT", CIS Bioindustries, Gif-Sur-Yvette, France).
The antisera is produced by rabbit immunisation and labelled
Cortisol is bound to I The anti-cortisol antibody is
bound to the inner surface of a polypropylene tube thus
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facilitating separation of bound and free Cortisol frac¬
tions .
The assay has been used by the Department of Clinical Chemi¬
stry at M.G.H. on a regular basis for a number of years and
the laboratory staff are experienced in the use of the kit,
performing the assay on about 50 clinical samples each week.
The assay performance specifications are published by the
manufacturer and accuracy of the assay is checked regularly
against NEQAS standards.
The sensitivity of the assay is reported by the manufactur¬
ers to be 6.8 nmol/L. The antiserum used in the assay shows
cross-reactivity with prednisolone [28% of the specificity
of Cortisol] but not with dexamethasone. The cross-reactivi¬
ties reported with corticosterone and 11-deoxycortisol are
4.3% and 7.9% respectively. The within assay coefficients
of variation are reported to be 5.5% at Cortisol concentra¬
tions of approximately 200 nmol/L, 3.6% at 600 nmol/L and
6.2% at 1500 nmol/L. The inter-assay coefficients of varia¬
tion are reported to be 7.9% for Cortisol concentrations of
200 nmol/L, 6.8% at 600 nmol/1 and 7.2% at 1500 nmol/L.
Nearly all the local experience with the assay involved
Cortisol concentrations below 1000 nmol/L, and the manufac¬
turers performance data does not give information on preci¬
sion at concentrations greater than 1500 nmol/L. Although
the kit contains a high dose standard Cortisol sample in
order to produce the standard curve, the jump in concentra¬
tion between the highest two standards is 825 nmol/L to 2750
nmol/L. The difference in expected gamma counts between
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these two concentrations is small compared to the differen¬
tials at lower concentrations. The concentrations of re¬
agents in RIAs are calculated to give maximum assay preci¬
sion within the range of concentrations in which the sub¬
stance to be measured most freguently occurs. For plasma
Cortisol this range is 100 - 1000 nmol/L. Many ICU patients
have plasma Cortisol concentrations above 2000 nmol/L, and
as a rule, the further from the intended measurement range a
sample becomes, the less precise the assay will be. It is
possible to dilute a sample with zero standard, but the
measurement of sample and dilution volume introduces further
potential inaccuracies, and so ideally dilution should be
avoided. It was therefore necessary to validate the assay
using samples from ICU patients with high Cortisol concen¬
trations .
Validation of Cortisol Assay
Intra-assay variation was calculated using 6 samples of
plasma taken from six ICU patients. The samples were chosen
to reflect the range of Cortisol concentrations regularly
encountered in ICU patients. Following initial plasma Corti¬
sol measurement each sample was divided into 10 portions.
Plasma Cortisol was measured in each portion from each of
the 6 samples, using the same assay kit for all 60 measure¬
ments. All remeasurements were performed on the same day by
a single technician. In Table 2.4, the intra-assay variation
in measurement of plasma Cortisol concentration is presented
as the coefficient of variation.
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Table 2.4 Mean [SD] plasma Cortisol concentration and
intra-assay coefficient of variation.
PLASMA CORTISOL CONCENTRATION [nmol/L]
SAMPLE MEAN SD CV [%]
1 326 16 .2 5.0
2 749 24.1 3.2
3 1127 76.0 6.7
4 1783 128.4 7.2
5 2012 158.9 7.9
6 2431 204.0 CO
The intra-assay coefficient of variation at lower plasma
Cortisol concentrations was similar to that published by the
manufacturers, but increased at concentrations above 1000
nmol/L. A coefficient of variation of 8.4% at a concentra¬
tion of 2431 nmol/L represents 95% confidence limits for a
sample of that concentration of 2023 - 2839 nmol/L. In other
words, if 2 samples both measure 2431 nmol/L, it is possible
that their true Cortisol concentrations differ by over 800
nmol/L. This is likely to be a considerable hindrance to the
interpretation of short dynamic tests of adrenocortical
function in patients with high basal Cortisol levels.
The inter-assay coefficients of variation were not further
validated. It is likely that they would be 1 or 2% greater
than the intra-assay coefficients at each concentration.
Since only a very small number of dynamic tests will involve
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the use of more than one assay kit, this error is less
important than the within-assay error.
There were some difficulties in interpretation of the re¬
sults of one assay kit. A series of dexamethasone tests
were performed on ICU patients and controls, but are not
included in this thesis. Following an oral dose of 2mg
dexamethasone in the evening, plasma Cortisol was sampled
at 0800h the next morning. In the 5 healthy controls, the
morning Cortisol concentrations ranged from 60 nmol/L to 160
nmol/L. The mean concentration had fallen from 216 nmol/1
[SD =51] prior to the dexamethasone to 107 nmol/1 [SD =
31], However, the post-dexamethasone levels were higher than
would be expected. The majority of individuals should have
Cortisol concentrations of less than 80 nmol/L on the morn¬
ing of a dexamethasone suppression test.
There are a number of possible interpretations of the appar¬
ent failure of Cortisol to suppress fully in 4 of the 5 con¬
trols. All were young females and may have been taking the
oral contraceptive pill which would increase CBG concentra¬
tions, although such an effect would be unlikely in itself
to account for all of the failure to suppress. Depression
is associated with a failure of Cortisol to suppress follow¬
ing dexamethasone, but this was not evident in any of the
controls. Three of the controls were nursing staff working
on the night shift in whom the normal diurnal rhythm of
Cortisol concentration would have been disrupted. However,
this should not have had a major effect on suppression
following dexamethasone, although the influence of shift
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work on mood may have had an effect. There may have been a
problem with the accuracy of the assay at low and low normal
concentrations. Although, the laboratory had not had pro¬
blems previously with low hormone concentrations, it may be
relevant that all five tests in controls were performed on
the same day, and samples were, therefore, assayed by a
single technician using the same assay kit.
The vast majority of Cortisol concentrations detailed in
this thesis were above 300 nmol/L. Any problem with the
assay at low concentrations would not, therefore, be a major
problem. However, the difficulty with the dexamethasone
suppression tests illustrates the potential difficulty
associated with the use of an assay at concentrations out-
with the usual range.
Diurnal Variation in Plasma Cortisol Concentration
Diurnal variation in plasma Cortisol concentration was
studied for two reasons. Firstly, repeated measurement of
plasma Cortisol concentration over a short period in the
same patient will give an impression of the extent of the
short term variability in Cortisol concentration during
critical illness. It is, of course, impossible to judge how
much of the variance is due to changes in the true hormone
concentration and how much is due to measurement error.
However, in terms of validating the Cortisol assay for use
in dynamic tests of adrenocortical function, an assessment
of the background short term variability in Cortisol con¬
centration would be very useful. Secondly, although the
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diurnal variation in Cortisol secretion is known to be
blunted during illness, it is not clear whether the rhythm
is completely abolished in critically ill patients. This is
important with respect to the timing of tests of adrenocor¬
tical function.
In order to determine the diurnal variation in plasma Corti¬
sol concentration in ICU patients, 10 consecutive admissions
to the unit who fulfilled the following criteria were in¬
vestigated: 1) acute illness of between 2 and 28 days dura¬
tion; 2) no anaesthetic within the past 24 hours; 3) not
receiving opiates, catecholamines, dopamine, steroids or
etomidate; 3) APACHE II score greater than 25.
Patients were investigated on a day when no stressful proce¬
dures were planned. Blood was taken for plasma Cortisol
estimation at 2 hourly intervals for 24 hours, starting at
0800h on the study day. The APACHE II score was calculated
on data collected during the study day. No patient underwent
haemodialysis or haemofiltration during the 24 hour period.
Physiotherapy and intravenous fluids were given as clinical¬
ly indicated.
The mean [SD] APACHE II score of patients studied was 31.7
[2.4]. Six were male, 4 female, and mean [SD] age was 61 [7]
years. Data collection was 97% complete. A single Cortisol
measurement was missing in 2 cases, and 2 measurements were
missing in a further case. No consistent pattern of diurnal
variation is seen in the individual cases [Fig 2.1]. How¬
ever, although the mean plasma Cortisol concentration re¬
mained fairly constant from lO.OOh to 20.00h, it did fall
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thereafter, reaching a low point at 06.00h. The absolute
decrease in plasma Cortisol concentration between 20.00h and
06.00h was significant [MD = 281 nmol/L, 99% CI = 119 - 442]
as was the trend between those times (regression slope =
0.21, P<0.01).
Table 2.5. Mean [SD] plasma Cortisol



















Although 5 cases had Cortisol concentrations consistently
greater that 1500 nmol/L, with the exception of case 10, the
2 hour changes in Cortisol concentration were seldom greater
than 250 nmol/L [Fig 3.1].
45








08 10 12 14 16 18 20 22 24 02 04 06 08
TIME [hours]
case 1 "X" case 2
case 6 ♦ case 7







The first observation of a daily rhythm in Cortisol secre¬
tion was made in man by Pincus (1943). The normal range of
Cortisol concentration is 220 - 720 nmol/1 at 0800h, and
less than 220 nmol/1 at midnight (Ismail, 1981). This rhyth-
micity may be related to light and dark variation, since
nocturnal animals show a pattern which is exactly opposite
to diurnal animals. Halberg (1959) showed that these pat¬
terns do not correspond exactly to 24 hours, and named them
circadian rhythms. These rhythms are thought to be induced
by an internal "clock" which integrates signals from a
number of external stimuli, or zeitgeber, such as light,
food and sleep. In critical illness this diurnal change is
blunted (Perkoff et al, 1959), and may be absent (Schein et
al, 1991). Similar changes occur following major surgery
(Mcintosh et al, 1981).
There are a number of factors, in addition to sustained
stress of critical illness, which might contibute to the
loss of circadian rhythm in Cortisol concentration. Shifts
in the sleep-wake pattern profoundly disturb the corticoid
rhythm (Orth et al, 1967). Indeed, sleep appears to be a
more powerful synchroniser than light (Krieger et al, 1969).
Many ICU patients are sedated and sleep all day. Unsedated
patients have little sleep pattern due to continuous noise,
monitoring and nursing care. Any consistent influence of
sleep on Cortisol secretion is likely to be lost. A constant
light environment markedly reduces the amplitude of the
circadian rhythm of Cortisol (Cheifetz et al, 1968; Krieger,
1973), and has been shown in rats to decrease the response
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to stress (Paluch et al, 1983). Intensive care units are
well lit over the whole 24 hour period. Alterations in
pattern of feeding alter adrenocortical rhythmicity (Krie-
ger, 1974; Wilkinson et al, 1979). This is relevant to ICU
patients, most of whom are fed by infusion. There are there¬
fore a number of external influences which might alter the
circadian rhythm of Cortisol secretion.
(6) Thyrotropin Measurement
Venous blood was used for all measurements of thyroid func¬
tion. Blood was sampled as detailed above for plasma Corti¬
sol. Blood was drawn into a plastic syringe and transferred
into a lithium-heparin tube. Storage and transfer of samples
was the same as that used for Cortisol samples.
Thyrotropin was measured using a sensitive immunoradiometric
assay (TSH MAIAclone, Serono Diagnostics, Woking, Surrey,
UK). This assay uses two high affinity monoclonal antibodies
and has a higher sensitivity and specificity than tradition¬
al assays (Rattle et al, 1984). The sample to be measured is
mixed with the two antibodies. Both antibodies, one attached
ioc
to I and one attached to fluorescein, bind to discrete
sites on the TSH molecule. Following incubation, anti-fluor-
escein antibody attached to a magnetic solid phase is added
in excess. The complex thus formed is separated using a
magnetic field, and the concentration of antigen is directly
proportional to the radioactivity bound to the separation
agent, measured using a gamma counter.
The performance characteristics of the assay are reported by
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the manufacturers for the range of values expected in this
study. No further validation of the assay was considered
necessary. The accuracy of the assay has been assessed by
recovery experiments performed by adding purified TSH to
serum samples. The percentage recovery ranged from 91% to
106% in 15 samples. The intra-assay coefficient of variation
did not exceed 3.2% at any point on the standard curve, and
the inter-assay variation was consistently below 4%. The
detection limit of the assay was between 0.02 and 0.04
mU/L. There was little cross-reactivity with hCG, FSH, or
LH. The assay gives equivalent values with serum and plasma
samples. Grossly haemolysed or lipaemic samples may inter¬
fere with the assay.
(7) Thyroid Hormone Measurement
Total T4 was measured using an unpublished, "in-house" RIA.
This is a double antibody, peg accelerated RIA technique.
First antibody is obtained from Scottish Antibody Production
Unit (SAPU), and 125i-t4 from Amersham International (Lon¬
don, UK). The normal range of T4 using this assay is 60 -
160 nmol/L. The intra-assay coefficient of variation is
5.4%, and the interassay coefficient is 7.2%. T3 was also
measured using an unpublished, "in-house" RIA. The method is
identical to that used in the T4 assay. The first antibody
is obtained from SAPU, and 1^5I-T3 from Amersham interna¬
tional. The normal range is 1.1 - 3.2 nmol/L, and intra-
assay coefficient of variation is 9.8%. Neither of the
thyroid hormone assays were further validated.
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(8) Interpretation of Total Hormone Concentrations during
Illness.
In this thesis, only total concentrations of thyroid hor¬
mones and Cortisol are measured. This limits the interpreta¬
tion of the data, but does not undermine the aims of the
thesis. The difficulties of interpretation of total hormone
concentration and measurement of free hormone levels are
discussed below.
Free Cortisol and Cortisol Binding
The concentration of CBG is reported to be increased during
severe illness (Barnton and Passingham, 1981). However, the
very high Cortisol concetrations found in many critically
ill patients would be expected to saturate CBG binding. The
excess Cortisol would bind more weakly to albumin, thereby
increasing free Cortisol concentration. Reliable free plasma
Cortisol assay is not widely available, but what data there
is suggests that free Cortisol does increase during illness
(Murray, 1967; Barton and Passingham, 1981). There is little
published work on Cortisol metabolism and excretion during
severe illness.
It was not possible to measure free plasma Cortisol in this
study. Urinary free Cortisol could have been measured. The
small amounts of unmetabolised Cortisol excreted in the
urine are measured by RIA. Urinary free Cortisol excretion
is dependent upon the output of Cortisol by the adrenal
cortex during the period of urine collection, and the plasma
free Cortisol concentration. It is a useful measurement in
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the diagnosis of adrenal hyperfunction. It is, however,
dependent upon renal perfusion and functional capacity, and
is liable to give low values in renal failure, and high
values in states of increased renal blood flow. This can be
partly corrected for by expressing urinary free Cortisol as
a ratio with urinary creatinine, but altered renal physio¬
logy still presents problems. Over half of patients on a
medical ICU have some impairment of renal function. The
proportion is higher in the severely ill patients who are
the subjects of much of this study. Many patients receive
diuretics and infusions of dopamine and adrenaline which
further alter renal physiology. It was therefore felt that
results of urine free Cortisol measurements would be diffi¬
cult to interpret. Measurement of CBG in the absence of an
index of plasma free Cortisol would not be particularly
helpful.
The lack of information about plasma free Cortisol concen¬
tration precludes any comment about the likelihood of tissue
insufficiency. It also makes an understanding of any changes
in the control of the hypothalamic-pituitary-adrenal axis
during illness difficult. However, these were not the aims
of this thesis. The relationships between total plasma
Cortisol and severity of illness and mortality can be use¬
fully interpreted and the response of the adrenal cortex to
ACTH may lead to meaningful conclusions.
Free Thyroid Hormones and Thyroxine Binding Globulin
As discussed in Chapter 1, the equilibrium between free and
protein-bound circulating thyroid hormones is altered during
illness. Total thyroid hormone concentrations are no longer
a useful surrogate measure of free thyroid hormone levels.
For the same reason, measurement of the concentration of
thyroid hormone binding proteins would not allow useful
conclusions to be drawn about free thyroid hormone avail¬
ability. If the concentration of binding proteins increased
during illness, the presence of binding inhibitors would
still be likely to result in increased concentrations of
free thyroid hormones. In fact, TBG concentrations are
normal or slightly reduced during illness (Chopra and Smith,
1975; Helenius and Liewendahl, 1979; Slag et al, 1981).
The need for serum free T4 measurement led to the develop¬
ment of the eguilibrium dialysis technigue (Sterling and
Brenner, 1966). This is technically demanding and so the T3
uptake test evolved as an estmate of the unoccupied T4
binding sites on serum TBG (Braverman et al, 1967). However,
the free T4 index (FT4I) has poor reliability in severely
ill patients in whom artefactually low FT4I values are
freguently encountered (Woeber and Maddux, 1981). In
recent years, the assay of free thyroid hormones has become
possible (Jackson and Ekins, 1986), and many clinical labor¬
atories now measure the free hormone directly rather than
measure total hormone. However, there is disagreement
between the direct and indirect methods of measuring free
thyroid hormone during critical illness (Kaptein et al,
1981; Vermaak et al, 1983; Surks et al, 1988). Melmed et al
(1982) reported a reduced FT4 by equilibrium dialysis in 43%
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of ICU patients. Commercial FT4 assays on the same patients
were subnormal in between 30% and 100% depending upon the
kit. Wang et al (1985) reported low FT4 values in ICU pa¬
tients using ultrafiltration and RIA methods. However, Surks
et al (1988) found that FT4 was normal in 30 ICU patients
using both ultrfiltration and eguilibrium dialysis. Finally,
Kaplan et al (1982) and Krenning et al (1987) reported
elevated FT4 values in 23% and 54% respectively of severely
ill patients.
Given the major difficulty in measurement and interpretation
of free thyroid hormone levels during illness, only total T3
and T4 levels were measured in this thesis. This limits any
comment on the possibility of hypothyroidism in the patients
studied and undermines any detailed understanding of the
altered control of the hypothalamic-pituitary-thyroid axis.
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Investigation of Adrenocortical Function
(1) Historical Background
(2) Anatomy, Biochemistry and Physiology of Adrenocortical Function
(3) The Concept of "Stress" and Adrenocortical Function
(4) Investigation of Adrenocortical Function
(1) Historical Background
The first detailed description of the adrenal glands, and their recogni¬
tion as an organ, was made in 1563 by Bartholomaeus Eustachius Sanctose-
verinatus in his treatise De Glandulis Quae Renibus Incumbunt. In 1849,
Thomas Addison presented a paper to the South London Medical Society,
entitled On Anaemia: Disease of the Suprarenal Capsules. In 1855 he
published a monograph, entitled On the Constitutional and Local Effects
of Disease of the Supra-Renal Capsules, in which he gave the first
description of chronic adrenocortical insufficiency. Early studies of
adrenal pathophysiology were conducted by men whose names are more often
linked with other fields of medicine. The year after Addison published
his monograph, Brown-Sequard discovered in animal experiments that the
adrenal glands are necessary for life. However, it was not until 1896
that Sir William Osier recognised the efficacy of orally administered
adrenal extracts in the treatment of Addison's disease.
The 20th Century has seen the elucidation of much of the biochemistry of
steroid hormones, and the mechanisms of regulation and control of adre¬
nocortical function. In 1926, Smith demonstrated that hypophysectomy led
to atrophy of the adrenals, and Evans succeeded in preventing this
atrophy by the administration of pituitary extracts. In 1942, Li and
Sayers isolated ACTH. In 1946, Seyle described his "General Adaption
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Theory" of adrenal function, and in 1948 Hench and collaborators detec¬
ted the anti-inflammatory effect of cortisone.
The development of radioimmunoassay during the late 1950s and the 1960s
coincided with a period of great advance in the chemistry of peptide
hormones. By 1962, Hofmann, Li, and Schwyzer had described the amino
acid sequence of ACTH, and in 1966, Schwyzer and Seiber succeeded in
synthesising the hormone. In the past decade corticotropin releasing
hormone [CRH] has been characterised and synthesised (Vale et al, 1981),
and many of the factors which control its secretion, such as opiates and
neural mechanisms, have been recognised.
(2) Anatomy, Biochemistry and Physiology of Adrenocortical Function
The functioning of the adrenal cortex is complex, and much of the
detail is beyond the scope of this thesis. However, in order to facili¬
tate discussion in later chapters, the basic anatomy, histology, bioche¬
mistry, and physiology of the adrenal cortex and control of the hypotha-
lamic-pituitary-adrenal [H-P-A] axis will be discussed. The adrenal
medulla is an embryologically, histologically, biochemically, and func¬
tionally different organ to the cortex, and will not be discussed.
The adrenal glands are paired organs lying in the retroperitoneal space,
anteromedial to the upper pole of the kidneys. In the adult human, the
size of the adrenal glands is about l/30th of that of the kidneys,
weighing between 3 and 5g, and measuring 5.0 cm in length, 2.5 cm in
width and only about 0.6 cm in thickness. The cortex develops from cells
of the coelomic epithelium and is therefore of mesodermal origin, while
the medulla is derived from the neural ectoderm. During illness the
adrenal glands hypertophy. Glands examined at autopsy after prolonged
illness have a mean weight of 6 g, and may weigh up to 9 g.
The blood supply to the adrenal gland derives from numerous small arter¬
ies arising from the inferior phrenic artery, aorta, and renal arteries.
The blood passes through the cortex and then medulla, the resulting high
intramedullary Cortisol levels being necessary for adrenaline synthesis.
Venous blood empties into a single vein, which enters the inferior vena
cava on the right, and the renal vein on the left.
The adrenal cortex constitutes approximately 80% of the gland, and is
divided into three distinct histological layers. The zona glomerulosa
comprises the outer 5% of the cortex, and is responsible for aldosterone
secretion. The zona fasciculata forms 70% of the cortex, and its cell
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columns are continuous with the cell groups of the zona glomerulosa. The
zona fasciculata is responsible for glucocorticoid and androgen secre¬
tion. The zona reticularis comprises the inner 25% of the adrenal cortex
and also produces glucocorticoids and androgens.
Among approximately 70 different steroids produced by the adrenal cor¬
tex, Cortisol, corticosterone, aldosterone, and androgenic steroids are
the main secretory products. During a 24 hour period the adult human
adrenal cortex secretes approximately 10 to 30 mg of Cortisol, 2 to 4 mg
of corticosterone, and 100 to 200 meg of aldosterone. The most prominent
androgens secreted by the cortex are androstenedione and dehydroepian-
drosterone.
Cholesterol is probably the precursor of all adrenal steroid hormones.
The cortex is second only to neural tissue in its stores of cholesterol
esters, which it derives mainly from plasma low density lipoproteins.
Cells are able to synthesise cholesterol de novo, but produce less than
20% of cholesterol used for hormone synthesis. The rate-limiting step in
steroid hormone synthesis involves cleavage of the side chain from the
27 carbon atom cholesterol molecule to form the 21-carbon steroid skele¬
ton, pregnenolone. The enzyme responsible is a desmolase complex con¬
taining a reaction-specific cytochrome P450.
Pregnenolone undergoes hydroxyoxidation and double-bond isomerisation in
the mitochondria, and 3 dehydrogenation reactions in the endoplasmic
reticulum to form Cortisol. Corticosterone and aldosterone are formed by
different combinations of hydroxlation reactions, but contain the same
basic carbon skeleton as Cortisol.
Cortisol diffuses rapidly into the circulation without significant
storage in the adrenal cortex. Cortisol represents approximately 80% of
total 17-hydroxysteroids in the blood. Steroid hormones are secreted
into the circulation as free hormones, where they bind to plasma pro¬
teins. Only free hormone is biologically active, and the amount of
hormone available to the tissues is determined by the equilibrium be¬
tween free and bound fractions. Between 3% and 10% of Cortisol is in the
free state. Of the remainder, 90% is bound to corticosteroid-binding
globulin [CBG] and 10% is bound to albumin. CBG is a glycoprotein syn-
thesised in the liver, containing one steroid binding site per molecule.
Albumin is present in the plasma in much higher concentration than CBG,
but binds Cortisol only very weakly.
The binding of corticosteroids to proteins such as CBG provides a reser-
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voir for the hormones in plasma, serves to dampen acute changes in
hormone levels, and protects the hormone against metabolic degradation.
During stress when Cortisol levels rise dramatically, the CBG binding
sites become saturated. Albumin sites do not, and under these circum¬
stances free Cortisol concentrations rise. Most studies of adrenocorti¬
cal function measure total Cortisol levels, and so factors which alter
binding protein levels are important. High CBG levels are found in
pregnancy and in women taking the contraceptive pill, due to oestrogens.
Low levels are seen in liver disease and states of protein loss. The
concentration of CBG is reported to be increased in severe illness
(Murray, 1967; Barnton and Passingham, 1981).
The liver and the kidney are the principal organs involved in clearing
steroid hormones from the circulation. Unconjugated steroids that are
filtered by the kidney are largely reabsorbed. Hepatic metabolism lead¬
ing to conjugation of steroids, mainly as glucuronides, serves two
functions: a decrease in biological activity of the hormones, and an
increase in their water solublity, thus enabling excretion by the kid¬
ney. The plasma half life of Cortisol is 60 - 100 minutes.
The adrenal steroids influence a wide variety of biochemical and physio¬
logical phenomena, and are essential for life. Steroid and thyroid
hormones share the same mechanism of action. These hormones diffuse
through the target cell membrane and interact with cytosolic hormone-
specific receptor proteins. There are 5000 to 100,000 glucocorticoid
receptors per cell. The hormone-receptor complex binds to specific DNA
sequences of the hormone responsive gene, leading to increased or de¬
creased gene transcription. The altered protein production is respons¬
ible for the hormonal response seen in that particular tissue.
There are six classes of steroid receptors, corresponding to the six
known biological activities of the steroid hormones: glucocorticoid,
mineralocorticoid, progestin, oestrogen, androgen, and vitamin D. A
given steroid hormone will exert an effects in tissues by its by inter¬
acting with the specific receptor that recognises that steroid. Cortisol
binds to two receptors, the glucocorticoid receptor and the mineralocor¬
ticoid receptor. Steroids may exert more than one effect in a given
tissue if they interact with more than one receptor in that tissue. The
relative affinity of a steroid for each receptor is a major determinant
of the bioactivity of that hormone. Cortisol is a potent glucocorticoid
with definite, but much weaker, effects on electrolyte and water meta-
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bolism. Aldosterone exerts its prime actions on electrolyte and water
metabolism, with less than one third the potency of Cortisol for gluco¬
corticoid receptors. In some tissues, Cortisol exerts very litle miner-
alocorticoid activity due to its inactivation by a receptor-associated
enzyme.
A given steroid may also exert diverse biological effects in different
tissues. The diversity of hormonal responses is determined by the dif¬
ferent genes that are regulated by the hormone in different tissues.
Glucocorticoids, for example, exhibit primarily metabolic effects in the
liver and primarily anti-inflammatory effects in lymphoid tissue. A
large number of genes can be regulated by steroid hormones. It should
also be noted that steroids also exert effects not mediated by classical
intracellular receptors, but possibly by actions in the cell membrane.
Since this thesis is primarily concerned with the glucocorticoid func¬
tion of the adrenal cortex, the actions of other steroid hormones will
not be discussed.
Cortisol interacts in a permissive fashion with other hormones, includ¬
ing insulin, glucagon, catecholamines, and growth hormone, to achieve
full homeostasis. Excess Cortisol increases hepatic glycogen and glucose
production and decreases glucose uptake and utilisation in peripheral
tissues, thereby tending to cause hyperglycaemia. Cortisol deficiency
has exactly the opposite effect. Glucocorticoids increase free fatty
acid levels by enhancing lipolysis, decreasing cellular glucose uptake,
and decreasing glycerol production which is necessary for the reesteri-
fication of fatty acids. Glucocorticoids exert a generally catabolic
effect on protein metabolism, with proteolysis in fat, skeletal muscle,
bone, lymphoid, and connective tissue. This increases amino acid sub¬
strates which can be used in gluconeogenesis. Cardiac muscle and the
diaphragm are almost entirely spared from this catabolic effect.
The physiological role of glucocorticoids in immune regulation is not
well understood. At high concentrations they inhibit most immunologic
and inflammatory responses. Glucocorticoids stabilise lysosomes and
inhibit prostaglandin synthesis and the actions of bradykinin. They
block histamine and slow-reacting substance of anaphylaxixs, and inhibit
production of cytokines. These actions inhibit vasoactive substances and
diminish the inflammatory process. Glucocorticoids cause lymphocytopenia
with a relative T-cell depletion, monocytopenia, and eosinopenia, while
increasing polymorphonuclear cell release. They tend to inhibit cell-
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mediated immunity, but have little effect on antibody production.
Glucocorticoids have a positive inotropic effect on the heart, increas¬
ing left ventricular work index (Davies et al, 1981). Moreover, they
have a permissive effect on the actions of adrenaline and noradrenaline.
In glucocorticoid deficiency, decreased cardiac output and shock may
develop (Dorin and Keanrns, 1988; Melby et al, 1988), and steroid excess
causes hypertension (Nasjletti et al, 1984). Glucocorticoids also influ¬
ence renal physiology. They increase glomerular filtration rate and
renal blood flow, and lead to an increase in free water clearance (Noda
et al, 1983). Glucocorticoids also have effects on bone, connective
tissue, gastrointestinal tract, blood constituents, and the central
nervous system, which are not of major relevance to this thesis and are
detailed elsewhere (Pescovitz et al, 1990).
The actions of glucocorticoid hormones are seen most clearly in "stress"
situations, when glucocorticoid secretion can increase almost ten fold.
This is believed to enhance survival through increased cardiac output,
increased sensitivity to the pressor effects of catecholamines, in¬
creased work capacity of skeletal muscles, and increased capacity to
mobilise energy through gluconeogenesis, proteolysis, and lipolysis.
Regulation and control of Cortisol concentration
Plasma Cortisol concentration is dependent upon Cortisol secretion by
the adrenal cortex, the degree of protein binding, and the rates of
metabolism and excretion of the hormone. In health, short term changes
in concentration are mainly determined by changes in Cortisol secretion.
Binding, metabolism and exceretion remain relatively constant in compar¬
ison. Cortisol secretion is regulated by the hypothalamic-pituitary-
adrenal axis. Cortisol secretion is directly dependent on the plasma
concentration of ACTH. ACTH is a 39 amino acid peptide produced by the
anterior pituitary gland from a larger precursor known as pro-opiomela-
nocortin [POMC]. ACTH interacts with membrane-bound receptors on adreno¬
cortical cells which activate adenylate cyclase and increase intracellu¬
lar cyclic-AMP [cAMP]. This, in turn, activates a protein kinase which
ultimately leads to conversion of cholesterol to pregnenolone. ACTH also
enhances the later steps in steroidogenisis, increasing uptake of cho¬
lesterol from the plasma lipoproteins, and promoting protein synthesis
in the cortex, thus maintaining the size of the adrenal gland. It ap¬
pears that increased cholesterol uptake from plasma is the main point of
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regulation by ACTH. ACTH has a number of extra-adrenal effects, the best
known of which is its lipolytic action on adipose tissue.
Cortisol secretion is therefore indirectly controlled by those factors
which determine ACTH secretion. In common with the other anterior pitui¬
tary hormones, ACTH secretion is principally dependent on factors
released by the hypothalamus. The anterior pituitary gland or adenopo-
physis has no direct neural connection to the hypothalamus or other
parts of the brain. Factors produced in the hypothalamus which are
responsible for release or inhibition of release of hormones by the
adenophysis reach their target cells via the hypophysial-portal venous
system. Transfer of neuroregulators from hypothalamic neurones to the
pituitary blood supply takes place in an anatomically specialised region
of the ventral hypothalamus known as the median eminence or tuberoinfun-
dibular region. The tuberoinfundibular neurones projecting to this
region terminate in close proximity to capillary walls within the median
eminance, which drain into the venous system, that in turn supplies the
sinusoids of the adenophysis.
The principal hypothalamic factor responsible for control of ACTH secre¬
tion is corticotropin-releasing hormone [CRH]. CRH is among the more
widely distributed neuroendocrine peptides and is also found outside the
CNS eg. in peripheral leukocytes. However, the paraventricular nucleus
of the hypothalamus [PVN] has been convincingly implicated as the source
of adenophysisotropic CRH (Makara et al, 1981). Specifically, the major¬
ity of CRH-immunoreactive neurones are located in the dorsal aspect of
the medial parvocellular subdivision of this nucleus (Swanson et al,
1983). This is supported by the finding that CRH mRNA and peptide levels
in the parvocellular neurosecretory zone of the PVN, and peptide content
of the median eminence and hypophyseal portal plasma are markedly upre-
gulated by corticosteroid withdrawal (Keller-Wood and Dallman, 1984;
Swanson and Simmons, 1989) in keeping with the negative feedback of
glucocorticoids on the hypothalamus. However, in addition to the parvo¬
cellular cells projecting to the median eminence, CRH-staining neurones
are also found in other parts of the PVN, where they project to other
neural sites including the brainstem and, in particular, the locus
ceruleus.
Although CRH is the primary and obligatory hypothalamic ACTH secretago-
gue, there are a number of other intrinsically weaker secretagogues,
including arginine vasopressin [AVP], oxytocin and adrenaline (Plotsky,
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1991). Vasopressin is considered to be the major secondary regulator of
ACTH release. These and other peptides are produced by the hypothalamic
CRH neurones and are capable of interacting with CRH to stimulate ACTH
secretion. Moreover, other hypothalamic cell types, notably magnocellu-
lar neurosecretory neurones may produce peptides which modify ACTH
secretion (Holmes et al, 1986). Opioid peptides, including fragments of
POMC, endorphins, and encephalins also inhibit CRH and vasopressin re¬
lease. The clinical relevance of these endogenous opioids is unclear. Of
direct relevance to intensive care patients, pharmacological doses of
exogenous opioids have been shown to suppress the H-P-A axis and reduce
Cortisol concentration, in contrast to naloxone which increases plasma
Cortisol levels (Ferri et al, 1980). Pharmacological doses of catecho¬
lamines inhibit ACTH release (Weiner and Ganong, 1978), but intravenous
adrenaline has been shown to markedly increase plasma Cortisol levels
(Tilders et al, 1985).
The H-P-A axis responds to a wide variety of stresses and a number of
disparate stress paradigms are capable of modifying CRH mRNA levels as
well as CRH release (Lightman and Young, 1988; Herman et al, 1989). The
H-P-A axis acheives a balance between the positive drive by various
forms of stress and the negative feedback regulation by corticosteroids.
Cortisol and synthetic adrenocortical hormones exert an inhibitory
effect on hypothalamic CRH secretion, as well as on ACTH secretion by
anterior pituitary corticotrophs, which parallells their glucocorticoid
and anti-inflammatory activity. Thus prednisolone is five times more
inhibitory than Cortisol and dexamethasone forty times more inhibitory.
The administration of high doses of glucocorticoids leads to gradual
functional impairment and atrophy of the adrenal cortex, which is pre¬
vented by concomitant administration of ACTH. In man, ACTH secretion is
completely suppressed by daily administration of 75 mg of cortisone
acetate, and adrenal atrophy develops rapidly.
In keeping with the great diversity of stimuli capable of inducing a
stress response, the hypophsysiotropic zone of the PVN is known to re¬
ceive a rich afferent innervation. The afferent sources may be grouped
into four classes (Sawchenko and Swanson, 1985). Firstly a series of
mainly catecholaminergic pathways relay visceral sensory information
from the nucleus of the tractus solitarius. These convey imputs from the
thoracic and abdominal viscera via the vagus and glossopharyngeal
nerves. Secondly, nearly all cell groups in the hypothalamus send pro-
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jections to the hypophysiotropic zone of the PVN, allowing integration
of the H-P-A axis with other neuroendocrine, autonomic and behavioural
regulatory mechanisms. Thirdly, a number of cell groups in the limbic
region of the telencephalon, including portions of the amygdaloid and
hippocampal complex, are thought to exert tonic inhibitory influences on
neuroendocrine functioning. More specifically, these areas are thought
to be potential sites for corticosteroid negative feedback on CRH secre¬
tion (Kovacs and Makara, 1988). Finally, a series of interconnected cell
groups constituting the lamina terminalis (the rostral margin of the
third ventricle), which lie outside the blood-brain barrier, may allow
blood-bourne factors, such as angiotensin II, to influence the H-P-A
axis (Gross, 1987). Emotional and other conscious stimuli are thought to
to traverse vaguely defined corticolimbic pathways funnelling to the PVN
via the bed nucleus of the stria terminalis, the lateral and medial
septum and the preoptic area (Gray, 1991).
In summary, the hypothalamus receives several stress related imputs and
responds by altering secretion of CRH and a number of other intrinsical¬
ly weaker ACTH secretagogues. The exact mechanisms by which the hypotha¬
lamus synthesises the various imputs are beyond the scope of this thesis
and for the most part remain to be determined.
The influence of cytokines on the hypothalamic-pituitary-adrenal axis
The specific interaction of cytokines with the H-P-A axis has been the
subject of much recent study. The febrile activity of bacterial and
other exogenous pyrogens was known to be mediated by an endogenous
pyrogen, which is now considered to be predominantly IL-1. Besedovsky et
al (1986) first reported that systemic administration of recombinant IL-
1 into mice caused a marked increase in plasma ACTH and corticosterone
levels. This work has been confirmed by several others using IL-1, and a
number of other cytokines, and it is now evident that cytokines activate
the H-P-A axis and mediate, at least in part, the response of the axis
to a variety of noxious insults.
Injection of IL-1 causes a prompt rise in plasma ACTH, with the peak
appearing at 30 minutes after intravenous injection (Uehara et al, 1987)
and 2 hours after intraperitoneal injection (Besedovsky et al, 1986).
Intracerebroventricular injection is more potent (Katsura et al, 1988)
suggesting that the site of action of IL-1 is in the central nervous
system. Intravenous injection of interleukin-6 [IL-6] and TNF-alpha have
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a similar though smaller effect on plasma ACTH in rats (Naito et al,
1988). The effect of IL-1, IL-6 and TNF-a on ACTH is abolished by pre-
treatment with CRH-antisera (Salposky et al, 1987). Interleukin-2 [11-2]
also has an ACTH-stimulating effect, but acts more slowly, reaching a
peak at 4 hours in man, and is unaffected by pre-treatment with CRH-
antisera (Lotze et al, 1985), suggesting a site of action other than the
hypothalamus. The ACTH-stimulating activity of cytokines can be disso¬
ciated from the pyrogenic activity (Naito et al, 1990), suggesting that
fever itself is not the factor causing activation of the H-P-A axis.
Cytokines are large molecules and should not, in theory, cross the
blood-brain barrier. Their site of action within the central nervous
system is not clear, but the action may be mediated by prostaglandin
release.
In-vitro studies have shown a stimulatory effect of IL-1 on murine and
human pituitary corticotrophs (Malarkay and Zvara, 1989), but the effect
follows a latent period of over 6 hours suggesting stimulation of pro¬
duction from the POMC gene rather than any effect on ACTH release. 11-2
and IL-6 also appear to have a similar effect (Fukata et al, 1989). TNF-
alpha appears to have no effect on pituitary corticotrophs in-vitro
(Kehrer et al, 1988). The physiological implications of such in-vitro
experiments are unclear.
Cytokines may act directly on the adrenal cortex, bypassing hypothala-
mic-pituitary control. 11-1, IL-2, IL-6, and TNF-alpha increase corti-
costerone release from dispersed rat adrenal cells (Tominaga et al,
1991). This effect of IL-1 has been confirmed in-vivo in rats (Roh et
al, 1987), but the effect was abolished by indomethacin, suggesting
mediation by prostaglandins.
There is evidence that a variety of cytokines activate the H-P-A axis at
all levels. 11-1 appears to be the most important, and this is confirmed
by the observation that IL-1 receptor antibody blocks the ACTH response
to lipopolysaccharide (River et al, 1989). The central nervous system
mediated effect is rapid and appears to depend upon CRH release, whereas
stimulation of ACTH production by corticotrophs and Cortisol release by
the adrenal cortex is slower and likely to be due to increased biosynth¬
esis of ACTH and Cortisol.
Glucocorticoids inhibit CRH release induced by IL-1 (Cambronero et al,
1989), and inhibit the production of IL-1 by peritoneal macrophages.
High IL-1 levels in endotoxic shock are reduced by dexamethasone treat-
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ment (Staruch and Wood, 1985). Therefore, there seems to be a complex
feedback system. Glucocorticoids exert negative feedback on the pitui¬
tary gland and hypothalamus, and also inhibit the H-P-A activation in¬
duced by cytokines. To what extent cytokines influence the H-P-A axis in
health is unclear, but the very high concentrations of cytokines found
in critical illness and sepsis (Michie et al, 1989; Calandra et al,
1991; Fisher et al, 1993) may alter the normal control of the H-P-A
axis.
(3) The Concept of "Stress" and Adrenocortical Function
"Stress Is certainly one of the most grandly
imprecise terms in the lexicon of science"
(Ganong 1963)
The development of the stress concept mirrors the evolution of biologi¬
cal and medical thinking. Claude Bernard's ideas regarding regulation of
the milieu interieur included the notion that the organism is capable of
counteracting external stimuli which would threaten the maintenance of
the internal balance. Cannon (1929) introduced the concept of homeosta¬
sis as a closed system of processes which defend the dynamic equilibrium
against external forces. It was Seyle (1936) who coined the term
"stress" to describe these external forces. Seyle developed his theory
of the "General Adaption Syndrome" after finding, in animal experiments,
that injection of a crude ovarian extract caused the same response as
the injection of any other toxic substance: adrenal hypertrophy, atrophy
of the thymus and gastric ulceration. He developed the concept that the
body reacts in the same way to any nonspecific noxious agent or tissue
damage. It was soon realised that this response was due in major part to
activation of adrenocortical secretion.
The concept of the General Adaption Syndrome includes three stages,
alarm reaction, resistance, and exhaustion. Cannon proposed that the
initial alarm reaction was an adrenomedullary response mediated by the
sympathetic nervous system. This results in arousal and a number of
physiological changes including tachycardia, glycogen breakdown and
lypolysis, providing the energy for the fight or flight reaction. This
is complemented by the adrenocortical reaction, starting a few minutes
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later, which serves to limit the consequences of the primary reflex by
suppressing tissue reactions to damage and the immune reaction to anti¬
gens, and leads to stimulation of protein breakdown and carbohydrate
formation.
The mechanism by which release of ACTH was induced by stress was un¬
clear. Long (1947) observed that adrenaline was a powerful stimulus for
ACTH secretion, and proposed that the adrenomedullary alarm reaction
directly induced ACTH secretion. However, it was soon found that removal
of the adrenal medulla did not prevent the adrenocortical stress re¬
sponse (Gordon, 1950; Vogt, 1951). Fortier (1951) was first to subdi¬
vide stress stimuli, and proposed that "neural" stimuli, such as pain
and fear, required intact neural connections to the hypothalamus,
whereas "systemic" stimuli, such as tissue damage or toxic agents might
stimulate the pituitary gland directly. Work with hypothalamic lesions
again suggested different pathways subserving neurogenic and systemic
stimuli. Smelik (1959) found that posterior hypothalamic lesions inhibi¬
ted the adrenal response to painful and emotional stimuli, but enhanced
the response to traumatic or systemic stimuli.
In the 1960s there was growing conviction that release of hypothalamic
CRF was the final common pathway for pituitary ACTH release, the hypo¬
thalamic cells being reached by both the circulation and neural connec¬
tions. The hypothalamic deafferentation technique, introduced by Halasz
and Pupp (1965), helped to confirm this. A number of stimuli, including
anoxia (Feldman et al, 1970), anaesthesia (Vermes et al, 1973) and
endotoxin (Makara et al, 1970), appeared to be capable of releasing ACTH
after complete neural isolation of the hypothalamus. The ACTH response
to painful stimulation of hind limbs in animal experiments is abolished
by peripheral nerve or spinal cord section (Greer et al, 1970). The
hypothalamic connections subserving the effects of visual and auditory
stimuli on ACTH release have also been defined (Feldman et al, 1972).
Although it is now accepted that the majority of stresses induce the
adrenocortical response via their effect on the hypothalamus, there is
evidence that certain factors act directly on the pituitary gland.
Eshericia coli endotoxin has been shown to stimulate ACTH secretion
after pituitary stalk section (Makara et al, 1971), and a number of
cytokines, including IL-1 (Fukata et al, 1989), IL-2 (Smith et al, 1989)
and IL-6 (Fukata et al, 1989), stimulate ACTH release from pituitary
cell suspensions in vitro.
65
Whilst, the mechanisms underlying Seyle's General Adaption Theory are
now becoming clear, it is increasingly recognised that very minor physi¬
cal and emotional stimuli also increase Cortisol secretion. It is diffi¬
cult, if not impossible, to differentiate between "stress" and everyday
life, and it is therefore preferable to consider the adrenocortical
system as a servomechanism which continuously follows the changing
demands of the environment, rather than a system intended to respond to
specific insults.
(4) Investigation of Adrenocortical Function
The majority of reviews of the investigation of adrenocortical function
are confined to the diagnosis of adrenal hyperfunction or hypofunction
in otherwise healthy individuals (Muller, 1986; Stewart et al, 1988;
Clayton, 1989). There is no published work concerning the validation of
standard adrenocortical function tests in intensive care patients.
Indeed, the standard approaches to testing adrenocortical function may
be inappropriate in critically ill patients with high Cortisol concen¬
trations. Despite the obvious difficulties, some workers have applied
the standard normal range of plasma Cortisol concentration to severely
ill patients. For example, Span et al (1992), in a study of 159 ICU pa¬
tients, concluded that because all patients had basal Cortisol concen¬
trations of greater than 250 nmol/1, there was no hypoadrenalism.
Strictly speaking, this conclusion would not be valid in healthy indi¬
viduals, and may be quite wrong in critically ill patients. Many ICU
patients have plasma Cortisol levels over ten times normal (Sainsbury et
al, 1981; Jurney at al, 1987; Schein et al, 1990), and an ability to
significantly increase Cortisol concentration in response to acute
illness is necessary for survival (Sibbald et al, 1977; Hinshaw et al,
1985). The increase in Cortisol concentration, and the degree of adreno¬
cortical responsiveness necessary, will depend on the type and severity
of the illness, and so a normal range for "illness" is inappropriate.
The standard adrenocortical function tests used in this thesis are
detailed below. The normal ranges for results in healthy populations are
given, but should not be applied in critically ill patients. One of the
aims of this work is to define normal ranges for tests of adrenocortical
function during critical illness.
Measurement of plasma Cortisol was discussed in Chapter 2. It is pos-
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sible to measure ACTH using RIA techniques. However, ACTH is unstable in
whole blood and plasma and also adsorbs strongly onto glass surfaces.
Rapid centrifugation and transfer to the laboratory are necessary. It is
the definitive test in differentiating between primary and secondary
adrenal failure, when very clear differences in ACTH concentration will
be found. In the setting of normal or mildly abnormal adrenocortical
function single ACTH measurements give little information. ACTH has been
measured in critical illness, but did not yield much useful information
(Vaughan et al, 1982; Barton et al, 1987). ACTH concentration does not
correlate with plasma Cortisol concentration (Vaughan et al, 1982). This
is, however, not unexpected in view of the episodic nature of ACTH
secretion.
Dynamic Tests of Adrenocortical Function
Dynamic endocrine tests provide additional information to that obtained
from measurement of single hormones or of trophic-target gland hormone
pairs. Such tests are based on either the stimulation or the suppression
of endogenous hormone production. Stimulation tests are utilised most
often when hypofunction of an endocrine organ is suspected, and are
designed to assess the reserve capacity of the organ to form and secrete
a hormone. The trophic hormone is usually an hypothalamic or pituitary
hormone.
The Standard ACTH Stimulation Test
There are many protocols for ACTH stimulation tests, but each aims to
assess the adrenocortical response to synthetic ACTH. These tests are
safer and at least as informative as the insulin tolerance test, and
have therefore replaced it as the standard tests of adrenocortical
reserve. The standard test in North America is the 8 hour intravenous
ACTH test, where 25 IU of ACTH is given as a constant infusion over 8
hours and multiple blood samples are taken for Cortisol measurement. In
the UK, the short Synacthen test or standard ACTH stimulation test, is
most widely used as the initial screening test of adrenocortical func¬
tion. It is more convenient than the 8 hour test and equally informative
(Lindholm et al, 1987).
The standard ACTH stimulation test was developed in the 1960s (Ney et
al, 1963; Wood et al, 1965; Grieg et al, 1966). The synthetic 24 amino
acid polypeptide ["Synacthen", Ciba] used in the test has equivalent
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activity to natural corticotropin (Landon et al, 1964). Corticotropin
stimulation testing had been described previously, but earlier workers,
using ACTH derived from animal pituitary extracts, had used indirect
measures of the glucocorticoid response such as eosinophil count and
urinary sodium/potassium ratio (Prunty, 1964). Wood et al (1965) de¬
scribed a rapid test which involved measuring plasma Cortisol by fluori-
metric assay immediately before and 30 minutes after an intramuscular
injection of 250 meg Synacthen. They demonstrated the ability of the
test to differentiate between normal controls, patients receiving ster¬
oids, and patients with Addison's disease. This work has been repeated
and the test altered and further validated by numerous workers (Speckart
et al, 1971; Nelson and Tindall, 1978; Lindholm and Kehlet, 1987). The
most frequently used variation now involves the intravenous administra¬
tion of 250 meg Synacthen, with measurement of plasma Cortisol at 30 and
60 minutes thereafter. This method has been shown to produce a Cortisol
response which correlates very closely with the response to a standard
insulin hypoglycaemia test (Kehlet et al , 1976; Stewart et al, 1988),
and which is independent of age and sex (Jensen et al, 1988), basal
Cortisol concentration and time of day (Dickstein et al, 1991). Compari¬
sons of this standard ACTH stimulation test with the metyrapone test
indicate that the test reliably assesses integral H-P-A function (Kehlet
et al, 1976) .
There is disagreement as to how a normal Cortisol response to the stan¬
dard ACTH stimulation test should be defined (Wood et al, 1965; Musa and
Dowling, 1967; Greig et al, 1969; May and Carey, 1985). Various diagnos¬
tic criteria, based on the basal Cortisol concentration (Greig et al,
1986), the stimulated Cortisol concentration (Dluhy et al, 1974), or the
difference between them (Greig et al, 1967), have been proposed. There
is some evidence that these three values may be independent (Kukreja and
Williams, 1981; May and Carey, 1985). Although recent editions of the
standard textbooks of endocrinology suggest that the Cortisol increment
is used (Bondy, 1985; Baxter and Tyrrell, 1987), most recent workers
conclude that the peak Cortisol concentration is the best criterion with
which to define a normal response to a standard ACTH stimulation test
(Dickstein et al, 1991; Lindholm an Kehlet, 1987). A useful compromise
is a peak plasma Cortisol concentration of greater than 500 nmol/L
and/or an increment in Cortisol concentration of greater than 200nmol/L
at 30 minutes (Crowely et al, 1991). All the above workers have defined
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the normal response to a standard ACTH stimulation test by identifying
the line of demarcation between the response to ACTH in patients dia¬
gnosed by other methods to be suffering from hypoadrenalism and the
response of individuals with apparently normal adrenocortical function.
As discussed in Chapter 1, this approach is not entirely appropriate to
investigation in critical illness.
The optimum time to sample blood for Cortisol following injection of 250
meg ACTH appears to be between 15 and 30 minutes (Crowley et al, 1991;
Dickstein et al, 1990). It has been suggested that in order to observe
the peak Cortisol response sampling should be carried out at 5 minute
intervals for the first 30 minutes following injection of ACTH (Crowley
et al, 1991), but this is expensive and there is little reduction in
Cortisol concentration between the peak and the 30 minutes sample
(Leclerecq et al, 1972).
Safety of Intravenous ACTH
Intravenous administration of Synacthen appears to be safe. Earlier use
of corticotropin from animal pituitary extracts was associated with a
significant risk of allergic reaction (Wood et al, 1965). This may have
been due to the different amino acid sequence in human corticotropin or
to impurities. The corticotropin content of the extract was difficult to
quantify and early tests were occasionally complicated by steroid rela¬
ted side-effects such as cardiac failure. Synacthen has an identical
amino acid sequence to the first 24 amino acids of the N-terminal end of
human ACTH, and should not, therefore, cause any significant allergic
reaction. Hypersensitivity reactions and, in one instance, death (Muller
et al , 1982) have been reported following the use of Synacthen. This
may be related to the markedly supraphysiological dose which is adminis¬
tered in the standard test.
The Low Dose ACTH Stimulation Test
The standard ACTH stimulation test uses a dose of ACTH sufficiently
large to achieve maximal adrenocortical secretory capacity. It is there¬
fore a measure of adrenocortical reserve rather than adrenocortical
sensitivity to ACTH. A normal Cortisol response to 250 meg Synacthen
does not necessarily indicate normal adrenal sensitivity to ACTH. In¬
deed, a normal response may be seen in steroid-treated patients who
subsequently fail to respond adequately to insulin-induced hypoglycaemia
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(Cunningham et al, 1983). It can be argued that the use of a pharmacolo¬
gical dose of ACTH is excessive and contributes to confusion in the
interpretation of results.
Recent work has confirmed observations by Landon et al (1967) that the
adrenal cortex responds to very low "physiological" doses of ACTH. This
has led to the development and standardisation of low dose ACTH stimula¬
tion tests (Graybeal and Fang, 1985; Crowley et al, 1991; Dickstein et
al, 1991). Doses of Synacthen as low as 0.5 meg (Crowley et al , 1991)
and 1.0 meg (Dickstein et al, 1991) produced a maximal Cortisol response
by 30 minutes. A dose of 0.09 meg ACTH produces a Cortisol response
greater than 200 nmol at 15 mins in some patients (Crowley et al, 1991).
In other words, the standard dose of Synacthen may be over 500 times
greater than is necessary to maximally stimulate the adrenal cortex.
Some patients on long-term low dose steroid treatment have a normal
response to 250 meg Synacthen, but a reduced response, compared with
controls, to 1.0 meg (Dickstein et al, 1991), suggesting reduced adreno¬
cortical sensitivity to ACTH. More work is required to fully validate
low dose ACTH stimulation tests, but they may be able to detect subtle
alterations in sensitivity of the adrenal cortex to ACTH, not apparent
on standard dose testing. The rise in plasma Cortisol after low doses of
ACTH is of much shorter duration and returns to baseline values in all
subjects by 90 mins (Crowley et al, 1991). It seems possible, therefore,
that a low dose of ACTH will facilitate release of immediately available
Cortisol, while a pharmacological dose of 250 meg, used in a standard
ACTH stimulation test, probably induces further synthesis or mobilisa¬
tion from other pools to sustain the rise.
The Depot ACTH Stimulation Test
If a patient suspected of having adrenocortical insufficiency has an
inadequate response to a standard ACTH stimulation test, then further
investigation is required. The next stage is a depot ACTH stimulation
test, in which the Cortisol response to 1000 meg of an ACTH/zinc phos¬
phate intramuscular depot injection is measured. Samples are taken for
Cortisol measurement at hourly intervals for 5 hours after the injec¬
tion. If the plasma Cortisol level increases by more than 100% then
primary adrenocortical insufficiency can be ruled out [Ismail et al,
1981]. The basal level usually doubles within the first hour and then
rises more slowly. The expected values in health are as follows: 1 hour,
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600-1250 nmol/1; 2 hours, 750-1500 nmol/1; 3 hours, 800-1550 nmol/1; 4
hours, 950-1650 nmol/1; 5 hours, 1000-1800 nmol/1. An initial normal
rise followed by a rapid and sustained fall suggests a limited adreno¬
cortical reserve capacity, and indicates abnormal adrenal function.
There have been no studies of depot ACTH stimulation tests in severe
illness.
Adrenal atrophy due to long-term steroid therapy or pituitary failure
may result in an abnormal depot ACTH stimulation test. In this situation
a three day Synacthen test is required to differentiate these from
primary adrenocortical insufficiency. In this test 24 hour urine samples
are collected for 5 consecutive days and urinary free Cortisol and
urinary 17-OHCS measured. On the mornings of days 3 to 5, 1000 meg
intramuscular depot Synacthen is given. In the majority of patients with
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The main aims of the studies detailed in this chapter were
as follows:
1) To determine the relationship between plasma Cortisol
concentration and severity of illness, as measured by APACHE
II scores during critical illness, and to define normal
ranges for plasma Cortisol concentration at different levels
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of illness severity.
2) To define the range of Cortisol responses to standard
dynamic tests of adrenocortical function during critical
illness.
3) To determine whether or not ICU patients with low con¬
centrations of Cortisol, taking into account the severity of
illness, or impaired responses to dynamic tests of adreno¬
cortical function have a higher than expected mortality.
(2) Patients and Methods
The background to the tests of adrenocortical function
detailed in this chapter was given in Chapter 3. The setting
in which the investigations were performed was given in
Chapter 2. All dynamic tests of adrenocortical function de¬
tailed in this chapter were performed in accordance with the
protocol given in Appendix 1. Apache II scores were calcu¬
lated for each patient on the day of each test.
(a) Admission Plasma Cortisol Measurement
Blood was taken for plasma Cortisol estimation in 260 conse¬
cutive admissions not receiving steroids or dopamine. Blood
was sampled, stored, and assayed as detailed in Chapter 2.
All samples were taken within 2 hours of admission. If
possible, blood was taken prior to commencement of sedation
or inotropes. A note was taken of all medications received
in the past 24 hours, and whether or not the patient had
received steroids in the past 28 days. APACHE II scores
were calculated on data collected during the first 24 hours
73
of admission. The physicians caring for the patients had
access to the results of the Cortisol assay.
(b) Standard ACTH Stimulation Tests
Corticotropin stimulation tests were performed in 79 pa¬
tients. Thirty two of these patients were suffering from
septic shock and are dealt with in more detail below. The 47
patients not suffering from septic shock were consecutive
admissions to the unit who fulfilled the following criteria:
a) acute illness of less than 28 days duration; b) no ster¬
oid medication in the past month; c) no history of active
tuberculosis or adrenal disease; d) no recent treatment with
etomidate. Although these patients were not suffering from
septic shock, a proportion showed evidence of secondary
organ failure. Patients with clinical evidence of infection
or positive blood cultures, but who were not shocked were
included.
Of the 47 non-shocked patients investigated 25 were female
and 22 male. Mean age was 62 years (range 23 - 84). The
primary diagnoses were: abdominal surgery for malignancy
(11); abdominal surgery for a non-malignant condition (8);
pneumonia or respiratory failure (10); pelvic or urological
surgery (5); septicaemia (5); upper gastrointestinal hae¬
morrhage (2); Guillain-Barre syndrome (2); others (6).
Corticotropin stimulation tests were performed on the second
morning after admission, unless the patient was undergoing
haemodialysis or any other procedure likely to compromise
the validity of the test. In these cases the test was per-
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formed on the next day. All tests were performed between
0900h and 1200h.
A baseline blood sample was taken and 0.25 mg tetracosactrin
("Synacthen", Ciba) was given as an intravenous bolus in 5ml
sterile water. Two further blood samples were taken 30 and
60 minutes after the injection, and plasma Cortisol was
measured. The Cortisol response was defined as the differ¬
ence between the basal concentration and the higher of the
30 and 60 minute concentrations.
ACTH stimulation tests were performed in 32 patients suffer¬
ing from septic shock. Patients were investigated if they
had a clinical diagnosis of septic shock, fulfilled the
criteria stated above for non-shocked patients and the
following additional criteria: a) reguiring inotropic sup¬
port in order to maintain mean arterial blood pressure above
80 mm Hg; b) urine output less than 20 ml/hour.
Eighteen men and fourteen women met these criteria. Mean age
was 59 years (range 25 - 86). The primary diagnoses were
pneumonia (16), peritonitis (11), wound infection (2),
pelvic abscess (1), salmonella enteritis (1) and acute pan¬
creatitis (1). In these patients, the test was performed
within 48 hours of the onset of shock in patients who deve¬
loped septic shock following admission. In those patients
who were admitted already fulfilling our criteria for septic
shock, the test was performed within 48 hours of admission.
All tests were performed between 0900h and 1200h. Patients
with septic shock received standard treatment. Adrenaline
infusions, with or without dobutamine, were used for inotro-
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pic support and all patients received low dose dopamine
infusions (2mcg/kg/min).
Patients with established acute renal failure were treated
with intermittent haemodialysis. At the time of the test 25
of the patients with septic shock and 28 non-shocked pa¬
tients reguired respiratory support using mechanical venti¬
lation with or without positive end expiratory pressure
(PEEP). The results of the ACTH stimulation tests were
available to the clinicians caring for the patients. No
patient received steroid treatment.
(c) Low Dose ACTH Stimulation Tests
Low dose ACTH stimulation tests were performed in 10 non-
shocked patients, 10 patients suffering from septic shock,
and 5 healthy controls. In Patients who had had a standard
ACTH stimulation test previously, the low dose test was
performed only after at least 24 hours had elapsed.
The controls comprised 2 men and 3 women with a mean age of
27 years (range 19 - 34). The non-shocked cases comprised 6
men and 4 women with a mean age of 56 years (range 34 - 76).
The septic shock patients comprised 5 men and 5 women with a
mean age of 59 years (range 47 - 69).
The low dose corticotropin stimulation test was performed
using 10 meg tetracosactrin (4% of the standard dose). One
vial of tetracosactrin was diluted in 49 ml sterile 0.9%
saline giving a concentration of tetracosactrin of 5 mcg/ml.
The solution was mixed in a plastic container and 2.0 ml was
withdrawn into a plastic syringe. The injection was given
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within 10 minutes of the tetracosactrin being diluted. The
remaining solution was discarded and a new solution made up
for each patient. The low dose test was performed in the
same manner as the standard dose test. All tests were per¬
formed between 0900h and 1200h.
(d) Depot ACTH Stimulation Tests
Five patients suffering from septic shock who had undergone
a standard ACTH stimulation test previously and in whom the
higher of the post-ACTH stimulation plasma Cortisol levels
was less than 1000 nmol/L, and who were still suffering from
septic shock, were further investigated with a 5 hour depot
ACTH stimulation test. Two women and three men were invest¬
igated. Mean age was 63 years (range 54 - 78). The same
control cases used for the low dose ACTH stimulation tests
were investigated again.
Immediately after the basal blood sample was taken, lmg of
depot tetracosactrin (Ciba Laboratories, UK) was given as an
undiluted 1 ml injection into deltoid muscle. Further blood
samples were taken for plasma Cortisol measurement at
1,2,3,4 and 5 hours after injection. The injection was
given at 0900h.
(e) Serial Plasma Cortisol Measurements in Septic Shock
Ten consecutive patients suffering from septic shock were
investigated. Following the standard ACTH stimulation test a
further blood sample was taken for plasma Cortisol measure¬
ment at 1800h on the same day. Subsequent samples were taken
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at 0900h and 1800h each day until death or ICU discharge.
Patients were treated as clinically indicated with no re¬
strictions. Six women and four men were investigated. Mean
age was 59 (range 25 - 73).
(f) Repeat Standard ACTH Stimulation Tests on Recovery
Ten patients who had undergone standard ACTH testing whilst
suffering from septic shock were investigated following dis¬
charge from the ICU. A standard ACTH stimulation test was
performed at least 7 days after discharge.
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(3) Results
Admission Plasma Cortisol Concentration
An admission plasma Cortisol measurement was available in
all 260 cases. The mean [SD] plasma Cortisol concentration
was 1012 [621] nmol/L. The frequency distribution of Corti¬
sol concentration is shown in Fig 4.1. Cortisol concentra¬
tions were not normally distributed, but were skewed towards
higher values. Ninety seven cases had Cortisol concentra¬
tions greater than 1000 nmol/L. Of these 47 were above 1500
nmol/L and 18 above 2000 nmol/L. Only 92 cases had admission
Cortisol concentrations below 720 nmol/L, the upper limit of
the distribution in health. The median plasma Cortisol
concentration was 916 nmol/L [range 162 - 3750].
There was a significant correlation between plasma Cortisol
concentration and APACHE II score [r = 0.436, P < 0.01, Fig
4.3]. Mean plasma Cortisol within 3 APACHE II score ranges
[< 16; 16-24; > 24] is shown in Table 4.1.
Table 4.1. Plasma Cortisol concentration on admission in 260
patients according to APACHE II score
APACHE SCORE <16 16-24 > 24
NUMBER OF CASES 89 105 66
CORTISOL [nmol/L]
MEAN [SD] 760 [302] 994 [640] 1381 [693]
MEDIAN [RANGE] 709 [162-1700] 921 [202-3200] 1210 [250-3750]
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Within each of the APACHE II score ranges the distribution
of Cortisol concentrations remained non-parametric [Table
4.2], although each distribution approximated more closely
than the original distribution to normal.
Table 4.2. The distribution of admission plasma Cortisol
concentrations according to APACHE II scores.
APACHE II SCORE GROUPS
CORTISOL [nmol/L] < 16 16 - 24 > 24 TOTAL
< 500 29 23 9 61
500 - 1000 41 36 15 92
1000 - 1500 16 25 19 60
1500 - 2000 3 14 12 29
2000 - 2500 0 3 6 9
> 2500 0 4 5 9
TOTAL 89 105 66 260
Since, the distributions of the Cortisol concentrations were
non-parametric, logarithmic transformations were performed
in order to define normal ranges. Logarithmic transformation
of all admission Cortisol measurements [Fig 4.3] and the
distributions within each of the APACHE II score ranges
resulted in an approximately normal distributions. Normal
ranges were calculated using the standard deviations of the
log distributions [Table 4.3].
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Table 4.3. The overall ranges of plasma Cortisol concentrations and the
ranges within APACHE II score groups.
CORTISOL RANGE APACHE II SCORE GROUP
[nmol/L] ALL CASES <16 16 - 24 >24
95% (2SD) 220 - 3000 200 - 1520 260 - 2080 400 - 3200
99% (3SD) 180 - 3500 160 - 1700 200 - 2800 320 - 4000
Admission plasma Cortisol concentration was higher in pa¬
tients who subsequently died than in those who survived
[Table 4.4]. There was a wide range of Cortisol concentra¬
tions in both groups with considerable overlap of values
despite significantly different mean [MD = 673 nmol/L, 95%
CI = 540 - 806] and median [P < 0.0001, Wilcoxan's Rank Sum
test] concentrations.
Table 4.4. Admission plasma Cortisol concentration and APACHE II




MEAN [SD] 785 [423]
MEDIAN [RANGE] 716 [162-2950]
MEAN [SD] APACHE SCORE 17.0 [8.0]
88 260
1458 [658] 1012 [521]
1260 [180-3750] 916 [162-3750]
26.5 [9.0] 20.2 [9.6]
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When plasma Cortisol measurements were split into 500 nmol/L
ranges [Table 4.5, Fig 4.4], there was a significant differ¬
ence in mortality among patients in the different admission
Cortisol groups [X2 for linear trend =31, P < 0.001].
Table 4.5. Mortality in ICU patients divided into 6 groups
dependent upon admission plasma Cortisol concentration.
SURVIVED DIED MORTALITY
CORTISOL [nmol/L] [n] [n] % [95%CI]
< 500 52 9 15 [7-26]
500 - 1000 75 17 18 [11-28]
1000 - 1500 34 26 43 [30-57]
1500 - 2000 7 22 76 [57-90]
2000 - 2500 3 6 67 [30-92]
> 2500 1 8 89 [50-99]
TOTAL 172 88 34 [28-40]
Table 4.6 shows that mortality increases over the three
APACHE II score groups. If patients are further grouped ac¬
cording to their admission Cortisol concentration, as well
as their APACHE II score [Figs 4.5 and 4.6], then it can be
seen that mortality decreases with decreasing Cortisol
concentration in the <16 and 16-24 APACHE II score groups
(X2 for linear trend: 4.2, P<0.05 and 19.4, P<0.001 respect¬
ively) . There is no similar trend in patients with APACHE II
scores > 24 [Table 4.6]. Patients with Cortisol concentra-
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tions of less than 500 nmol/L and APACHE II scores of great¬
er than 24 have a high mortality. Although this group is
small, the mortality is significantly higher than that of
patients with higher Cortisol concentrations [500-1000
nmol/L], but the same range of APACHE II scores [80% vs 27%,
Fisher exact test (1 tailed) P = 0.01].
Table 4.6. Mortality in patients grouped according to admission
plasma Cortisol concentrations and APACHE II scores.
% MORTALITY [DEATHS/CASES]
APACHE II SCORES: <16 16 - 24 >24
CORTISOL [nmol/L]
< 500 4 [1/29] 9 [2/23] 80 [8/10]
500 - 1000 15 [6/41] 17 [6/36] 27 [4/15]
1000 - 1500 19 [3/16] 44 [11/25] 67 [12/18]
> 1500 33 [1/3] 76 [16/21] 83 [19/23]
All patients 12 [11/89] 33 [35/105] 64 [42/66]
Mortality among 7 patients in the lower two APACHE II score
groups with admission plasma Cortisol concentrations more
than two standard deviations below the mean Cortisol concen¬
tration in their APACHE II score groups was 71% [95% CI,
29-96] compared with 22% [95% CI, 16-28] mortality in the
remainder of those groups [Fisher exact test (1 tailed), P <
0.01].
There was no correlation between plasma Cortisol concentra¬
tion and the time of day at which the sample was taken.
83
Plasma Cortisol concentration did not correlate with length
of illness prior to ICU admission, age, sex, or arterial
pC>2, but correlated significantly with plasma urea concen¬
tration [r = 0.29, P < 0.05]. Patients with renal failure
[urea > 30 mmol/L] on admission [N = 41] had a higher mean
[SD] plasma Cortisol concentration than those [N = 219] with
plasma urea concentration of less than 30 mmol/1 [1493 (712)
nmol/L vs 917 (509) nmol/L, P < 0.05]. However, the correla¬
tion between urea and Cortisol disappeared when the Cortisol
concentration was corrected for severity of illness by
dividing it by the non-renal element of the APACHE II score.
Standard ACTH Stimulation Tests
The combined results of the standard ACTH stimulation tests
in septic shock cases and non-shocked cases are outlined in
Table 4.7. Two cases in which the 30 minute plasma Cortisol
measurement was not available were not included in the
results.
Table 4.7. Mean [SD] plasma Cortisol concentration following
standard ACTH stimulation tests in 77 ICU cases.
MEAN [SD] CORTISOL CONCENTRATION [nmol/L]
TIME [minutes] 0 30 60
SURVIVED [N=42] 731 [347]
DIED [N=35] 893 [477]
TOTAL [N=77] 803 [418]
1039 [467] 1147 [398]
1102 [444] 1114 [423]
1067 [458] 1132 [410]
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In survivors and nonsurvivors, both the 30 and 60 minute
plasma Cortisol levels were significantly higher than the
basal levels. The range of Cortisol responses to ACTH varied
from -80 nmol/L to 1000 nmol/L. The mean Cortisol response
was 358 nmol/L [SD = 205]. The basal Cortisol concentration
in nonsurvivors was higher than survivors [MD = 162 nmol/L,
90% CI = 8 - 316] but this was not significant at the 95%
level of confidence. The Cortisol response in survivors was
significantly higher than in nonsurvivors [449 nmol/L vs 248
nmol/L, MD = 201 nmol/1, 99% CI = 69 - 333], but there was
no difference between the stimulated Cortisol concentra¬
tions .
The basal plasma Cortisol concentration did not correlate
with APACHE II scores, but there was a significant inverse
correlation between APACHE II scores and the Cortisol re¬
sponse to ACTH (r= -0.53, P<0.01). The results of the ACTH
stimulation tests stratified by the three APACHE II score
groups used above are given in Table 4.8.
Table 4.8. The mean [SD] basal plasma Cortisol concentration and Corti¬
sol responses to a standard ACTH stimulation test statified by APACHE II
scores.
APACHE II SCORES: <16 16 - 24 >24
Number of cases 17 32 28
Basal Cortisol (nmol/L) 793 [327] 844 [346] 766 [382]
Cortisol response (nmol/L) 456 [269] 381 [211] 272 [183]
The basal plasma Cortisol concentration did not vary signif-
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icantly across the three APACHE II score groups. The mean
plasma Cortisol response to ACTH was lower in patients with
an APACHE II score >24 than in the other two groups [<16 vs
>24: MD = 184 nmol/L, 95% CI = 48 - 320. 16-24 vs >24: MD =
109 nmol/L, 95% CI = 7 - 212].
Overall, there was a significant correlation between basal
plasma Cortisol concentration and the Cortisol increment [r
0.271, P<0.05]. In nonsurvivors, the correlation was
more marked [r = -0.41, P<0.02], but there was no signif¬
icant correlation in survivors. There was no significant
correlation between either basal Cortisol concentration or
Cortisol increment and age, and no difference between the
sexes.
Table 4.9. Mortality among patients stratified by APACHE II score and
the Cortisol response to a standard ACTH stimulation test.
APACHE II SCORES: <16 16 - 24 >24 Total
Cortisol increment < 250 nmol/1:
Number of cases 4 8 13 25
Deaths (n) 2 6 11 19
Mortality (%) 50 75 85 76
Cortisol increment > 250 nmol/1:
Number of cases 13 24 15 52
Deaths (n) 2 7 7 16
Mortality (%) 15 29 47 31
Totals:
Number of cases 17 32 28 77
Deaths (n) 4 13 18 35
Mortality (%) 23 41 64 45
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Mortality was significantly higher in patients with a Corti¬
sol increment of less than 250 nmol/1 [76%, 95% CI 55-91]
than in patients with a greater increment [35%, 95% CI 19-
45]. The same trend was present in each of the three APACHE
II score groups [Table 4.9] and was statistically signif¬
icant in the 16-24 and > 24 APACHE II score groups (Fisher
exact test, 1-tailed, both P<0.05].
The results in the non-shocked cases and the septic shock
cases were also analysed separately.
Non-Shocked Cases
Forty seven non-shocked patients were investigated and data
were complete in 45 cases [Figs 4.7 - 4.9]. The Mean (SD)
APACHE II score of patients studied was 18.2 (6.6). In 3 of
the 45 cases investigated the plasma Cortisol concentration
did not increase during the test. In a further 5 cases the
Cortisol increase was less than 200 nmol/L. In 12 cases the
Cortisol increase was greater than 500 nmol/L. Overall, the
mean plasma Cortisol concentration was significantly higher
than the mean basal concentration at 30 minutes [MD = 293
nmol/L, 99% CI = 86 - 491], and 60 minutes [MD = 343 nmol/L,
99% CI = 134 - 522, Table 4.10]. There was no significant
difference between the mean Cortisol concentrations at 30
and 60 minutes.
In survivors [Fig 4.7] and non-survivors [Figs 4.8 and
4.9], the 30 and 60 minute Cortisol levels were significant¬
ly higher than basal [Nonsurvivors - 30 mins: MD = 244
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nmol/L, 95% CI = 106 - 383, 60 mins: MD = 267 nmol/L, 95% CI
= 117 - 432. Survivors - 30 mins: MD = 312 nmol/L, 99% CI =
147 - 466. 60 mins: MD = 381 nmol/L, 99% CI = 164 - 598].
The mean [SD] Cortisol response was 371 [218] nmol/L. The
response was significantly greater in survivors than nonsur-
vivors [mean (SD) = 413 (212) nmol/L vs 289 (223) nmol/L,
MD = 123 nmol/1, 95% CI = 2 - 257]. Basal Cortisol concen¬
tration was significantly higher in non-survivors than
survivors [mean (SD) = 1028 (488) nmol/L vs 746 (335)
nmol/L, MD = 282 nmol/L, 95% CI = 39 - 525].
Table 4.10. Mean [SD] plasma Cortisol concentration during
a standard ACTH stimulation test in 45 ICU patients.
MEAN [SD] CORTISOL CONCENTRATION [nmol/L]
TIME [minutes] 0 30 60
SURVIVED [N=29] 747 [335] 1059 [355] 1128 [338]
DIED [N=16] 1028 [488] 1272 [438] 1295 [414]
TOTAL [N=45] 842 [416] 1135 [400] 1185 [374]
Patients with high basal Cortisol concentrations tended to
have a smaller Cortisol increments than patients with lower
basal levels. The correlation between basal plasma Cortisol
concentration and the Cortisol increment was significant [r
= -0.36, P<0.05]. This negative correlation between basal
plasma Cortisol concentration and Cortisol increment was
more marked in survivors [r = - 0.483, P<0.05, Fig 4.10],
and did not reach statistical significance in nonsurvivors
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[r = -0.248, P=0.08, Fig 4.10]. There was no significant
correlation between basal plasma Cortisol concentration and
APACHE II scores, but there was a significant negative
correlation between APACHE II scores and the Cortisol re¬
sponse to ACTH [r = - 5.8, P<0.01].
Septic Shock Cases
Data collection was complete in all 32 cases. The mean (SD)
APACHE II score of patients studied was 25.6 (8.4). In 2
cases the plasma Cortisol concentration did not increase
during the test. In a further 11 cases, the increase was
under 250 nmol/L, and in 9 cases the increase was greater
than 500 nmol/L [Figs 4.11 and 4.12]. The 30 and 60 minute
plasma Cortisol levels were both significantly higher than
the basal levels [30 min: MD = 291 nmol/L, 95% CI = 71 -
511. 60 min: MD = 309 nmol/L, 99% CI = 23 - 595, Table
4.11] .
Table 4.11. Mean [SD] plasma Cortisol concentration during a
standard ACTH stimulation test in 32 cases of septic shock.
MEAN [SD] CORTISOL CONCENTRATION [nmol/L]
TIME [minutes] 0 30 60
SURVIVED [N=13] 692 [372]
DIED [N=19] 778 [437]
TOTAL [N=32] 745 [414]
1154 [528] 1190 [510]
950 [390] 961 [367]
1036 [464] 1054 [445]
Patients who subsequently died had higher basal plasma
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Cortisol levels than patients who survived, but this did not
reach statistical significance. There was no significant
difference between the Cortisol concentrations in survivors
and nonsurvivors at 30 or 60 minutes. In both survivors
[Fig 4.11] and nonsurvivors [Fig 4.12], the mean 30 and 60
minute Cortisol levels were significantly higher than the
mean basal level [Survivors: 30 min, MD = 462 nmol/L, 99% CI
= 41 - 832; 60 min, MD = 498 nmol/L, 99% CI = 83 - 859.
Nonsurvivors: 30 min, MD = 170 nmol/L, 95% CI = 61 - 310; 60
min, MD = 182 nmol/L, 99% CI = 40 - 323].
The mean [SD] plasma Cortisol increment was significantly
higher in survivors than nonsurvivors [528 (251) nmol/L vs
213 (200) nmol/L, MD = 315 nmol/L, 99% CI = 96 - 535]. All
13 patients with plasma Cortisol increments of less than 250
nmol/L subseguently died. There were 6 deaths among the 19
patients with Cortisol responses greater than 250 nmol/L [P
< 0.001, X2 with Yate's correction].
Overall, there was no correlation between the Cortisol
response and the basal plasma Cortisol concentration. How¬
ever, there was a significant positive correlation between
basal Cortisol concentration and the Cortisol increment in
survivors [r = 0.522, P<0.05, Fig 4.13 ], and a significant
negative correlation between the Cortisol response and the
basal Cortisol concentration in nonsurvivors [r = -0.507,
P< 0 . 05, Fig 4.13] .
The Cortisol response was lower in patients with Gram-nega¬
tive organisms on blood culture [mean (SD) = 281 (196)
nmol/L] than in those with gram-positive organisms or nega-
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tive blood cultures [mean (SD) = 407 (236) nmol/L], but this
did not reach statistical significance.
Low Dose ACTH Stimulation Tests
Data were complete in the 25 tests performed. The mean (SD)
APACHE II scores of the non-shocked cases [Group 2] and the
septic shock cases [Group 3] were 16.9 (5.3) and 23.4 (7.1)
respectively. Plasma Cortisol concentration increased in
all control cases [Fig 4.14] and all non-shocked cases
following low dose ACTH [Figs 4.15]. Cortisol concentration
increased in 7 of the 10 septic shock cases [Fig 4.16].
Table 4.12. Mean [SD] plasma Cortisol concentration following
a low dose ACTH stimulation test.
MEAN [SD] CORTISOL CONCENTRATION [nmol/L]
TIME [minutes] 0 15 30 60
CONTROLS [N=5] 522 [87]
GROUP 2 [N=10] 844 [253]
GROUP 3 [N=10] 702 [309]
674 [133] 724 [144] 655 [129]
972 [250] 1008[252] 959 [255]
754 [284] 765 [277] 744 [297]
Basal Cortisol concentration was significantly higher in the
ICU patients than in the controls [Group 2 : MD = 322 nmol/L,
95% CI = 60 - 578. Group 3: MD = 306 nmol/L, 95% CI = 119 -
493, Table 4.12]. In the control cases, plasma Cortisol
concentration was significantly higher the than basal con-
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centration, at 15, 30 and 60 minutes after injection of the
ACTH [15 mins: MD = 152 nmol/1, 99% CI = 17-287. 30 mins: MD
= 182 nmol/1, 99% CI = 83-311. 60 mins: MD = 133 nmol/1, 99%
CI = 28-239]. In the non-shocked patients, plasma Cortisol
concentration was higher than basal at 15, 30 and 60 minutes
[15 mins: MD = 128 nmol/L, 99% CI = 89-168. 30 mins: MD
162 nmol/L, 95% CI = 112-212. 60 mins: MD = 114 nmol/L, 95%
CI = 62-165]. In the septic shock cases, the increase in
mean Cortisol concentration was smaller than in the non-
shocked cases, but was still significant [15 mins: MD = 62
nmol/L, 95% CI = 22-101. 30 mins: MD = 91 nmol/L, 95% CI
27-154. 60 mins: MD = 66 nmol/L, 95% CI = 5-127].
The mean [SD] Cortisol increments in the 3 groups were:
controls, 204 [38] nmol/L; non-shocked cases, 168 [46]
nmol/L; septic shock cases, 76 [50] nmol/L. There was no
significant difference between the responses in the controls
and in the non-shocked cases, but the mean response in the
septic shock cases was significantly lower than in the
controls [MD = 128 nmol/1, 99% CI = 51-205] and the non-
shocked cases [MD = 92 nmol/1, 99% CI = 30-154]. There was
no difference in the Cortisol increment between survivors
and nonsurvivors in either group of cases.
Depot ACTH Stimulation Tests
Data collection was complete in the 5 cases and 5 controls
investigated. The mean (SD) APACHE II score of the septic
shock cases was 23.5 (6.2). In both the control group and
the septic shock group, plasma Cortisol concentration in-
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creased in all cases between basal and 1 hour and between 1
hour and 2 hours [Figs 4.17]. The basal plasma Cortisol
concentrations were similar in both groups [Table 4.13]. Two
hours after ACTH administration plasma Cortisol concentra¬
tions were significantly higher in the controls than in the
septic shock patients [MD = 156 nmol/L, 95% CI = 16 - 314].
Mean plasma Cortisol concentration remained significantly
higher in the control group for the remainder of the test,
the difference between the 2 groups steadily increasing [3
hours, MD = 268 nmol/L, 95% CI = 74 - 462; 4 hours, MD = 462
nmol/L, 95% CI = 104 - 820; 5 hours, MD = 566 nmol/L, 95% CI
= 166 - 966].
Table 4.13. Mean [SD] plasma Cortisol concentration during depot
ACTH stimulation tests in septic shock cases and healthy controls.
MEAN [SD] CORTISOL CONCENTRATION [nmol/L]
TIME [h] 0 1 2 3 4 5
CASES 452[111] 642[141] 817[124] 861[175] 816[307] 788[306]
CONTROLS 458[61] 808[93] 982[75] 1129[68] 1278[162] 1354[239]
In the control group, plasma Cortisol concentration in¬
creased between 2 and 3 hours in all cases, but fell in 2 of
the septic shock cases. Mean plasma Cortisol concentration
was significantly higher at 3 hours than at 2 hours in the
control group [MD = 147 nmol/1, 99% CI = 116 -177], but not
in the septic shock group. In the septic shock group plasma
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Cortisol concentration fell between 3 and 5 hours in 4 cases
compared with only 1 case in the control group.
The mean plasma Cortisol concentration in controls remained
within the expected range for the duration of the test. In
the septic shock group the mean Cortisol concentration fell
below the lower limit of normal after 3 hours [Fig 4.18].
Serial Plasma Cortisol Measurement
Data collection was incomplete in 2 cases. The mean (SD)
APACHE II score of patients studied was 23.6 (4.9). Of the
130 samples taken for Cortisol assay, measurements were
available in 127. Case 4 received hydrocortisone replacement
when, after a downward trend for 48 hours, the plasma Corti¬
sol concentration fell below 200 nmol/1 [Fig 4.19]. This
case will be excluded from the analysis. Of the remaining 9
cases, 4 survived and 5 died. The mean period from initial
investigation of survivors to ICU discharge was 9.5 days.
Excluding case 4, the mean period from initial investigation
of nonsurvivors to death was 3.5 days.
There was no significant difference in plasma Cortisol
concentration between initial measurement and measurement
before death or discharge. There was no consistent pattern
in Cortisol measurement in either survivors or nonsurvivors.
In 2 nonsurvivors [cases 4 and 20] plasma Cortisol concen¬
tration fell below 200 nmol/1 on at least one occasion.
Repeat Standard ACTH Stimulation Tests on Recovery
Data were complete in the 10 cases studied. It was not pos-
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sible to calculate APACHE II scores at the time of the
repeat test because of insufficient data. All patients had a
basal Cortisol concentration greater than 250 nmol/L, and no
patient had a Cortisol increment following ACTH of less than
250 nmol/L [Table 4.14].
Table 4.14. Mean [SD] plasma Cortisol concentration during a
standard ACTH stimulation test on recovery.
MEAN [SD] PLASMA CORTISOL CONCENTRATION [nmol/L]
TIME [minutes] 0 30 60
ORIGINAL TEST 629 [341] 911 [418] 1023 [381]
RECOVERY TEST 435 [246] 787 [219] 933 [326]
The basal Cortisol concentrations were not significantly
different. The Cortisol increment during the recovery test
[mean (SD) = 509 (186) nmol/L] was greater than during the
original test [mean (SD) = 421 (89) nmol/L], but this did
not quite reach statistical significance [MD = 88, 95% CI =
-15 - 177].
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FIG 4.3. ADMISSION PLASMA CORTISOL CONCENTRATION VERSUS
APACHE II SCORE.
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FIG 4.4. MORTALITY IN PATIENTS GROUPED
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FIG 4.6. MORTALITY IN PATIENTS GROUPED ACCORDING
TO ADMISSION CORTISOL CONCENTRATION AND
APACHE II SCORE.
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MISSING DATA IN CASES 19 AND 30.
CASE 31 [NOT SHOWN]: 0 MINS, 1850 nmol/L; 30 MINS, 2310 nmol/L; 60 MINS, 2143 nmol/L.






















CASE 35 [NOT SHOWN]: 0 MINS, 2340 nmol/L; 30 MINS, 2294 nmol/L; 60 MINS, 2320 nmol/L.
FIG 4.10. PLASMA CORTISOL INCREMENT FOLLOWING ACTH
STIMULATION VERSUS BASAL CORTISOL CONCENTRATION
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CASE 30 [NOT SHOWN]: 0 MINS, 596 nmol/L; 60 MINS, 1208 nmol/L.
CASE 31 [NOT SHOWN]: 0 MINS. 663 nmol/L; 30 MINS, 727 nmol/L; 60 MINS, 689 nmol/L.
CASE 32 [NOT SHOWN]: 0 MINS, 994 nmol/L; 30 MINS, 1263 nmol/L; 60 MINS, 957 nmol/L.
FIG 4.13. PLASMA CORTISOL INCREMENT FOLLOWING ACTH
STIMULATION VERSUS BASAL CORTISOL CONCENTRATION IN
SEPTIC SHOCK
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FIG 4.17. DEPOT ACTH STIMULATION TESTS
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(5) Discussion
Plasma Cortisol Concentration and Severity of Illness
Cortisol was measured on blood taken within 2 hours of
admission to the ICU. This ensured that all patients were
investigated at a uniform time during their ICU stay. In
view of the loss of circadian rhythm of Cortisol concentra¬
tion, this was felt to be more important than measurement at
a fixed time of day, and is supported by the lack of a
correlation between the time of ICU admission and the Corti¬
sol concentration.
The distribution of plasma Cortisol concentration was non-
parametric, with a long tail of high concentrations. Logar¬
ithmic transformation produced a parametric distribution.
Eighteen percent of patients had a concentration greater
than 1500 nmol/L and 7% had a concentration greater than
2000 nmol/L. These Cortisol concentrations are well above
the normal range for healthy controls, the upper limit for
which is quoted as 720 nmol/L at 0800h (Ismail, 1981). Only
92 patients [35%] had an admission plasma Cortisol concen¬
tration below 720 nmol/L. High Cortisol concentrations have
been found previously in acutely ill and intensive care
patients [Table 4.15]. A number of the papers listed below
have been published since this study began.
The Cortisol concentrations in this study [mean = 1012
nmol/L (SD = 621) and median = 940 nmol/L (range 100
3790)] are similar to those found in previous studies.
However, meaningful comparison is difficult without a method
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of comparing the patients in each of the studies. In the
majority of the studies listed in Table 4.15, little infor¬
mation is given about the severity of illness or primary
diagnoses of patients studied. The mean APACHE II scores in
the patients studied by Span et al and those studied by
Jurney et al were 19 and 18.5 respectively. These are simi¬
lar to the mean score in this study, suggesting that the
severity of illness was similar, although the range of
illnesses may have differed.
Table 4.15. Previous studies looking at Cortisol concentration in acute¬
ly ill and intensive care patients.
REFERENCE NUMBER OF PRINCIPAL CORTISOL
CASES DIAGNOSES [nmol/L]
Span et al, 1992 159 General ICU 600 [SD = 280] *
Jurney et al, 1987 70 General ICU 988 [SD = 265]*
Schein et al, 1990 37 Septic shock 1430 [520 - 9000]
Patel et al, 1991 50 General medical 665 [288 - 1585]
Frayn et al, 1983 51 Hip fracture 910 [350 - 2310]
Sainsbury et al, 1981 30 General ICU 1200 [130 - 4920]
Feibel et al, 1983 65 Stroke 552 [240 - 1000]
Ross et al, 1991 6 General ICU 567 [SD = 57]*
Sibbald et al, 1977 26 Septic shock 710 [SD = 390] *
Stoner et al, 1979 270 Acute trauma 820 [200 - 1500]
Jensen et al, 1988 18 Myocardial infarct 750 [SD = 250]*
Drucker et al, 1985 40 General medical 980 [212 - 8430]
* = mean [SD], otherwise median [range].
One of the aims of this work was to produce normal ranges of
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Cortisol concentration. A normal range is usually two stan¬
dard deviations about the mean of the concentration of a
given substance in a reference population, usually healthy
controls. It follows that in 95% of cases, if the subject
under study is comparable to the reference population, and
has a normally functioning endocrine system, the concentra¬
tion will fall within the normal range. It is more difficult
to define a normal hormone concentration with which to
compare an individual ill patient. Strictly, this would
reguire a large group of subjects who were suffering from
the same illness, and in whom the illness was egually severe
in each case. Clearly, this is not possible.
Seyle's General Adaption Theory suggests that different
stresses produce similar responses from the adrenocortical
system. It follows that different illnesses which induce the
same degree of stress should produce comparable adrenocorti¬
cal responses. If this is the case, then a normal range of
Cortisol concentration in ill subjects will depend more upon
the degree of stress or illness, than upon the nature of the
illness itself. The degree of stress to which a patient is
subjected is often equated with the degree to which the
homeostasis of the patient is deranged. This is the basis of
measuring illness severity by the APACHE system [Knaus et
al, 1985]. The positive correlation between admission
APACHE II scores and admission Cortisol levels in this study
supports Seyle's General Adaption Theory. The more marked
the stress, measured by APACHE II scores, the higher the
plasma Cortisol concentration.
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Only 3 studies have commented on a correlation between
Cortisol concentration and measures of illness severity.
Stoner et al (1979) found a positive correlation between
plasma Cortisol concentration and the Injury Severity Score
in trauma patients investigated within 8 hours of injury.
Vaughan et al [1982] studied patients who had suffered major
burns, and found a positive correlation between burn size
and plasma Cortisol concentration. Span et al [1992] invest¬
igated 159 ICU patients and found a clear correlation of
plasma Cortisol concentration with APACHE II scores.
Given the strength of the association between Cortisol
concentrations and severity of illness, any attempt to
define a normal range for plasma Cortisol concentration
during illness, must take illness severity into account.
APACHE II scores are the most widely used and validated
measure of illness severity. The admission Cortisol data
were therefore presented as a series of normal ranges for
differing degrees of illness severity, based on bands of
APACHE II scores. There is much overlap of Cortisol concen¬
tration at all APACHE II scores, and it therefore made
little sense to have more than 3 bands. In order that each
group contained sufficient measurements to produce a mean¬
ingful normal range, the following bands were chosen: < 16,
16-24, and > 24.
Whilst the normal ranges of all the bands do overlap, the
mean Cortisol concentrations do differ significantly. The
differences between the 95% ranges for APACHE II scores of
<16 and >24 are important, the lower limits being 200 nmol/L
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and 400 nmol/L respectively. A severely ill patient with a
high APACHE II score would not be expected to have a plasma
Cortisol level of less than 400 nmol/L, whereas this would
be acceptable in a normal control or a less severely ill pa¬
tient. A concentration outwith the normal range does not
necessarily indicate an abnormality of adrenocortical func¬
tion, but may require further investigation.
The overall correlation between plasma Cortisol concentra¬
tion and mortality was as expected. As plasma Cortisol
concentration increased, so did mortality. The mean admis¬
sion Cortisol concentration in survivors was significantly
lower than in patients who died. Previous studies have
produced conflicting results. Jurney et al (1987) produced
similar results to this study, but Schein et al (1990) found
no correlation between plasma Cortisol concentration and
mortality. However, the latter study was confined to pa¬
tients with septic shock all of whom were very ill and had a
narrow range of APACHE II scores. There was no correlation
between baseline Cortisol concentration and APACHE II scores
in the subgroup of 32 septic shock patients who underwent
standard ACTH stimulation tests in this study.
Whilst in general mortality does increase with increasing
Cortisol concentration, patients with low Cortisol concen¬
trations for their severity of illness also have a high
mortality. In the upper APACHE II score band [> 24] the
mortality among patients with the lowest Cortisol concentra¬
tions [< 500 nmol/L] was significantly higher than the
mortality of patients in the same band who had higher corti-
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sol levels [500-1000 nmol/L]. Similarly, in the less severe¬
ly ill patients, Cortisol concentrations below the normal
range for their APACHE II score were also associatd with a
higher than expected mortality. This association between
high mortality and low Cortisol in very severely ill pa¬
tients has not been reported previously, and illustrates the
importance of interpreting Cortisol concentrations in the
context of illness severity. The implications of these
findings for clinical trials of Cortisol replacement in
critical illness are discussed in Chapter 8.
Higher admission Cortisol concentrations were associated
with acute renal failure. However, the association disap¬
peared when a correction was made for differing non-renal
APACHE II scores, suggesting that the association was due to
more severe illness in patients with acute renal failure.
Research in animals has shown that hypoxia is a profound
stimulus to Cortisol secretion (Raff et al, 1981), and
prolonged hypoxia in human volunteers leads to a persistent
50% rise in Cortisol concentration (Hale et al, 1957). In
this study there was no correlation between arterial partial
pressure of oxygen [p02] and plasma Cortisol concentration.
However, hypoxia was only one of a large number of physiolo¬
gical stresses affecting the patients studied, and any
independent effect on Cortisol concentration was therefore
likely to be lost. Furthermore, a single p02 measurement is
unlikely to accurately represent the overall exposure to
hypoxia over the preceding hours. Indeed, the admission
arterial blood gas sample is often not taken until the
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patient has been intubated and ventilated, and would probab¬
ly bear little resemblance to a pre-admission measurement.
Admission Cortisol concentration did not correlate with
length of illness prior to ICU admission, nor did post-
anaesthetic patients have higher levels than non-anaesthetic
cases. Both these findings are in agreement with previous
work (Span et al, 1992).
Serial Plasma Cortisol Measurements
There were two reasons for looking at serial measurements of
plasma Cortisol. Firstly, to determine how much plasma
Cortisol concentration varied over the short term following
ICU admission. The lack of diurnal variation has already
been demonstrated, but variability in Cortisol concentration
due to evolution of illness or medical interventions might
still undermine the value of a single measurement. Secondly,
if outcome in patients suffering from septic shock was in
some way shown to be related to admission plasma Cortisol
concentration, then monitoring Cortisol levels until death
or recovery might reveal a consistent pattern depending upon
the outcome.
The variation in Cortisol measurements over the first 48
hours of the study was no greater than would be expected on
the basis of the intra-assay coefficients of variation for
high Cortisol concentrations demonstrated in Chapter 2. This
suggests that a single admission Cortisol measurement is a
reasonable valid index of the Cortisol concentration during
the first 48 hours after admission.
121
Interpretation of the trends in Cortisol concentration over
the whole admission is difficult. In 3 of the 6 nonsurvivors
Cortisol concentration fell steadily to very low levels
prior to death, one patient requiring Cortisol replacement.
However, in the remainder of nonsurvivors, no such pattern
was seen. Cortisol concentration remained relatively con¬
stant in the survivors, although a tendency to fall from
very high to more normal levels was seen at recovery. No
similar studies have been published since the advent of
modern intensive care. However, as detailed in Chapter 1,
there is some useful early work. Jennings (1951 and 1952)
followed the circulating eosinophil counts of 50 severely
ill patients, all of whom died. In 47 of these, the eosino¬
phil count fell to zero or near zero prior to death, probab¬
ly indicating a strong adrenocortical reaction. Sandberg et
al (1956) studied 17-hydroxycorticosteroids in dying pa¬
tients. In the great majority of these, the plasma steroids
were elevated. Done et al (1958) investigated 64 severely
ill adults a few minutes after death. Plasma corticosteriods
were raised in the majority of cases. Interestingly, in a
small group of 11 cases who had suffered prolonged hypoten¬
sion or apnoea, no rise in plasma corticosteroids had taken
place.
Standard ACTH Stimulation Tests
Interpretation of the results of ACTH stimulation tests in
critical illness is difficult and only limited conclusions
can be drawn. In the absence of information about free
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Cortisol concentrations, and for that matter tissue Cortisol
requirements, the ACTH stimulation test cannot be used to
identify adrenocortical insuffuciency in the way that it can
in health. All work validating ACTH stimulation tests has
been carried out in healthy controls (Wood et al, 19 65;
Crowley et al, 1991) or in out-patient populations (Lindholm
and Kellet, 1987; Stewart et al, 1988). Moreover, even if
relative adrenocortical insufficiency did occur during
severe illness, there is no clinical gold-standard for its
diagnosis against which ACTH stimulation tests could be
validated.
ACTH stimulation tests cannot provide any information about
the sufficiency of adrenocortical function during critical
illness. However, as was discussed in Chapter 1, they can be
used to determine any relationship between the Cortisol
response to ACTH and severity of illness or mortality. In
this study, the Cortisol response to a standard dose of ACTH
was very variable, ranging from no response at all to in¬
creases of 1000 nmol/L. The interpretation of this varied
response is also difficult. In healthy controls, a poor re¬
sponse can be interpreted as suggesting impairment of adre¬
nocortical responsivness to ACTH e.g. following prolonged
steroid therapy. However, in critically ill patients inter¬
pretation is complicated by the fact that, in the majority
of cases, the baseline Cortisol concentration is high. In
healthy controls, the Cortisol increment following ACTH
stimulation is independent of the basal Cortisol concentra¬
tion (Kukreja and Williams et al, 1981; May and Carey, 1985;
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Dickstein et al, 1991), but this may not be the case in
patients with markedly raised Cortisol concentrations.
In this study, there was a relatively minor overall tendancy
for the Cortisol increment following ACTH stimulation to de¬
crease as basal Cortisol concentration increased. However,
this was only apparent in patients who subsequently died,
and was only a modest effect in the group as a whole.
Previous studies of ACTH stimulation tests during severe
illness [Table 4.16] found that the Cortisol increment re¬
mained constant as basal Cortisol increased. Indeed, in the
studies by Sibbald et al (1977) and Jurney et al (1987),
those patients with the highest basal Cortisol concentra¬
tions had the greatest response to ACTH. In this thesis,
many patients with high baseline Cortisol concentrations did
produce a large Cortisol increment following ACTH. Overall,
it appears that a response to ACTH should still be expected
in individuals with high Cortisol concentrations. Apparent
impairment of the adrenocortical response to ACTH may there¬
fore be a valid finding requiring interpretation and further
study.
In none of the previous studies was the response to ACTH
reported in relation to severity of illness or mortality. In
this study, the basal Cortisol concentration did not vary
with severity of illness, but the mean Cortisol increment
following ACTH stimulation fell as the APACHE II score in¬
creased. Furthermore, in both non-shocked and septic shock
cases, the fall in Cortisol increment with increasing APACHE
II score was especially marked in patients who subsequently
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died. Indeed, non-survivors as a whole had lower increments
than survivors. These results indicate that the variability
in response to a standard ACTH test in critical illness has
clinical relevance.
Table 4.16. Previous studies looking at the Cortisol response to
standard ACTH stimulation tests during illness.
REFERENCE NUMBER OF BASAL CORTISOL CORTISOL INCREMENT
CASES mean [range] mean [range]
Sibbald et al, 1977 28 820 [210 - 2420] 450 [0 - 2000]
Jurney et al, 1981 70 980 [226 - 2184] 560 [0 - 1200]
Patel et al, 1991 50 706 [288 - 1585] 374 [10 - 740]
In both septic shock and non-shocked patients, a plasma
Cortisol increment of less than 250 nmol/L was associated
with an increased mortality, irrespective of the APACHE II
score. It is, of course, unclear why a poor response to ACTH
is accociated with a high mortality. It may simply be a
particularly sensitive indirect index of illness severity.
Function of most organs is impaired to a greater or lesser
extent during critical illness. There is no reason to sus¬
pect that the adrenal cortex should be an exception. Indeed,
as was detailed in Chapter 1, there is much evidence of
impairment of adrenocortical function in animal models of
shock and sepsis. The results of this study suggest that in
125
certain patients critical illness is associated with an
impaired response to ACTH. The implications of the associa¬
tion between the response to a standard ACTH stimulation
test and mortality for clinical trials of Cortisol replace¬
ment in critical illness will be discussed in Chapter 8.
Only one patient was as suffering from adrenocortical insuf¬
ficiency by standard criteria, with a basal Cortisol concen¬
tration of 220 nmol/L and an increment of only 93 nmol/L
following ACTH stimulation. This patient was suffering from
severe Gram-negative sepsis and died despite Cortisol repla¬
cement therapy. However, such clear adrenal insufficiency is
rare. None of the 50 patients investigated by Patel et al
had stimulated Cortisol concentrations below 550 nmol/1. Two
patients investigated by Jurney et al had stimulated Corti¬
sol concentrations below 400 nmol/1. Both were suffering
from sepsis, recovered with Cortisol replacement therapy,
and had a normal response to a repeated ACTH stimulation
test on recovery. Sibbald et al identified five patients
suffering from sepsis syndrome with stimulated Cortisol
concentrations of less than 490 nmol/L, and with Cortisol
increments of less than 100 nmol/L.
The septic shock cases had lower basal Cortisol concentra¬
tions than the non-shocked cases, despite a greater mean
severity of illness according to APACHE II scores. The main
difference in management was the more frequent use of adre¬
naline infusions for inotropic support in the septic shock
cases. However, intravenous adrenaline is reported to in¬
crease Cortisol concentrations (Tilders et al, 1985). Within
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the septic shock group, those patients with proven Gram-
negative sepsis had lower Cortisol increments following ACTH
stimulation than patients with Gram-positive infection. It
has been shown previously that in septic shock, patients
with Gram-negative infection have lower baseline plasma
Cortisol levels than those with Gram-positive infection
(Schein et al, 1990; Khosla et al, 1989). The findings in
this study are consistent with the experimental evidence
linking impaired adrenocortical function with Gram-negative
infection reviewed in Chapter 1.
In summary, it appears that the Cortisol response to ACTH is
fairly well maintained in critical illness, despite high
basal Cortisol concentrations. However, a proportion of
patients with high basal Cortisol concentrations have a poor
Cortisol increment. This is most frequently seen in patients
suffering from septic shock, and is associated with a high
mortality.
Low Dose ACTH Stimulation Tests
As was discussed in Chapter 3, low dose corticotropin stimu¬
lation tests have been shown to be more sensitive to steroid
suppression of adrenocortical function than standard ACTH
stimulation tests (Dickstein et al, 1991). There is no
published data on the Cortisol response to low dose ACTH
during critical illness. The purpose of using low dose tests
in this study was to determine whether the adrenal cortex
was as sensitive to low doses of ACTH during illness as it
is during health.
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The Cortisol response to low dose ACTH in control cases was
similar to previously reported results (Graybeal and Fang,
1985; Crowley et al, 1991; Dickstein et al, 1991). The re¬
sponse in the non-shocked ICU patients did not differ sig¬
nificantly from that of the control cases, despite the
higher basal Cortisol concentration in these patients.
However, the response to the low dose ACTH in the septic
shock cases was significantly smaller than that in the non-
shocked cases. These findings suggest a normal sensitivity
to ACTH in non-shocked critically ill patients, but a re¬
duced sensitivity to ACTH or decreased secretory capacity in
septic shock patients. This is consistent with the results
of standard ACTH stimulation tests in septic shock cases.
Depot ACTH Stimulation Tests
There are no published data on the Cortisol resonse to depot
ACTH tests during critical illness or septic shock. The
purpose of these tests in this study was to assess the
adrenocortical reserve in septic shock patients. The Corti¬
sol response of the control cases was within the expected
normal range, but the response in the septic shock patients
was less marked and less well maintained. The mean Cortisol
concentration fell below the lower limit of the normal range
at 4 and 5 hours after the injection, suggesting that these
patients may have had a limited adrenocortical reserve capa¬
city. Unfortunately no tests were performed in non-shocked
critically ill patients for comparison.
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Repeat Standard ACTH Stimulation Tests on Recovery
The mean Cortisol increment in the 10 septic shock patients
investigated following recovery was higher than the mean
increment in the original tests, but this did not reach
statistical significance. These data are difficult to inter¬
pret, but suggest that in the patients studied there was no
significant difference between adrenocortical responsivness
to a standard dose of ACTH during illness and following
recovery. However, it should be noted that the cases invest¬
igated had a good response to ACTH during their illness.
The majority of patients in whom adrenocortical responsive¬
ness to ACTH was impaired during illness died.
There are isolated reports of patients suffering from sepsis
or septic shock, with no history of steroid treatment during
or prior to their illness, who do not respond to ACTH during
their illness but regain normal function on recovery (Jacobs
and Nabarro, 1969; Jurney et al, 1987; Varma et al, 1990).
The significance of such isolated reports is difficult to
assess.
(6) Conclusions
The aims of this study were limited. No attempt was made to
determine whether or not relative adrenocortical insuffi¬
ciency does occur in critical illness. However, a number of
interesting findings have emerged. The main conclusions are
as follows:
1) The majority of critically ill patients have plasma
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Cortisol concentrations above the upper limit of normal in
health. In keeping with Seyle's General Adaption Theory,
plasma Cortisol concentration correlates with severity of
illness. The normal ranges of plasma Cortisol concentration,
defined as population mean +/- 2 standard deviations, differ
according to the severity of illness. A plasma Cortisol
concentration above 200 nmol/L would be within the 95% range
for a moderately ill patient (APACHE II score <16) whereas a
concentration of under 400 nmol/L would be below the expec¬
ted range in a severely ill patient (APACHE II score >24).
2) The relationship between mortality and plasma Cortisol
concentration is not linear. Rather, this study suggests a
J-shaped relationship. In other words, mortality increases
as Cortisol concentration increases above normal, but low
Cortisol concentrations are also associated with a higher
than expected mortality. The implications of this finding
for clinical trials of Cortisol replacement during critical
illness are discussed in Chapter 8.
3) The Cortisol response to a standard ACTH stimulation
test varies between -100 and 1000 nmol/L in critically ill
patients. In patients who subsequently survive, the Cortisol
response is maintained despite very high basal Cortisol
concentrations. In patients who subsequently die, the Corti¬
sol response tends to fall as basal plasma Cortisol concen¬
tration increases. Overall, there is a negative correlation
between the Cortisol response to a standard ACTH stimulation
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test and APACHE II scores.
4) The Cortisol response to a standard ACTH stimulation
test was related to mortality. The mortality among patients
with Cortisol responses of less than 250 nmol/1 was 76%
[95% CI, 55-91] compared with 31% (95% CI, 19-45) mortality
among patients with Cortisol responses greater than 250
nmol/L. Although the former patients tended to have higher
APACHE II scores, the same mortality trend was present in
the three standard APACHE II score groups. The implications
of this finding for clinical trials of Cortisol replacement
during critical illness are discussed in Chapter 8.
5) There was evidence of impairment of adrenocortical
function in some critically ill patients, particularly those
suffering from septic shock. Septic shock patients had lower
Cortisol responses to standard and low dose ACTH stimulation
tests than critically ill controls and the Cortisol response
to depot ACTH was not maintained in septic shock patients.
Directions for Future Research
The studies outlined in this chapter have helped define the
critically ill patients in whom pilot studies of Cortisol
replacement could be most efficiently performed. This will
be discussed in detail in Chapter 8.
The apparent impairment of adrenocortical function in some
critically ill patients reguires further study. Post mortem
studies of adrenal gland pathology comparing patients with
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good responses to standard ACTH stimulation tests with
patients with poor or absent responses would be worthwhile.
Although not falling within the remit of this thesis, the
guestion of whether high mortality among patients with
apparent impairment of adrenocortical function is due to
Cortisol insufficiency could be further investigated. Do
these patients have lower circulating free Cortisol concen¬
trations? In other words, is tissue availability of Cortisol
reduced? If not, then the argument that their high mortality
is due to impaired adrenocortical function would be diffi¬
cult to maintain. Measurement of free Cortisol concentration
and the concentrations of Cortisol binding globulin and
albumin during critical illness would therefore be interest¬
ing. However, since we do not know what the range of tissue
reguirement for free Cortisol during critical illness is
likely to be, it does not necessarily follow that a high
measured concentration is sufficient. The guestion of whe¬
ther critically ill patients actually benefit from Cortisol
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(1) Historical Background
References to the thyroid gland and thyroid diseases can be found
throughout ancient medical literature. Thyroid enlargement was described
by the Greeks. Galen used the term bronchocele, meaning hernia of the
windpipe. Pliny introduced the Latin term tumid gutter, meaning swollen
throat, which subsequently evolved into the French goitre, the English
goitre, and the American goiter. However, it was not until the 1700s
that it was established that the thyroid was a single glandular organ
(Thompson, 1970).
There was much speculation regarding the function of the gland. Wharton
suggested that the gland was intended to "round out and beautify the
neck by filling the vacant spaces about the larynx .... particularly in
females to whom for this reason a larger gland has been assigned."
Vercelloni argued that "the thyroid is a bag of worms" which occasional¬
ly cross, for digestive purposes, into the oesophagus (Vercelloni,
1711)..
Ancient Chinese physicians are said to have treated endemic goitre with
seaweed (Matovinovic, 1958). However, it was not until the late nine-
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teenth century that the functional role of the thyroid and parathyroid
glands was elucidated. Much work had been done on experimental thyroi¬
dectomy, but it was not until 1896 that Vassale and Generali separated
the syndrome of myxoedema from that of tetany. At about the same time it
was found that injection of thyroid extract (Murray, 1891) or feeding
lightly cooked sheep thyroid (Vermeulen, 1893) would relieve the signs
and symptoms of myxoedema.
The first descriptions of hyperthyroidism were given by Parry (1825) and
Graves (1835), and shortly afterwards von Basedow (1840) described the
ophthalmic manifestations.
The association between iodine and the thyroid gland was made in 1896
(Baumann, 1896] and in 1915 L-thyroxine was crystallised from thyroid
extract (Kendall, 1915). It was later discovered that a second compound
with only three iodine atoms, 3,5,3'-triiodothyronine, was present in
the thyroid gland and plasma (Gross, 1954). It was subsequently proven
that T3 was produced by peripheral monodeiodination of T4, and that it
was the main physiologically active form of the hormone (Braverman,
1970).
The concept of pituitary control of the thyroid gland stretches back to
the observation (Niepce, 1851) that the pituitary gland was markedly
enlarged in cretins, and the work demonstrating hypertrophy of the
anterior pituitary after thyroidectomy in the rabbit (Rogowitsch, 1889).
This concept was confirmed by the demonstration that ablation of the
tadpole pituitary resulted in thyroid atrophy and prevented metamorph¬
osis (Smith, 1915) and that the atrophied thyroid gland could be made to
hypertrophy by injections of beef anterior pituitary extracts (Smith,
1922). Shortly thereafter the negative feedback control system of the
pituitary-thyroid axis was defined (Aron , 1931). More recently the
structure of the pituitary TSH and the control of its secretion by the
hypothalamic thyrotropin releasing hormone [TRH] has been established.
(2) Anatomy, Biochemistry and Physiology of the Thyroid Gland
The normal adult thyroid gland consists of two lobes connected by an
isthmus and weighs about 15 to 25g. The vascular supply is derived from
the superior and inferior thyroidal arteries, and the gland contains a
rich lymphatic network. The thyroid gland is divided into lobules, each
of which contains 20 to 40 follicles. The follicles are lined by epithe-
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lial cells which surround central deposits of colloid. It is estimated
that the adult thyroid gland contains approximately three million folli¬
cles. The colloid serves as a store for thyroglobulin, iodine and thyr¬
oid hormones.
The thyroid hormones, L-thyroxine [T4] and L-triiodothyronine [T3], are
synthesised in specialised cells of the thyroid gland. Iodine is essen¬
tial for the synthesis of thyroid hormones. T4 contains 4 iodine atoms
per molecule and is 66% iodine by weight. T3 is 58% iodine by weight
with 3 atoms per molecule. Iodine is actively transported into the
thyroid gland and concentrations 30 times greater than serum iodine are
reached. This is one of the rate limiting steps in thyroid hormone
synthesis and is under the control of TSH. Within the thyroid cells
iodine ions are rapidly "organified" or converted to iodine and bound to
one of the 110 tyrosine residues of thyroglobulin molecules synthesised
by the cell.
Iodothyronines are formed by coupling of iodotyrosines on neighbouring
thyroglobulin molecules. The coupling process is enzyme dependent and is
controlled by TSH. T3 is formed by the coupling of a monoiodotyrosine
with a diiodotyrosine, and T4 is formed by coupling of two diiodotyro-
sine molecules. The newly formed hormone remains part of the thyroglobu¬
lin molecule, and is stored in the colloid. Ordinarily, less than 1% of
stored hormone turns over each day.
Regulation of Thyroid Function
Like the gonads and adrenal cortex, the thyroid interacts with the
hypothalamus and the pituitary gland in a classic type of feedback
control. Thyrotropin releasing hormone [TRH] is a modified tripeptide
[pyroglutamyl-histidyl-proline amide] which is synthesised by peptider¬
gic neurones in the supraoptic and paraventricular nuclei of the hypo¬
thalamus. It is transported to and stored in the median eminence. From
here it enters the hypophyseal portal venous system and traverses the
pituitary stalk. Thyrotropic and lactotropic cells contain specific
saturable receptors to which TRH binds and stimulates adenylate cyclase.
Under the influence of TRH, secretion of TSH is promptly stimulated and
enhanced TSH synthesis follows. The response to TRH requires extracellu¬
lar calcium and oxidative phosphorylation within the pituitary, but it
is unclear whether cyclic AMP or translocations of calcium mediate the
response.
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Regulation of TSH secretion results from an interaction, possibly en¬
tirely at the level of the thyrotropic cell, between stimulation of
synthesis and release by TRH and inhibition by thyroid hormones. Inhibi¬
tion of TSH synthesis and release by thyroid hormones is not merely a
direct antagonism of TRH, since it can be observed in the experimental
absence of TRH. Moreover, the degree of hypothyroidism that results from
destruction of the appropriate areas of the hypothalamus is less severe
than that which follows hypophysectomy. In the former circumstance,
residual TSH secretion can be varied by changing the concentration of
thyroid hormones in the blood. Thus, thyroid hormones mediate the feed¬
back regulation of TSH secretion and TRH determines its set point. There
is no convincing evidence that thyroid hormones directly modify the
secretion of TRH.
TSH is a glycoprotein made up of two subunits. The alpha subunit is
identical to the alpha subunits of follicle stimulating hormone [FSH],
luteinising hormone [LH] and human chorionic gonadotropin [hCG]. Each
hormone differs in its beta subunit. Production of the beta subunit is
the rate limiting step in the synthesis of TSH. The mechanism of nega¬
tive feedback on TSH production by thyroid hormones is incompletely
understood. Briefly, although in peripheral tissues T4 is probably a
prohormone of T3, T4 appears to have an important role in regulation of
TSH at the pituitary level. Intra-pituitary T3 is derived from circula¬
ting T4 which is deiodinated within the pituitary cells. Thus TSH will
rise in response to decreased serum T4 levels despite normal or elevated
T3 levels (Wehmann and Nisula, 1984).
Numerous factors modulate TSH secretion. A number of substances appear
to play a role as TSH inhibitory factors. Infusions of dopamine decrease
circulating TSH levels in euthyroid and hypothyroid subjects (Delitala,
1977; Kaptein, 1980), and reduce the TSH response to TRH (Besses et al,
1975). Dopamine antagonists such as metoclopramide (Scanlon et al, 1977)
and domperidone (Pourmand et al, 1980) both promptly increase TSH le¬
vels. Domperidone does not cross the blood-brain barrier suggesting that
dopaminergic inhibition of TSH is exerted at the level of the pituitary
gland. Dopamine is found in high concentration in the portal blood and
dopamine receptors are present on thyrotrophs, suggesting that dopamine
is an important physiological inhibitor of TSH secretion. Somatostatin
(Vale et al, 1974) and cholecystokinin (Morley et al, 1979) also appear
to play similar roles.
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Glucocorticoids exert multiple effects on the H-P-T axis. It has been
suggested that the circadian rhythm of TSH secretion is the result of an
inhibitory action of plasma Cortisol (Nicoloff et al,1970). TSH concen¬
trations peak in early hours of the morning and are lowest at midday.
Pharmacological doses of steroids inhibit basal TSH secretion, the
nocturnal surge in TSH secretion, and the response to TRH (Re at al,
1976). TSH levels are low in Cushing's syndrome (Van Cauter et al, 1974)
and high in Addison's disease, falling to normal on steroid replacement
(Topliss et al, 1980). It is thought that steroids influence the H-P-T
axis at both the pituitary and hypothalamic levels (Morley, 1981).
Men have lower TSH responses to TRH than women (Sawin et al, 1978).
Androgens decrease the TSH response to TRH in men with hypogonadism
(Morley et al, 1981) and are thought to be physiological inhibitors of
TSH secretion. Oestrogens enhance TRH receptor density on the surface of
the thyrotropic cell and increase the TSH response to TRH. Endogenous
opiates probably have little effect on TSH secretion (Morley, 1981).
High concentrations of exogenous opiates have an inhibitory effect on
TSH secretion (Morley et al, 1980). Catecholamines stimulate TSH secre¬
tion via an effect on hypothalamic TRH release (Montoya et al, 1979).
Psychological stress has a weak stimulatory effect on thyroid hormone
levels. Falconer and Hetzel (1964) showed that a dog barking at sheep
led to a rapid increase in thyroid hormone secretion associated with
increased circulating TSH. Similar results have been found in humans
exposed to mock battle conditions (Levi, 1972). Temperature changes
alter thyroid function. Exposure to cold leads to enhanced TSH secretion
in the rat and other animals (D'Angelo, 1960). This response is mediated
via the hypothalamus. In humans the response of TSH to cold stress is
demonstrable but small (Goldstein-Golaire et al, 1970). Heat exposure
leads to a decline in serum TSH and release of thyroid hormones in
humans (O'Malley et al, 1980).
TSH is the major regulator of thyroid structure and function. However,
there is some activity of thyroid cells in the absence of TSH, although
this is not sufficient to maintain a euthyroid state. There is also a
degree of thyroid autoregulation which is independent of TSH. This is
most evident in the regulation of uptake of iodide. However, it is
unclear to what extent autoregulation is an important determinant of
thyroid hormone concentration. It appears to act to maintain relatively
constant thyroid hormone stores.
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TSH is the principal controller of thyroid gland function. Removal of
TSH stimulation results in hypovascularity and atrophy of the gland. TSH
acts via cyclic AMP dependent stimulation of protein kinases which in
turn stimulate the steps in thyroid hormone synthesis. TSH appears to
enhance essentially all processes leading to the synthesis and secretion
of thyroid hormones. Neural regulation of thyroid gland function probab¬
ly exists but is not considered to be important. Adrenergic and pepti¬
dergic innervation increase hormone secretion and cholinergic innerva¬
tion decreases hormone secretion
Thyroid Hormone Circulation and Protein Binding
The concentration of thyroid hormones in the blood are determined to a
great extent by their association with thyroid hormone-binding proteins.
Interpretation of circulating thyroid hormone concentrations in the
absence of information on protein binding is therefore difficult. Ap¬
proximately 120 nmol of T4 and 45 nmol of T3 are secreted daily. T4 is
99.97% protein bound in the plasma, and T3 is 99.7% bound. Approximately
75% of the hormones are bound to thyroxine-binding globulin [TBG], 15%
to thyroxine-binding pre-albumin [TBPA] and 10% to albumin. TBPA binds
T4, but only very small amounts of T3. This very high degree of protein
binding has several important consequences. The plasma has a large
capacity to store hormone, acting as a buffer against fluctuations in
blood levels. Very little hormone is lost through renal glomerular
filtration of free hormone. Changes in the levels of binding proteins
will alter the amount of free hormone available for cellular uptake. T4
is more highly bound than T3, and has a smaller volume of distribution.
The half life of T4 is about 1 week compared to 1 day for T3. Albumin
and TBPA are present in the blood in much higher concentration than TBG
and have a greater capacity than TBG to bind T4. However, the affinity
of TBG for binding T4 is several orders of magnitude greater than albu¬
min or TBPA, although only about 30% of binding sites for T4 on TBG are
occupied. TBG is a glycoprotein with a molecular weight of approximately
54,000 and a half-life of five days. TBG concentration is altered in
certain clinical circumstances and may lead to increased or decreased
total thyroxine levels. Factors increasing TBG concentration include
oestrogens, pregnancy, hepatitis and porphyria. Low TBG levels are
associated with androgens, cirrhosis, nephrosis and large doses of
steroids.
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Metabolism of Thyroid Hormones
Thyroid hormones undergo peripheral metabolism following secretion. T4
is metabolised by sequential removal of its iodine atoms. This process
is termed deiodination. Although all tissues are able to do this, most
T4 is metabolised in the liver and kidney. Removing either iodine atom
from the outer ring [the 3' or 5' positions] of T4 yields T3. By conven¬
tion this is referred to 5'-deiodination. T3 has greater metabolic
activity and so this process represents activation of T4. Removing
either iodine atom from the inner ring of T4 yields 3,35'-triiodothyr¬
onine, known as reverse T3 [rT3]. Reverse T3 has little or no metabolic
activity, and so 5-deiodination represents inactivation of T4. About 30%
of the T4 secreted each day is deiodinated to produce T3; this accounts
for 85% of the T3 produced each day. Deiodination is effected by speci¬
fic enzymes, three of which have been identified (Leonard, 1990). Type 1
deiodinase effects both 5 and 5' deiodination and is inhibited by 6-
propylthiouracil. Type I deiodinase is found mainly in the liver, kidney
and thyroid. Type II deiodinase is present in brain, pituitary and brown
adipose tissue and active in only 5'-deiodination. Type III deiodinase
if found in brain, skin and placenta deiodinates at both locations. Both
type II and type II enzymes are insensitive to propylthiouracil.
Thyroid hormones influence function of nearly all organs and tissues.
The extent of the influence is proportional to the degree of nuclear
receptor binding of T3 in the tissue. High T3 binding is found is thyr¬
oxine responsive tissues such as liver and kidney, whereas low binding
is found in tissues such as spleen in which thyroid hormones exert less
powerful effects. Entry of T3 across the cell membrane and into the
cytoplasm is by simple diffusion, as is T3 entry into the nucleus.
Nuclear receptors have been characterised and are tightly bound to
chromatin. Although T4 binds to nuclear receptors, 90% of nuclear thyr¬
oid hormone is T3. In many respects T4 is simply a prohormone of T3. The
marked effects of T3 on development, growth and function of the organism
are subserved in large part via regulation of gene expression. There is
also some evidence that T3 has direct actions on mitochondria and exerts
a degree of control over oxidative phosphorylation.
(3) Investigation of Thyroid Function
In common with reviews of the investigation of adrenocortical function,
most reviews of the investigation of thyroid function concentrate on the
139
use of tests to confirm or exclude specific thyroid disorders in other¬
wise healthy individuals. However, in contrast to the investigation of
adrenocortical function, most standard tests of thyroid function have
been validated in severe illness. The background to the tests used in
this thesis will be given below. The results of previous studies in
severe illness will be reviewed in Chapter 6.
Circulating Thyroid Hormone Concentrations
Serum T4 is the most useful first line test of thyroid function. It is
now measured by radioimmunoassay or by enzyme-mediated immunoassay
techniques. Knowledge of the state of thyroid protein binding is re¬
quired for strictly accurate interpretation of results, but is not
usually investigated routinely. The normal adult range of total T4 is 60
-160 nmol/L, with small variations between laboratories. T3 is measured
by radioimmunoassay and ranges from 1.2 - 3.4 nmol/L. T4 concentrations
remain constant in old age, but T3 levels tend to fall. This is most
probably a result of the increasing frequency of illness with age.
No special patient preparation is necessary when taking blood for thyr¬
oid hormone concentrations. Hormone levels are unaffected by exertion,
posture, or the stress of venepuncture. There is no detectable circadian
rhythm of T4, but a minor rhythm in T3 concentration has been documented
(Nimalasuriya et al, 1986). The same principals of performance and vali¬
dation of immunoassays detailed in Chapter 2 apply to assays of thyroid
hormones.
The concentrations of the free fractions of thyroid hormones are now
used increasingly frequently as an alternative to total hormone levels
in screening healthy individuals for thyroid disease. There are, how¬
ever, considerable difficulties in the interpretation of both free
thyroid hormone indices and free hormone concentrations during severe
illness (Slag et al, 1981; Kaptein et al, 1981; Becket et al, 1991). No
attempt was made to measure free thyroid hormones in this study.
Thyrotropin Concentration
Measurement of serum TSH is used primarily as a screening test for
hypothyroidism. The first generation of TSH RIAs were accurate within
the mid range of normal TSH values and accurately measured high values.
They were not able to differentiate between low normal values and sup¬
pressed values found in hyperthyroidism. These assays were not able to
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provide quantitative TSH values below 1 mU/L. Approximately 10% of
euthyroid individuals had TSH levels which were unmeasurably low.
In recent years, with the advent of ultrasensitive TSH assays, it has
become possible to detect very low concentrations of TSH in hyperthyroid
individuals (Wehmann et al, 1983; Eggersten et al, 1988). These immunor-
adiometric assays use 2 or 3 monoclonal antibodies targeted against
specific epitopes of the TSH molecule. This produces a more stable
radioligand and a higher assay sensitivity. These assays are accurate
down to TSH concentrations of 0.1 mU/L. Even greater assay sensitivity
is possible with immunochemiluminometric assays, which have working
sensitivities down to 0.05 mU/L and can easily separate euthyroid from
hyperthyroid patients (Weeks et al, 1984). Confirmation of TSH suppres¬
sion by TRH testing is therefore less often required.
Despite the increased sensitivity of modern TSH RIAs, the specificity
has remained high with little significant cross reactivity with LH, FSH
of hCG. The finding of a significant proportion of euthyroid individuals
with subnormal TSH levels measured using sensitive assays has led to
some diagnostic confusion. Recent studies of the significance of subnor¬
mal TSH levels in various clinically euthyroid populations are discussed
in Chapter 6.
Thyrotropin Releasing Hormone Stimulation Test
The TRH stimulation test provides a standard supraphysiological chal¬
lenge to pituitary TSH secretion. It allows the measurement of the
intrinsic TSH secretory reserve and the extent to which TSH secretion is
inhibited. TRH is effective in activating TSH secretion whether given
orally, intramuscularly, or intravenously. The standard test involves
the intravenous administration of either 200 or 400 meg TRH which pro¬
duces a maximal TSH response. In the UK, 200 meg TRH is the standard
dose (Ismail, 1981), whereas physicians in Europe and the USA tend to
use 400 meg. Irrespective of TRH dosage, the TSH concentration rises
rapidly, reaching a peak at 20 - 30 minutes. In normal individuals a TSH
increment of between 5 and 30 mU/L is expected, with a mean increment of
around 15 mU/L. In premenopausal women there is minor variation in the
TSH response with the menstrual cycle, and there is some decline in the
TSH increment with age. The factors discussed above, which inhibit or
augment basal TSH concentration tend to have the same effect on the TSH
increment following TRH.
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In clinical practice the TRH test is used most frequently to confirm the
diagnosis of hyperthyroidism. A normal TSH response excludes thyrotoxic¬
osis. In primary hypothyroidism the TSH response is accentuated, al¬
though, in the presence of an high basal TSH level, such confirmation is
not usually necessary. Suspected hypothyroidism with a low or normal TSH
concentration suggests pituitary or hypothalamic hypothyroidism. The TRH
test is of some use in this context. In pituitary hypothyroidism the TSH
response is small or absent, whereas in hypothalamic hypothyroidism the
response is normal but delayed. This approach is, however, far from
infallible. TRH stimulation often leads to small increments in thyroid
hormone concentrations, but the inconsistent response is of no diagnos¬
tic value, and is not routinely measured. The use of the TRH test during
illness will be discussed in Chapter 6.
There are no recognised contra-indications to TRH testing, although
caution is recommended in patients suffering from asthma and myocardial
ischaemia. The test is well tolerated , with only mild side effects such
as nausea, facial flushing, and a strange taste in the mouth.
Thyrotropin Stimulation Test
The TSH stimulation test involves the administration of purified bovine
TSH and the measurement of the thyroid hormone response. The test for¬
merly played a prominent role in the diagnosis of hypothyroidism, but is
now rarely used in clinical practice. It is occasionally used to deter¬
mine whether a patient taking thyroxine therapy has primary hypothyroid¬
ism. It can be used to investigate suspected subclinical primary hypo¬
thyroidism and to assess thyroid reserve. It may be used to differenti¬
ate between primary and secondary hypothyroidism. Stimulation with
exogenous TSH in conjunction with thyroid scintiscans is used to assess
whether or not thyroid nodules are functional. Used in this manner it is
of value in detection of remnants of thyroid carcinoma. Finally, bovine
TSH may be used therapeutically as an adjunct in the management of cer¬
tain types of functioning thyroid carcinoma.
Protocols for the performance of TSH stimulation tests vary depending
upon which of the above uses the test is to be put. The investigation of
patients receiving thyroxine replacement, the differentiation between
primary and secondary hypothyroidism, and the investigation of patients
with longstanding myxoedema require daily administration of TSH for 3
days (Querido and Stanbury, 1950; Skanse, 1953). To aid the diagnosis of
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thyroid cancer remnants requires administration for up to 7 days. A
single dose of TSH may be used to assess borderline or subclinical
hypothyroidism and to determine thyroid reserve (Fore and Wynn, 1966)).
A single dose as low as 1 IU has been used (Perlmutter et al, 1952), but
5 IU is required to produce a maximal thyroid response (Faber et al,
1976) and 10 IU is the recommended standard dosage (Taunton et al,
1965).
The expected response to the subcutaneous or intramuscular administra¬
tion of a single 10 IU dose of TSH is well defined. In normal individ¬
uals the thyroid radioiodine uptake and plasma protein-bound iodine are
increased at 4 hours, peak at 12 to 18 hours and begin to decline by 24
hours. The increment of both these indices range from 25 to 50% in
normal individuals and less than 10% in hypothyroid patients (Jefferies
et al, 1959). The serum T4 increment should be at least 20 nmol/L
(Burke, 1968). The fractional increase in T3 concentration is usually
greater than T4 (Faber et al, 1976).
A low thyroid reserve in clinically euthyroid individuals is found after
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I treatment or surgical therapy for Grave's Disease, and also in
Hashimotos's thyroiditis (Jefferies et al, 1956). The significance of a
low thyroid reserve in clinically euthyroid patients is unclear. In one
study 10 such patients, with no history of thyroid disease, were identi¬
fied (Burke, 1968). On follow-up for a mean of 4 years only 2 of the 10
patients developed clinical hypothyroidism. There has been virtually no
work on TSH testing published over the past 20 years, and there have
been no studies of TSH testing during illness.
TSH testing is a relatively safe procedure. Exogenous TSH is contraindi-
cated following myocardial infarction, in cardiac failure, and in un¬
treated Addison's disease. There were no serious toxic reactions in the
87 euthyroid patients studied by Taunton et al (1965) or the 211 pa¬
tients studied by Burke (1968). Pain at the site of injection is not
infrequent, and very occasionally urticaria may develop. In rare in¬
stances anaphylaxis has been reported. It has been suggested that pa¬
tients should be given a small subcutaneous test dose of TSH prior to
the full test in order to detect any allergic tendency. Systemic symp¬
toms such as nausea, vomiting, fever and tachycardia are unusual after
administration of 10 IU TSH, but are frequent at higher doses (Querido
and Stanbury, 1950).
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(4) Factors Confounding the Interpretation of Thyroid Function Tests
During Critical Illness
The changes in thyroid function which take place during illness were
detailed in Chapter 1. A number of other factors complicate the inter¬
pretation of these changes in an intensive care population.
Age and Thyroid Function
Critical illness increases in frequency with age. The effects of age on
thyroid function must, therefore, be considered before interpreting the
interrelationships between thyroid hormone concentrations, illness and
mortality. Total T4 concentration is normal or only slightly decreased
in old age (Hesch et al, 1976; Nishekawa et al, 1981; Kabadi and Rosman,
1988), although metabolic clearance and T4 turnover are decreased
(Gregerman et al, 1962). Free T4 concentration remains normal with
advancing age (Lipson et al, 1979). Many studies have demonstrated a
decline in serum T3 with increasing age (Jefferys et al, 1972; Nishekawa
et al, 1981; Wartofsky and Burman, 1982), but this may be due to the
high frequency of concomitant illnesses in the elderly population (Olsen
et al, 1978; Simons et al, 1990). Basal TSH levels are normal or mildly
elevated (Hermann et al, 1974; Lipson et al, 1979) with advancing age,
while the TSH response to TRH may be blunted (Snyder and Utiger, 1972;
Demeester-Mirkine et al, 1981; Finucane et al, 1991). It has been sug¬
gested that a normal TSH may not be a valid index of euthyroidism in the
elderly, since only 50% of aged patients will augment their TSH response
to TRH after iodine-induced decrements in their serum T3 and T4 levels
(Ordene et al, 1981).
Drugs and Thyroid Function
The effects of some drugs on TSH secretion and TBG concentration are
discussed above. However, a number of other drugs are worthy of mention.
Amiodarone, a heavily iodinated antiarrythmic agent, is a potent inhibi¬
tor of 5'-monodeiodinase for T4. Administration leads to a decline in T3
concentration and and increase in rT3 concentration. Amiodarone is also
apt to induce hyperthyroidism or hypothyroidism, probably as a result of
iodine release as the drug is metabolised. Propranolol is also capable
of inhibiting peripheral 5'-monodeiodinases. Again serum T3 falls and
rT3 increases, but TSH concentration and responsivness to TRH are un-
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changed. Small intravenous doses of heparin are followed within a few
minutes by increases in the serum T4 value and the percentage of free
T4. Serum T3 remains normal but TSH concentration is decreased. Inhibi¬
tion of T4 protein binding is thought to be involved.
Surgery and Thyroid Function
The serum total and free T3 levels fall rapidly after surgery (Adami et
al, 1978; Chernow et al, 1983), and are related to the severity of the
surgical trauma and prognosis (Philips et al, 1981). T4 levels fall on
the day following surgery and rT3 levels rise (Kehlet et al, 1979). TSH
levels measured with sensitive assays fall following surgery (Chu et al,
1991). If recovery is uncomplicated, hormone levels tend to normalise by
the 5th postoperative day.
Nutrition and Thyroid Function
In the first few days of severe illness patients are frequently deprived
of nutrition. In the absence of illness this would alter thyroid func¬
tion and is therefore a potential confounding variable in the analysis
of the response of the H-P-T axis to illness. With total caloric depri¬
vation the serum T3 concentration falls within 24-48 hours, rT3 levels
rise and serum T4 may fall (Burman et al, 1979; O'Brian et al, 1980;
Borst et al, 1983). The basal TSH concentration and the TSH response to
TRH are usually diminished (Borst et al, 1983). Refeeding with glucose
returns hormone concentrations to normal if given orally (Burman et al,
1979), but not if given intravenously (Westgren et al, 1977). Refeeding
with fat or protein has little effect (Azizi, 1978; O'Brian et al,
1980).
In calorie-deprived patients, the pulse rate decreases and the QKd
interval and systolic time interval are prolonged (Meyers et al, 1980).
Basal metabolic rate decreases (Huang et al, 1981), and can be restored
to normal with T3 replacement (Mince et al, 1980). On the basis of this
evidence it has been suggested that starvation leads to an hypothyroid
state intended to limit catabolism (Wartofsky and Burman, 1982). Whilst,
not proven, it would be surprising if evolution had not led to the
development of such a response.
Renal Failure and Thyroid Function
When considering the effect of acute renal failure on thyroid function,
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it is difficult to distinguish between effects of renal failure and
effects of coexisting illness. However, the changes in thyroid hormone
levels during severe illness are reported to be similar in patients with
and without acute renal failure (Kaptein et al, 1981). The main differ¬
ence is a smaller increase in rT3 levels in patients with renal failure.
The same problem arises in patients with chronic renal failure, but
certain changes do appear to be associated with chronic renal failure,
irrespective of associated illness. Serum T4 and free T4 are reduced to
subnormal levels in approximately 25% of cases and TSH levels tend to be
low normal (Hardy et al, 1988; Van Leusen and Meinders, 1982). Following
haemodialysis T3 and TSH remain normal, but T4 and free T4 rise, return¬
ing to normal after 48 hours (Van Leusen and Meinders, 1982). Haemodia¬
lysis should be avoided during dynamic tests of thyroid function, but
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The main aims of the studies detailed in this chapter were
as follows:
1) To determine the range of concentration of TSH during
critical illness using a sensitive assay in patients not
receiving dopamine or steroids.
2) To determine the range of concentrations of total thyr¬
oxine and total triiodothyronine and to relate the concen¬
tration of these hormones to metabolic rate, severity of
illness and mortality.
3) To determine the range TSH responses to a standard TRH
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test during critical illness using a sensitive assay in
patients not receiving dopamine or steroids.
4) To determine the thyroid hormone response to a TSH
stimulation test during severe illness.
(2) Patients and Methods
The background to the tests used in this chapter was discus¬
sed in Chapter 5 and details of the patients investigated
and the setting of the study were given in Chapter 2.
(a) Measurement of Thyroid Hormones and TSH on Admission
Blood was taken for measurement of serum TSH, thyroxine, and
triiodothyronine in 260 consecutive admissions not receiving
steroids or dopamine. If possible, blood was taken prior to
commencement of sedatives or inotropes. A note was taken of
all medications taken in the past 24 hours. APACHE II scores
were calculated on data obtained during the first 24 hours
of admission. The physicians caring for the patients in the
study had access to the thyroid function results. Plasma
Cortisol concentration was measured on blood sampled at the
same time as the blood for measurement of thyroid function.
In patients in whom TSH was raised on admission, a repeat
blood sample was taken following recovery and discharge from
the ICU. No set time after discharge was specified.
(b) Estimation of Metabolic Rate
Metabolic rate was estimated indirectly by measuring carbon
dioxide production. Carbon dioxide production was measured
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in 100 consecutive patients who were ventilated on admission
to the ICU or within the first 12 hours of admission. A
measurement was made within 12 hours of admission or venti¬
lation and repeated 12 hours later.
All expired respiratory gases were collected from the venti¬
lator "exhaust port" using a 150 litre Douglas bag. Between
100 and 150 litres of gas was collected over an accurately
timed period. A sample of the gases was obtained, using a
glass syringe, and passed through an automatic blood gas
analyser [Investigation Laboratories 1312]. Readings of the
partial pressure of carbon dioxide, the ambient atmospheric
pressure and the temperature of the sample were obtained.
The volume of gas was measured by passing the contents of
the Douglas bag through a modified gas meter, giving a
reading of volume in cubic feet which was then converted to
litres. Respiratory gases were collected with the patient at
rest and procedures such as physiotherapy and haemodialysis
were avoided.
All the above data were then entered into a computer con¬
taining a software package which calculated the metabolic
rate of the patient using the rate of carbon dioxide produc¬
tion and assuming a respiratory guotient of 0.8. A measure¬
ment of the weight of the patient, obtained on the day of
admission to the ICU, was used to correct the metabolic rate
for body mass.
(c) Thyrotropin Releasing Hormone Tests
Thyrotropin releasing hormone stimulation tests were per-
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formed on 30 patients and 8 healthy controls. Patients
investigated fulfilled the following criteria: a) acute
illness of less than 28 days duration; b) no history of
thyroid or pituitary disease; c) no dopamine or steroid
medication for at least 72 hours; d) APACHE II score greater
than 15. Patients were investigated at any point in their
ICU stay, and no time of day was specified.
Blood was sampled for measurement of basal TSH concentra¬
tion. An intravenous injection of 400 meg TRH (TRH-Roche,
Roche Products Limited, Hertfordshire, UK) was then adminis¬
tered and further blood samples taken 20 and 60 minutes
after the injection. Blood transfusion and haemodialysis
were avoided during the tests, but no other limitations were
specified. Measurements of thyroxine and Cortisol were made
on blood taken at the time of the basal TSH sample. APACHE
II scores were calculated on data obtained on the day of the
test.
(d) Thyrotropin Stimulation Tests
Thyrotropin stimulation tests were performed in two groups
of patients. All patients had an acute illness of less than
28 days duration, no past history of thyroid or pituitary
disease, no steroid or dopamine medication for the past 72
hours and an APACHE II score of greater than 15. Patients in
Group 1 had T4 concentration less than 20 nmol/L, TSH con¬
centration less than 0.5 mU/L and a TSH increment following
TRH of less than 5 mU/L. Patients in Group 2 had a T4
concentration of greater than 60 nmol/L and TSH concentra-
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tion was greater than 2.0 mU/L. Group 1 comprised 7 patients
and Group 2 comprised 6 patients.
Twelve hours before the full TSH stimulation test was per¬
formed, a small subcutaneous injection of TSH was given.
This comprised 0.25 units of bovine TSH in 0.5 ml saline. If
there was any evidence of a local or systemic allergic
reaction over the subsequent 12 hours the full TSH test was
not performed.
Blood was sampled for a basal measurement of TSH, thyroxine,
and triiodothyronine concentrations. Immediately after the
basal sample was taken an intramuscular injection of 10
units of bovine TSH (Thyrotropar, Armour Pharmaceutical
company, Eastbourne, Sussex, UK) was given. The TSH was
diluted with 5 ml 0.9% saline prior to injection. All injec¬
tions were given into deltoid muscle. Blood was taken for
measurement of total T4 and T3 concentrations at 4, 12 and
24 hours after injection. No limitations were placed on the
timing of the test or on patient management during the test,





Measurements of TSH, thyroxine, triiodothyronine and Corti¬
sol were available in 260 cases. The distribution of thyro¬
tropin concentration was non-parametric with a tail of
higher values [Fig 6.1]. Logarithmic transformation gave a
normal distribution [Fig 6.2]. Seventy four patients [29%]
had TSH concentrations outside the normal range of the assay
used [0.4 - 5.0 mU/L]. Thirty nine patients had low TSH con¬
centrations, of whom 15 had concentrations below 0.1 mU/L.
Thirty five patients had high TSH concentrations, none of
whom had a past history of thyroid disease. Mean [SD] admis¬
sion TSH concentration was 2.58 [3.35] mU/L. The median TSH
concentration was 1.6 mU/L [range < 0.1 - 21.0].
There was no relation between time of admission, age or sex
and TSH concentration. There was a negative correlation
between TSH concentration and APACHE II score [r = -0.355,
P<0 . 01 ] .
Table 6.1. TSH concentrations on admission in 260 patients according to
APACHE II score.
APACHE SCORE < 16 16-24 > 24
NUMBER OF CASES 89 105 66
TSH [mU/L]:
MEAN [95% CI] 3.6 [2.8-4.4] 2.3 [1.9-2.7] 1.4 [0.9-1.8]
MEDIAN [RANGE] 2.4 [<0.1-21] 1.6 [<0.1-13] 1.0 [<0.1-8]
95% RANGE 0.4 - 16 0.1 - 10 < 0.1 - 5
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The mean, median and 95% range (obtained by log transforma¬
tion) of TSH concentration is given within the three stan¬
dard APACHE II score groups in Table 6.1. The mean APACHE II
scores differed significantly between the three groups. Each
of the groups contained TSH concentrations above and below
the normal range. However, TSH concentrations below the
normal range for health [0.4 mU/L] are outwith the 95% range
for patients with APACHE II scores <16, and concentrations
above the normal range for health [5.0 mU/L] are outwith the
95% range for patients with APACHE II scores > 24.
Mortality decreased as TSH concentration increased [Fig
6.3]. Mortality of patients with TSH concentations below
the normal range in health was 72%(95% CI, 55-85) compared
with 30% (95% CI, 24-37) among patients with TSH concentra¬
tions within the normal range and 11% (95% CI, 2-27) in
patients with concentrations above the normal range (X for
trend, P<0.001, Table 6.2).
Table 6.2. Mortality, thyroxine [T4], triiodothyronine [T3], Cortisol
and APACHE II scores in patients with low, normal and high TSH concen¬
trations [ mean (SD)]
TSH CASES DEATHS T4 T3 CORTISOL APACHE II
mU/L [%] nmol/L nmol/L nmo1/L SCORE
<0.4 39 28 [72] 26 [13] 0.21 [0.1] 1692 [741] 32 [11]
0.4-5 186 56 [30] 69 [21] 0.34 [0.16] 974 [470] 22 [10]
>5.0 35 4 [11] 83 [23] 0.62 [0.19] 587 [274] 16 [7]
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TSH concentration correlated positively with T4 concentra¬
tion [r = 0.48, p<0.001, Fig 6.4] and negatively with Corti¬
sol concentration [r = -0.57, p<0.001, Fig 6.5]. The corre¬
lation between TSH concentration and T3 was less marked, but
remained significant [r = 0.26, p<0.05].
TSH concentrations were higher in patients who subseguently
survived than in those who died [Table 6.3]
Table 6.3. Median [range] concentrations of TSH and Cortisol, and






















In 21 cases with a raised TSH concentration on admission, a
repeat measurement was made after ICU discharge. The mean
[SD] TSH on admission was 9.6 [6.1] mU/L, and mean [SD] T4
concentration was 76 [24] nmol/L. Following discharge TSH
was within the normal range in 14 cases, and had fallen in
17 cases. The mean [SD] TSH and T4 concentrations after dis¬
charge were 6.1 [3.9] mU/L and 89 [28] nmol/L respectively.
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Thyroid Hormone Concentrations
The distribution of T4 concentration was approximately para¬
metric [Fig 6.6]. Mean admission T4 concentration was 66
nmol/L [SD = 28]. Thyroxine concentration was below the
normal range for the assay [60 nmol/L] in 138 cases. In 14
cases, T4 concentration was below 10 nmol/L. A raised T4
concentration [> 160 nmol/L] was found in 2 cases.
Thyroxine concentration correlated inversely with APACHE II
scores [r = -0.44, p<0.005] and plasma Cortisol concentra¬
tion [r = -0.39, p<0.01]. There was no correlation with age
or sex. Admission T4 concentration was related to outcome
with mortality increasing as T4 concentration fell [Fig
6.7]. Thyroxine concentration was significantly higher in
survivors than nonsurvivors [Table 6.4].
Table 6.4. Median [range] concentrations of thyroxine, triiodothyr¬




























Allocation of patients into the three APACHE II score groups
produced significantly different mean T4 concentrations
(Table 6.5). The 95% range of thyroxine concentration also
differed between the three APACHE II score groups. In pa¬
tients with an APACHE II score < 16, thyroxine concentra¬
tions will usually be greater than 40 nmol/L whereas pa¬
tients with APACHE II scores > 24 will often have thyroxine
concentrations of less than 10 nmol/L.
Table 6.5. Mean, median and ranges of thyroxine concentration in
patients grouped according to APACHE II score.
APACHE SCORE < 16 16-24 > 24
NUMBER OF CASES 89 105 66
THYROXINE [nmol/L] •
MEAN [SD] 82 [19] 55 [31] 33 [29]
MEDIAN [RANGE] 75 [26 - 177] 52 [12 - 146] 30 [<10 - 117]
95% RANGE 40 - 160 20 - 140 <10 - 110
Although nonsurvivors had lower thyroxine concentrations
than survivors, mortality was not strongly related to thyr¬
oxine concentration within the three APACHE II score groups
[Table 6.6]. Overall, mortality fell as thyroxine concentra¬
tion increased, but this was less evident within the APACHE
II score groups. Patients with low thyroxine concentrations
did not have a significantly higher mortality than the
remainder of their APACHE II score group.
Triiodothyronine concentration was below the normal range of
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the assay [1.1 nmol/L] in 182 cases [70%], and below 0.4
nmol/L in 151 cases [58%]. The distribution was non-para¬
metric [Fig 6.8]. Triiodothyronine concentrations were lower
in nonsurvivors than survivors [Table 6.4].
Table 6.6. Mortality according to APACHE II score group and admission
thyroxine concentration.
APACHE II % MORTALITY [DEATHS/CASES]
SCORE: <16 16-24 >24 TOTAL
T4 [nmol/L]
< 10 0 [0/0] 60 [3/5] 67 [6/9] 64 [9/14]
10 - 30 22 [2/9] 39 [9/23] 71 [15/21] 49 [26/53]
30 - 60 21 [5/24] 29 [8/28] 74 [14/19] 38 [27/71]
> 60 7 [4/56] 31 [15/49] 41 [7/17] 21 [26/122]
TOTAL 12 [11/89] 33 [35/105] 64 [42/66] 34 [88/260]
Thyroid Hormones and Metabolic Rate
The mean [SD] APACHE II score of patients studied was 25.2
[9.4]. Thirty eight patients [38%] died. The results de¬
tailed below refer to the mean of the two measurements of
metabolic rate obtained on each patient. The difference
between the two measurements was expressed as a percentage
of the mean of the measurements. The mean [SD] variation
between the two measurements in the 100 cases studied was
6.8% [2.2] .
The mean metabolic rate was 132 kJ/kg/24 hours. There was no
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difference between males and females [134 vs 129 kJ/kg/24h].
The predicted basal metabolic rate [PBMR] during health,
corrected for weight and sex, was obtained in each case from
standard tables. The difference between the measured metabo¬
lic rate and the PBMR was expressed as the percentage excess
of the former over the latter. This is termed the "excess
metabolic rate [EMR]".
In 3 cases, one of whom was hypothermic, the EMR was egual
or less then zero. In the remaining 97, cases the EMR was
greater than the zero. In 81 cases, the EMR was greater than
25% and in 28 cases it was greater than 50% [Fig 6.9].
Nonsurvivors had a higher mean (SD) EMR than survivors [52%
(23) vs 37% (21), MD = 15%, 95% CI = 6.2-23.8]. There was no
relationship between EMR and age, sex, or previous surgery.
The EMR correlated positively with APACHE II scores [r
0.27, p<0.05] and negatively with admission thyroxine con¬
centration [r = -0.35, p<0.05, Fig 6.10]. The EMR also
correlated with body temperature [r = 0.31, p<0.05]. There
was no significant correlation with thyrotropin, triiodo¬
thyronine or Cortisol concentrations.
TRH Tests
The mean [SD] APACHE II score of patients studied [14 fe¬
male, 16 male] was 23.4 [5.1]. The mean TSH concentration
increased significantly following administration of TRH in
both cases and controls [Table 6.7]. The TSH increment was
defined as the difference between the basal TSH concentra¬
tion and the higher of the 20 and 60 minute levels. The
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range of TSH increments was greater in cases than controls.
In 5 cases there was no detectable TSH increment, and in a
further 8 cases the increment was less than 2 mU/L [Figs
6.11 and 6.12]. The mean [SD] TSH increment in the control
cases was 11.7 [2.1]. All of the control cases had a TSH
increment of greater than 9 mU/L [Fig 6.13]. In 26 [87%] of
the ICU cases, the TSH increment was less than 9 mU/L. The
median TSH increment in the ICU cases was 3.2 mU/1 [range 0
- 14.1]
There was a significant correlation between the basal TSH
concentration and the TSH increment following TRH [r = 0.68,
p<0.01]. The TSH increment correlated positively with T4 con¬
centration [r = 0.49, p<0.05]] and negatively with Cortisol
concentration [r = -0.52, P<0.05]] and APACHE II score [r =
-0.46, p<0.05]]. The mean (SD) TSH increment following TRH
was 8.6 [3.1] mU/L in survivors [n = 19] and 1.8 [1.3] mU/L
in nonsurvivors [MD = 6.8 mU/L, 95% CI = 4.8 - 8.8]. There
was no correlation between the TSH increment and either age
or sex.
Table 6.7. The mean [SD] thyrotropin response to TRH stimulation
tests in cases and controls.
THYROTROPIN CONCENTRATION [mU/L]
TIME [mins] 0 20 60
CASES [N=30] 1.05 [0.54] 4.1 [3.4] 5.3 [4.7]
CONTROLS [N=8] 1.15 [0.44] 10.1 [1.3] 14.4 [1.2]
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TSH Tests
The mean [SD] APACHE II scores of patients in Group 1 [4
male, 3 female] was 31.1 [4.0], and the mean [SD] score in
Group 2 [4 female, 2 male] was 19.1 [2.7]. There were no
allergic reactions to the subcutaneous test dose of TSH, and
no reactions to the full TSH dose during the test. In the 4
control cases, both T4 and T3 concentrations were increased
at 4 hours after injection of TSH, and remained higher at 24
hours [Fig 6.14]. The mean concentration of T4 was signific¬
antly higher than the basal level at 12 hours [MD = 34
nmol/L, 95% CI 11.5 - 56.5], but this no longer reached
significance at 24 hours [Table 6.8]. The increment in
hormone concentration was defined as the difference between
the basal concentration and the highest of the subseguent
measurements. The mean [SD] increment in T4 concentration in
control cases was 33.8 [12.9] nmol/L. The mean [SD] incre¬
ment in T3 concentration was 1.78 [0.66] nmol/L.
In Group One, concentrations of both T4 and T3 were in¬
creased in all 7 cases at 4 hours, and remained higher than
the basal level at 24 hours [Fig 6.15]. The mean T4 concen¬
tration was significantly higher than the basal level at 4
hours [MD = 37 nmol/L, 95% CI = 17 - 57], and remained so at
12 and 24 hours. The mean T3 concentration was higher than
basal at 4 hours [MD = 1.44 nmol/L, 95% CI = 0.74 - 2.14],
and remained so at 12 and 24 hours. The mean [SD] incre¬
ments in T4 and T3 concentration were 48.9 [19.5] and 1.9
[1.3] nmo1/L.
In Group Two, concentrations of T4 and T3 were increased in
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all 6 cases at 4 hours, and remained higher than their basal
concentrations at 12 and 24 hours [Fig 6.16]. The mean T4
level was higher than the mean basal concentration at 4
hours [MD = 18.4 nmol/L, 95% CI = 4 -23] and 12 hours [MD
18.2 nmol/L, 95% CI = 8 - 28], but fell back towards the
basal level at 24 hour. The mean T3 concentration was higher
than basal at 4 hours [MD = 1.21 nmol/L, 95% CI = 0.55 -
1.87] and remained significantly higher at 12 and 24 hours.
The mean [SD] increment in T4 concentration was 21.5 [9.3]
nmol/L. The mean [SD] increment in T3 concentration was
1.53 [0.82] nmol/L.
Table 6.8. The mean [SD] concentrations of thyroxine and triiodo¬
thyronine during thyrotropin stimulation testing.
TIME [hours] 0 4 12 24
CONTROLS:
T4 100 [14.2] 119 [11.7] 134 [11.7] 120 [12.4]
T3 1.5 [0.41] 2.6 [0.62] 3.3 [0.65] 2.6 [0.58]
GROUP 1:
T4 13 [3.7] 50 [24.5] 56 [16.3] 49 [11]
T3 0.4 [0.07] 1.9 [0.85] 2.3 [1.28] 1.5 [0.85]
GROUP 2:
T4 72 [8.3] 91 [13.8] 91 [6.8] 78 [12.9]
T3 0.9 [0.41] 2.1 [0.60] 2.2 [0.87] 1.5 [0.39]
The mean T4 increment in Group One was significantly higher
than that in Group Two [MD = 27.4, 95% CI = 8.2 - 46.6]. The
mean increment in T3 concentration in Group One was greater
than in Group Two, but this did not reach statistical sig-
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nificance. The proportional increase in the concentration of
both hormones was clearly much greater in Group One than in
Group Two. There was a significant fall in the T4 concentra¬
tion in Group Two between 12 and 24 hours [MD = 13.2 nmol/L,
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FIG 6.7. MORTALITY IN PATIENTS GROUPED ACCORDING
TO ADMISSION THYROXINE CONCENTRATION
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FIG 6.14. THYROXINE AND TRIIODOTHYRONINE RESPONSES TO A
THYROTROPIN STIMULATION TEST IN CONTROLS
"•"control 1 "X"control 2 ♦control 3 ▼ control 4
Solid line: thyroxine Dotted line: Triiodothyronine
FIG 6.15. THYROXINE AND TRIIODOTHYRONINE RESPONSES TO A
THYROTROPIN STIMULATION TEST: GROUP ONE
THYROXINE [nmol/L] TRIIODOTHYRONINE [nmol/L]
TIME [hours]
♦ case 1 ♦case 2 ♦case 3 ♦case 4 ▼case 5 "X" case 6 "X- case 7
Solid line: Thyroxine Dotted line: Triiodothyronine
FIG 6.16. THYROXINE AND TRIIODOTHYRONINE RESPONSES TO A
THYROTROPIN STIMULATION TEST: GROUP TWO
THYROXINE [nmol/L] TRIIODOTHYRONINE [nmol/L]
TIME [hours]
"■"case 1 "X~case 2 ♦case 3 ♦ case 4 "X- case 5 ♦case 6
Solid line: Thyroxine Dotted line: Triiodothyronine
Discussion
TSH Concentration, Severity of Illness and Mortality
The majority of TSH concentrations in this study were within
the reported working range of the assay. However, 15% of
cases had subnormal TSH concentrations. How should this be
interpreted. Studies of the ability of modern TSH assays to
identify cases of hyperthyroidism (Spencer et al, 1987;
01 Hare et al, 1991) have demonstrated a high sensitivity but
a relatively low specificity. In other words, a significant
proportion of cases with subnormal TSH concentrations did
not have hyperthyroidism, although an undetectable TSH level
(<0.1 mU/L), using a sensitive immunoradiometric assay, was
more specific. Studies of the range of TSH concentrations in
other populations are detailed in Table 6.9. The prevalence
of low TSH levels in the ICU-based studies was high, but a
significant proportion of patients were receiving dopamine
or steroids. There is no published data concerning the range
of TSH concentrations in a large number of severely ill
patients not receiving dopamine or steroids.
Chosich et al (1989) demonstrated a low prevalence of sub¬
normal TSH levels in a heterogeneous group of hospital
patients [Table 6.9]. On repeat sampling, 80% of these cases
still had subnormal concentrations. The causes of subnormal
TSH levels were treated hyperthyroidism [35%], thyroxine
replacement therapy [12%], euthyroid multinodular goitre
[17%], pituitary disease [8%] and acute illness [28%].
Excluding patients with pituitary or thyroid disease, the
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prevalence of subnormal TSH levels fell to 1.2%. Exclusion
of cases with biochemical hyperthyroidism from the study by
Arem et al (1990) gave a prevalence of subnormal TSH levels
of 4.1% in outpatients and 5.6% in inpatients. However, this
was a retrospective study, and the proportion of patients
with a history of pituitary or thyroid disease, or receiving
steroids, dopamine, or thyroxine replacement therapy was not
given.
Table 6.9. Previous studies of TSH concentration, measured using a
sensitive immunoradiometric assay, during illness.
STUDY TYPE [number] NORMAL % ABNORMAL VALUES (95% CI)
OF PATIENTS RANGE [mU/L] LOW HIGH
Wehmann et al ICU (35) 0.3-5.0 31 [17-49] 0 [0]
(1985)
Chosich et al Hospital >0.3 4.3 [3.3-5.5] 3.8 [2.8-4.9]
(1989) (1400)
Arem et al Outpatients 0.3-5.0 11.6[8-16] 5.6 [3.2-9]
(1990) (267)
" Inpatients 0.3-5.0 8.5 [6-11.6] 6.8 [4.6-10]
(411)
ICU (37) 0.3-5.0 16 [6-32] 22 [10-14]
Spencer et al Hospital 0.4-5.0 23 [21-25] 12 [10-14]
(1987) (1580)
Boles et al ICU (34) 0.4-5.0 38 [22-56] 0 [0]
(1987)
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On the basis of the published evidence it seems likely that
the prevalence of subnormal TSH levels in hospital popula¬
tions, excluding patients with known thyroid disease, is in
the region of 1-5%. The 15% [95% CI = 10.7-19.3] prevalence
of subnormal TSH concentrations in this study is unlikely to
be due solely to an high incidence of undiagnosed hyperthyr¬
oidism or multinodular goitre. However, although individual
TSH assays are reported to have low coefficients of varia¬
tion, Piketty et al (1987) found that disagreement between
different immunoradiometric TSH assays kits at subnormal and
low normal concentrations was much greater. This must
undermine the validity of low TSH concentrations measured
using a single assay. On the other hand, the negative
correlation between TSH concentration and APACHE II scores
in this study, and the association between low TSH levels
and high mortality, suggest that a low TSH level has clini¬
cal validity.
Why TSH levels correlate so strongly with severity of ill¬
ness is unclear. There was no correlation between TSH levels
and the potential confounding factors such as recent surg¬
ery, time of day, nutritional state and renal failure, when
the effect of severity of illness was taken into account.
The inverse correlation between plasma Cortisol concentra¬
tion and TSH concentration suggests that the very high
concentrations of Cortisol found during severe illness may
suppress TSH synthesis and/or secretion.
The prevalence of raised TSH levels in this study was 13.5%
[95% CI = 9.3-17.6]. There is no published work detailing
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the frequency of increased TSH concentration in a large
group of critically ill patients, with no history of thyroid
disease. No raised TSH concentrations were found by Boles et
al (1987) in 34 ICU patients or Wehmann et al (1985) in 35
severely ill patients undergoing bone marrow transplanta¬
tion. However, patients in both studies received steroids
and dopamine. Increased TSH concentrations have been repor¬
ted in small numbers of patients on recovery from illness
(Bacci et al, 1982; Hamblin et al, 1986), but these findings
coincided with cessation of dopamine therapy. Brent et al
(1986) reported 3 critically ill patients with TSH concen¬
trations in the hypothyroid range [>20 mU/L], in whom
investigation revealed high normal thyroid hormone levels
and a normal response to TRH. Wong et al (1981) reported two
similar cases. On the basis of this evidence, Spencer [1988]
argued that raised TSH concentrations during acute illness
do not necessarily indicate hypothyroidism. This is con¬
firmed by the findings in this thesis. Indeed, patients with
raised TSH concentrations had the highest concentrations of
total T4, and raised TSH concentrations tended to fall on
recovery from illness. It has been suggested that high TSH
levels indicate recovery from illness and precede the in¬
crease in T3 an T4 levels (Bacci et al, 1982; Spencer et al,
1987). However, in this study, high TSH levels were found
early in the evolution of the illness.
The high mortlality in cases with low TSH is not unexpected
given the correlation between TSH and severity of illness.
The association of high TSH levels with a very low mortality
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is more difficult to explain. This prognostic value of TSH
concentration in critical illness has not been reported
previously.
TRH Tests
TRH tests are useful in determining the significance of
isolated low TSH concentrations. The expected response to
TRH is an increment in TSH concentration of between 5 and 30
mU/L. In two thirds of the ICU patients studied, the TSH
increment was below 5 mU/L, and there was virtually no
overlap in TSH increment between cases and controls. Impair¬
ment of TSH responsiveness to TRH has been documented pre¬
viously during illness [Table 6.10].
Table 6.10. Details of previous studies of TSH responsiveness to TRH
stimulation tests during illness, including whether or not patients
studied were receiving treatment with dopamine or steroids.
Study PATIENTS N MEAN [SD] TSH DOPAMINE OR
INCREMENT STEROIDS
Maturlo et al (1980) Medical 15 3.8 [0.5] No
Vierhapper et al (1982) ICU 16 4.4 [1.8] Yes
Becker et al (1982) Burns 10 9.5 [4.6] No
Quint et al (1985) ICU 13 8.0 [5.6] DK
Boles et al (1987) ICU 34 5.1 [0-14]* DK
* median [range]
A number of other studies gave only gualitative results of
TRH tests. Heinen et al (1980) investigated 7 ICU patients
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with low T4 levels and found the TSH response to TRH to be
"minimal" or absent in all 7 cases. However, all cases were
treated with high doses of dopamine and steroids. Similarly
impaired responsiveness in dopamine-treated ICU cases was
noted by Faber et al (1987). Some studies have reported no
impairment of TSH response to TRH during illness. Talwar et
al (1976) found a mean [SD] TSH increment following TRH of
14.3 [2.1] mU/L in 12 febrile patients suffering from infec¬
tions. Boles et al (1987] found that severely ill patients
with subnormal basal TSH levels had near normal responses to
TRH.
The present study suggests that pituitary responsiveness to
TRH is impaired in the majority of severely ill patients,
and absent in a significant proportion. Impaired TSH respon¬
siveness has been reported in renal failure (Czernichow et
al, 1976), and as a consequence of fasting (Borst et al,
1983), but there was no association between renal dysfunc¬
tion or absence of nutritional replacement and impaired TSH
responsiveness in this study. Patients with a poor response
to TRH tended to have low basal TSH and total T4 concentra¬
tions raising the possibility that in some patients reduced
TSH secretion might contribute to the low circulating thyr¬
oid hormone levels.
TSH Tests
TSH stimulation tests during illness have not been reported
previously. The increases in thyroid hormone concentrations
in controls were within the expected range. The finding that
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patients with low basal T4 and TSH concentrations and a poor
response to TRH had the highest increments in thyroid
hormone levels following TSH is interesting. Interpretation
of increased thyroid responsivness to TSH in critically ill
patients with apparent impairment of TSH secretion is diffi¬
cult, but the finding is not inconsistent with the hypoth¬
esis that reduced TSH secretion may contribute to the low
concentrations of thyroid hormones in some critically ill
patients. Furthermore, it suggests that function of the
thyroid gland itself is not commonly impaired during criti¬
cal illness, even in patients with otherwise widespread
organ failure.
Thyroid Hormone Concentrations
The T4 and T3 concentrations found in this study are con¬
sistent with previous studies of thyroid function in criti¬
cal illness [Table 6.11]. However, the comparatively small
size of previous studies has not allowed accurate definition
of the expected range of T3 and T4 concentrations during
illness, and although hormone levels have been shown to fall
as illness severity increases, the exact relationship has
not been defined in terms of APACHE II scores.
In addition to the work outlined in Table 6.11, 2 further
studies of thyroid hormones should be mentioned. Song et al
(1991) investigated 133 severely ill patients and found that
60% had a T4 concentration below 78 nmol/L, 53% had T3
concentrations below 0.9 nmol/L, and that there was a strong
association between low T4 levels and a poor outcome. Ham-
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blin et al (1986) investigated 60 ICU patients and found
that 24 [40%] had T4 levels below 35 nmol/1. In the study by
Slag et al (1981), 19 out of 86 [22%] ICU patients had T4
levels of less than 40 nmol/L, and this group had an 84%
mortality compared with a 15% mortality among patients with
T4 levels within the normal range.
Table 6.11. Previous studies of thyroid hormone concentrations in severe
illness.
STUDY TYPE (NUM) THYROXINE [nmol/L] TRIIODOTHYRONINE [nmol/L]
OF CASES MEAN [SD] RANGE MEAN [SD] RANGE
Slag et al ICU 89.7 [16] <38-150 n/a n/a
(1981) (86)
Bacci et al ICU 52.8 [19] n/a 0.50 [0.3] n/a
(1982) (51)
Kaplan et al Medical 53.4 [12] 37-72 n/a n/a
(1982) (14)
Baue et al ICU 54.2 [26] n/a 0.85 [0.4] n/a
(1984) (25)
Surks et al ICU 68.2 [24] 13-131 1.25 [0.14] n/a
(1988) (30)
The 95% ranges of T4 concentration defined in this study for
different degrees of illness severity might be of some use
to clinicians. For example, a T4 concentration of 10 nmol/L
in a patient with an APACHE II score > 24 is not unexpected,
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whereas the same concentration in a patient with an APACHE
II score of 16-24 would be subnormal, and the same concen¬
tration in a patient with an APACHE II < 16 would certainly
require further investigation. These ranges might therefore
be of some value in determining which critically ill pa¬
tients have the Sick Euthyroid Syndrome and which if any
might have preexisting thyroid disease.
The prognostic value of T4 levels has been documented pre¬
viously, and will be discussed in Chapter 7. As expected
mortality increases as total T4 concentration falls. How¬
ever, total T4 concentration correlated inversely with
APACHE II scores, and the mortality among patients with very
low concentrations of total T4 was no greater than would be
expected on the basis of severity of illness alone. In other
words, very low total T4 levels do not appear to be detri¬
mental in themselves. The implications of this finding for
thyroid replacement during critical illness will be discus¬
sed in Chapter 8.
The distribution of T3 concentration was as expected. There
was a very high incidence of the low T3 syndrome with 70% of
patients having subnormal T3 concentrations, and nearly 60%
having levels below assay sensitivity. This is in keeping
with the findings of the previous studies (Chapter 5). The
high incidence of low T3 levels meant that it was not
possible to define any distinct ranges of T3 concentration
based on illness severity. For the same reason T3 has less
prognostic value than T4.
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Thyroid Hormones and Metabolic Rate
It is frequently postulated that the "purpose" of the sick
euthyroid syndrome is to limit metabolic rate and protein
catabolism, which are stimulated during illness by the high
concentrations of Cortisol and catecholamines (Wartofsky and
Burman, 1982; Chopra et al, 1983; Wehmann et al, 1985). This
teleological argument is based on the similar changes in
thyroid hormone metabolism which occur during starvation.
There is, however, very little published work concerning the
relationship between thyroid function and metabolic rate
during illness.
Critically ill ventilated patients have an increased energy
expenditure which is usually about 30 - 40 % in excess of
the estimated basal metabolic rate (Carlsson et al, 1984;
Lanschott et al, 1987; Soop et al, 1989). The findings of
this study are in agreement with this, the majority of
patients studied having an EMR of between 20 and 50%.
Estimation of metabolic rate using only carbon dioxide pro¬
duction and assuming a specific value for the respiratory
quotient [RQ] is not ideal. Measurement of both carbon
dioxide production and oxygen utilisation and the use of
either a metabolic computer or the Weir equation to derive
metabolic rate is more accurate (Forsberg et al, 1991;
Kemper et al, 1992). However, there appears to be remarkably
little variation in RQ during severe illness (Forsberg et
al, 1991), and assuming an RQ of 0.8, although introducing a
small error, is unlikely to lead to any bias towards or away
from a relationship between thyroid status and metabolic
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rate. The high reproducibility of the measurement of carbon
dioxide production is encouraging, and the very similar EMR
results to previous studies suggest that the method used was
adequate. Indeed, variability in the conditions of measure¬
ment are likely to be more of a problem. Minor intensive
care activities, such as passive physiotherapy increase
metabolic rate significantly (Weissman et al, 1984). In this
study, carbon dioxide production was measured under strict
pre-specified conditions.
The correlation between EMR and body temperature is expec¬
ted. In normal subjects, energy expenditure increases by 10
13% for each 1°C increase in body temperature. There was
no correlation between T4 and temperature, suggesting that
the relationship between EMR and T4 was not confounded by
temperature. Confounding by a consistent effect of thyroid
hormone concentration on RQ, and hence, a consistent bias in
the estimation of metabolic rate is also unlikely. Confound¬
ing by sedative or inotropic drugs is possible. Sedation
reduces metabolic rate (Robertson et al, 1984; Swinamer et
al, 1988) and might lead to a bias. However, the ICU has a
standard sedation policy, and there is unlikely to have been
sufficient variation in sedative dosage to introduce signif¬
icant bias. High doses of inotropes are likely to increase
energy expenditure, and tend to be used in more severely ill
patients. A confounding effect of inotropes cannot be exclu¬
ded .
The inverse correlation between total T4 concentration and
EMR argues against any clinically significant hypothyroidism
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in patients with low total thyroid hormone levels. It would
be consistent with the hypothesis that the changes in thyr¬
oid function during severe illness are, at least in part, a
response to excessive metabolic rate. However, as T4 and EMR
both correlate with severity of illness, as measured by
APACHE II scores, the association between T4 and EMR may be
confounded by other factors also related to illness sever¬
ity. Moreover, the lack of any information about free thyr¬
oid hormone levels makes interpretation of the changes in
metabolic rate in relation to the Sick Euthyroid Syndrome
difficult.
(6) Conclusions
The aims of this section of the thesis were limited. The
guestion of whether or not some severely ill patients may be
biochemically hypothyroid was not addressed. Despite the
lack of measurements of free thyroid hormone, a number of
interesting findings have emerged. The main conclusions are
as follows:
1) In patients without known preexisting thyroid disease,
not receiving treatment with dopamine or steroids, the range
of TSH concentrations found during illness is broader than
in health. In approximately 15% of patients, TSH concentra¬
tions are subnormal, and in a third of these the TSH concen¬
tration is less than 0.1 mU/L. In approximately 13% of pa¬
tients, TSH concentrations are raised during illness, de-
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spite relatively normal total T4 levels. In the majority of
cases, TSH concentrations return to normal on recovery.
There is a strong inverse correlation between TSH concentra¬
tion and severity of illness, with different normal ranges
at different levels of illness. There is also a strong
inverse correlation between TSH concentration and plasma
Cortisol concentration.
2) The TSH response to a TRH test is reduced or absent
during critical illness. The response correlates positively
with T4 concentration and inversely with APACHE II score and
plasma Cortisol concentration.
3) There is a positive correlation between the concentra¬
tion of TSH and total thyroxine. Patients with low concen¬
trations of both hormones have a subnormal or absent TSH
response to TRH and an increased thyroid hormone response to
TSH. These findings suggest that pituitary function may be
impaired or suppressed during critical illness whereas the
thyroid gland appears to function well. Low TSH concentra¬
tions may contribute to the changes of the Sick Euthyroid
Syndrome.
4) Metabolic rate is increased in the majority of critical¬
ly ill patients. There is an inverse correlation between
metabolic rate and total thyroxine concentration.
5) Mortality increases as total T4 levels fall. However,
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patients with low total T4 concentrations do not have a
higher mortality than would be expected on the basis of
their severity of illness. Taken together with the inverse
correlation between total T4 concentration and metabolic
rate, this casts doubt on the suggestion that critically ill
patients with low total thyroid hormone concentrations might
benefit from hormone replacement.
Directions for Future Research
There are a number of guestions which would be interesting
to answer. More detailed investigation of pituitary function
during illness would be worthwhile. Are the low concentra¬
tions of TSH and impaired responsiveness to TRH due to the
effects of cytokines on thyrotropic cells or due to raised
concentrations of free thyroxine? Concentrations of FSH and
LH are reduced during severe illness. Is there evidence of
more widespread pituitary suppression or impairment? What
is the TSH and thyroid hormone response to treatment with
the monocloncal anti-cytokine antibodies now used in clini¬
cal practice? Given the frequency of widespread organ
failure during critical illness, is there any pathological
evidence of damage to the pituitary gland?
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Chapter 7
Prognostic Value of Thyrotropin, Thyroid Hormones








There have been many pleas for rationalisation of the use of
intensive care, which is expensive and can unnecessarily
prolong the process of dying. Provision of intensive care
accounts for between 10 and 20% of hospital expenditure
(Birnbaum, 1986), and survival is inversely related to cost
of treatment and length of stay (Detsky et al, 1981). At
least 15% of ICU patients are admitted with underlying
conditions from which there is no likelihood of survival,
and die on the ICU, or a short time after discharge (Knaus
et al, 1984). Most clinicians recognise the problem, yet are
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reluctant to make the decision to withhold or withdraw
intensive care from those to ill to benefit (Singer et al,
1983; Editorial, Lancet, 1985). Prognostic uncertainty-
appears to be an important factor in determining the expen¬
diture of resources in the ICU (Detsky et al, 1981). Al¬
though it is recommended that predictions of a patients
prognosis influence triage decisions (CDC, 1983), physicians
predictions of outcome are frequently wrong (Kruse et al,
1988; Brannen et al, 1989). Different physicians caring for
the same patient often disagree about the likelihood that
the patient will survive (Poses et al, 1989), and often take
a more optimistic view of the survival chances of patients
under their own care than similar patients cared for by
other clinicians (Poses et al, 1991). The accurate predic¬
tion of patient outcome has become a major objective of
intensive care clinicians, and several prognostic scores
based on estimates of illness severity have been developed
(Knaus et al, 1985; Le Gall et al, 1984; Chang, 1989).
The most widely used prognostic system is the APACHE II
system. When first developed the APACHE score contained 33
variables, each measuring physiological derangement. The
APACHE II score was subsequently developed, based on 12 of
the original 33 variables. Other similar scores in wide¬
spread use include the Mortality Prediction Model (Limeshow
et al, 1987; Teres et al, 1987) and the Simplified Acute
Physiology Score (Le Gall et al, 1984). Each of these models
measure the deviation from normal of selected physiological
parameters and equate loss of homeostasis with severity of
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illness. However, prognosis is not always strongly correla¬
ted with physiological derangement. Diabetic ketoacidosis is
associated with gross physiological abnormalities, but with
correct treatment has a mortality of less than 5% (Wagner et
al, 1986). There is a wide variation, 7 - 56%, in the
observed death rates of patients with failure of 3 or more
organ systems, suggesting that a number of factors may be
important in determining outcome.
Prognosis is dependent on at least 4 factors, in addition to
illness severity: (1) disease type, (2) age, (3) prior
health status, and (4) the therapy available. Each of these
must be considered in the step between measurement of ill¬
ness severity and predicting outcome. The APACHE system and
the other commonly used scores take each of these factors
into account. Many other prognostic systems have been deve¬
loped in recent years, including scores based on the number
of organ systems failing (Fagon et al, 1993), electrolyte
imbalance (Broner et al, 1990) and gastric pH (Doglio et al,
1991). However, despite much refinement, no score has proved
accurate enough to influence clinical decision making in
individual patients (Schaffer et al, 1993). At the present
time prognostic scores are used to compare groups of ICU pa¬
tients, either in research or audit, although, even their
validity in this role has been questioned (Boyd and Grounds,
1993)
Although, prognostic scores do not predict individual out¬
come accurately, there is evidence that routine use of a
prognostic system does influence the "intensity" of manage-
195
merit (Murray et al, 1993). Physicians are being encouraged
to continue to study measures of illness severity and to
develop new prognostic systems (Knaus, 1993). Alternative
approaches to the measurement of severity of illness are
needed. One possibility is the endocrine response to the
physiological stress of critical illness. Certain individual
endocrine parameters have been shown to predict outcome in
critical illness (Slag et al, 1981; Schein et al, 1990; Span
et al, 1992), but there has been no attempt to develop a
prognostic index using a number of different endocrine
parameters measured at a uniform time in a large number of
intensive care patients.
(2) Aims
The aim of this study was to determine the prognostic value
of an index combining thyroid hormones, TSH and Cortisol, in
patients not receiving hormone replacement or drugs which
alter endocrine function.
(3) Patients and Methods
The 260 patients investigated were described in Chapter 2.
Briefly, they formed 90% of all ICU admissions over a 2 year
period. Of the 29 patients excluded, 21 were receiving
dopamine on admission, which alters thyroid and pituitary
function, 5 were on longterm steroid therapy, and 3 were
receiving T4 replacement. The average age of patients stu-
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died was 59.6 years [range 14-86] and there was a slight
excess of males, 137 vs 123 females.
All patients were investigated on admission to the ICU.
Blood was taken within 1 hour of admission, prior to treat¬
ment with dopamine, and stored at 4°C. A plasma sample was
obtained for Cortisol assay, and serum samples were taken
for measurement of T4, T3 and TSH. All samples were trans¬
ferred to the clinical chemistry laboratory within 24 hours.
APACHE II scores were calculated using data gathered during
the first 24 hours of admission. Outcome was measured at
hospital discharge.
Cox's multiple logistic regression analysis was performed to
define and weight the variables which were independently
predictive of outcome. Statistical analysis was performed
using a commercial software package (SPSS/PC+, version 3.0,
SPSS, Chicago, USA).
(4) Results
Overall mortality was 31%, and median duration between ICU
admission and death was 10 days (range, 2 hrs - 69 days).
The overall mean (SD) APACHE II score was 19.8 (8.6) with
mean (SD) predicted mortality 38% (19.6%).
The concentrations of each of the hormones measured and
APACHE II scores differed significantly between survivors
and nonsurvivors (Table 7.1). A multiple logistic regression
analysis showed that of the hormones measured only Cortisol,
T4 and TSH were independent predictors of outcome. The
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logistic model based on SI units was P = 1/[1 + exp(0.174
TSH + 0.044 T4 - 0.0015 Cortisol - 0.51). In standard Ameri¬
can units: P = 1/[1 + exp(0.174 TSH + 0.568 T4 - 0.042
Cortisol - 0.51)], where P is the probability of death. The
predictive power of this Endocrine Index, measured by the
area under the receiver operating curve [ROC], was 0.94 (95%
CI = 0.91 - 0.96). The area under the APACHE II score ROC
was 0.85 (95% CI = 0.81 - 0.89) indicating significantly
lower predictive power (Figure 7.1).
At the 0.5 cut off point of the ROC both scores predict
outcome with the greatest accuracy (Table 7.2). The Endo¬
crine Index predicted outcome with 82% accuracy compared to
72% accuracy using APACHE II scores.
Table 7.1. Age, TSH, T4, T3, and Cortisol concentrations, and APACHE
II score with outcome predicted percentage mortality in survivors
and nonsurvivors. Median and range unless stated otherwise.
SURVIVORS NONSURVIVORS
Number 172 88
Age [yrs]* 58.1 [15] 61.3 [13]
Thyrotropin; mU/L 2.2 [0.1-21] 0.7 [0.1-8.4] #
Thyroxine; mcg/dL 6.1 [<0.8-14] 2.9 [<0.8-10] #
Triiodothyronine; ng/dL 32 [<10-169] 13 [<10-91] #
Cortisol; mcg/dL 27 [5.6-89] 47 [7-134] #
APACHE II score* 17 [7] 26 [7] +
APACHE II outcome* 26 [14] 60 [19] +
* = mean [SDJ. # = p < 0.001 (Wilcoxon's Rank Sum test).
+ = p < 0.001 (Student's t-test).
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Table 7.2. Prediction of outcome at the 0.5 cut off point on the receiv¬
er operating curve for the Endocrine Index and APACHE II scores.
OUTCOME PREDICTION
ENDOCRINE INDEX APACHE II SCORE
DIE SURVIVE DIE SURVIVE TOTAL
OUTCOME
DIED 59 29 35 53 88
SURVIVED 19 153 20 152 172




+ve PREDICTIVE VALUE: 76% 63%
-ve PREDICTIVE VALUE: 84% 74%
Tables 7.3 and 7.4 detail the prediction of death by both
scores at the upper and lower 4 cut off points of the ROC.
The Endocrine Index has the greater accuracy than the APACHE
II score at all points on the ROC. It predicts survival with
greater than 90% specificity in 125 patients (73% of survi¬
vors), and predicts death with greater than 95% specificity
in 55 patients (63% of deaths). Both scores predicted survi¬
val with greater sensitivity than they predicted death.
An outcome prediction equation produced by multiple regres¬
sion analysis performed using both the APACHE II score and
the endocrine parameters did not predict outcome more accur¬
ately than the Endocrine Index alone (area under ROC
0.94). Of the 48 incorrect outcome predictions by the Endo-
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crine Index at the 0.5 cut off point, 41 were also predicted
incorrectly by the APACHE II score at that cut off point
(85% concurrence). Similarly of 29 patients predicted to
survive by the Endocrine Index who subsequently died, 27
were predicted to survive by APACHE II scores (93% concur¬
rence ) .
Table 7.3. Prediction of death by the Endocrine Index and APACHE II
scores at the lower four points of the receiver operating curve.
CUT-OFF OUTCOME OUTCOME PREDICTION
ENDOCRINE INDEX APACHE II SCORE
DIE SURVIVE DIE SURVIVE
0.1 DIED 17 71 0 88
SURVIVED 0 172 0 172
SENSITIVITY = 19% 0%
SPECIFICITY = 100% 100%
ACCURACY = 73% 66%
£NO DIED 33 55 6 82
SURVIVED 4 168 3 169
SENSITIVITY = 38% 7%
SPECIFICITY = 98% 98%
ACCURACY = 77% 67%
0.3 DIED 47 41 11 77
SURVIVED 8 164 5 167
SENSITIVITY = 53% 13%
SPECIFICITY = 95% 97%
ACCURACY = 81% 68%
0.4 DIED 54 34 19 69
SURVIVED 12 160 10 162
SENSITIVITY = 61% 22%
SPECIFICITY = 93% 94%
ACCURACY = 82% 70%
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Table 7.4. Prediction of survival by the Endocrine Index and APACHE
II scores at the top four points of the receiver operating curve.
CUT-OFF OUTCOME OUTCOME PREDICTION
ENDOCRINE INDEX APACHE II SCORE







0.6 SURVIVED 142 30 142 30




0.7 SURVIVED 134 38 113 59




0.8 SURVIVED 117 55 69 103




0.9 SURVIVED 88 84 5 167











FIG7.1.PREDICTIVEPOWERSOFTHENDOCRINEIN EXAAPACHEI SCORESASMEASU EDBYAREAUNDTHROCCU VE SENSITIVITY(TRUEPOSIT ES) 1-SPECIFICITY(FALSEPOSIT V S)
(6) Discussion
The changes in thyroid and adrenocortical function which
accompany critical illness have been detailed in earlier
chapters. Low concentrations of TSH and total T4, and high
concentrations of Cortisol have been shown to indicate a
poor prognosis. The value of a combined endocrine prognostic
index has not previously been fully assessed. The results of
this study demonstrate that the response of thyroid and
adrenal function to critical illness is of significantly
greater prognostic value than APACHE II scores.
None of the prognostic scores devised for use in ICU pa¬
tients have proved accurate enough to influence clinical
decision making in individual cases (Schaffer et al, 1993).
The reason for this is that the predictions lack specifi¬
city. Patients predicted to die, often survive, and patients
predicted to survive, often die. The scores do not therefore
help ICU clinicians allocate resources to patients most
likely to benefit. At least in terms of specificity of
prediction, the Endocrine Index is an improvement on some
previously published scores [3-5]. The index predicted death
with 100% specificity in 17 (20%) nonsurvivors, and 98%
specificity in 37 (42%) nonsurvivors. It predicted survival
with 98% specificity in 90 (52%) survivors. This is far from
perfect, but the high specificity of prediction in signif¬
icant numbers of patients is encouraging. Outcome prediction
using APACHE II scores achieved high specificity in very few
patients.
It is interesting that combining APACHE II scores with the
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endocrine parameters did not improve outcome prediction. The
high concurrence of incorrect predictions is unexpected with
two scores based on such different data. It is also notewor¬
thy that both the Endocrine Index and APACHE II scores
predicted survival with greater sensitivity than they pre¬
dicted death. The accuracy of both scores was limited by the
same unexpected deaths. This apparent flaw in the predictive
power of physiological scoring systems reguires further
consideration.
Survival depends on the maintenance of homeostasis. By
measuring loss of homeostasis, physiological scoring systems
predict survival with a high sensitivity. Prediction of
death is less sensitive. This is probably because causes of
death in ICU patients, such as myocardial infarction, pulmo¬
nary embolus, gastrointestinal haemorrhage etc, although
induced by illness, may not be closely related to illness
severity. These "unexpected" deaths in patients with relat¬
ively well maintained homeostasis will impair the sensitiv¬
ity of prediction of death by physiological scoring systems.
This ability of physiological scores to highlight "unexpec¬
ted" deaths might be helpful in directing audit. The death
of a patient who was predicted to survive by two independent
physiological scoring systems deserves detailed audit. Such
patients will not have had severe multi-organ failure and
their deaths should be regarded as having been potentially
preventable.
The Endocrine Index reguires validation on other cohorts of
ICU patients. In its present form it predicted outcome with
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98% specificity in about half of the patients. Further work
is required to discover whether addition of other endocrine
parameters to the index will improve prediction of outcome.
However, any prognostic index based on measurement of ill¬
ness severity will have limited accuracy because of the
frequency of deaths in patients who do not have severe
impairment of homeostasis. Using physiological scoring
systems to direct audit might reveal preventable causes of




Implications of the Results of these Studies For Clinical
Trials of Hormone Replacement During Critical Illness
(1) Absolute Risk and Sample Size in Clinical Trials
(2) Implications for Trials of Steroid Replacement
(3) Implications for Trials of Thyroid Hormone Replacement
The randomised controlled clinical trial is the accepted
methodology for the determination of the efficacy of medical
treatments. Before a treatment can be tested in a clinical
trial, there must be some evidence that the treatment has
potential for benefit. Much of this thesis has been con¬
cerned with the question of whether or not there is an
association between low hormone concentrations or a poor
response to stimulation tests and mortality. Given the
difficulties with interpretation of total circulating hor¬
mone concentrations during illness, any association with
mortality must be viewed with caution and is not evidence
of tissue insufficiency of these hormones. However, the
findings in this thesis do have some useful implications for
future clinical trials of hormone replacement in critical
illness.
Large clinical trials with considerable statistical power
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are often required in order to convince clinicians of the
presence or absence of a treatment effect and to change
clinical practice. Such trials are expensive, time consuming
and rely heavily on the good will of participating patients
and clinicians. In order to maximise the power and limit the
size of initial trials, it is necessary to perform them in
patients who appear most likely to benefit from the treat¬
ment. The relevance of the findings of the studies in this
thesis to the determination of entry criteria and size of
initial trials of hormone replacement during critical ill¬
ness are discussed below. Firstly, a number of general
principals are discussed.
(1) Absolute Risk and Sample Size in Clinical Trials
The number of patients required to test the null hypothesis
in a clinical trial depends to some extent on the relative
treatment effect. However, the absolute untreated risk of
the trial outcome in the patients studied is of equal impor¬
tance. The trials in Table 8.1 illustrate the fact that a
significant result in a clincal trial is more dependent on
the number of outcomes in the trial than the number of
patients. In other words, the statistical power of a trial,
for a given relative treatment effect, is determined mainly
by the absolute untreated risk rather than the trial size.
Thus, in Table 8.1, the significance of the smaller treat¬
ment effects in the higher risk patients is greater than the
larger treatment effects in the lower risk patients. For
example, a 15% treatment effect is significant in a trial
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with 500 patients per group with an untreated risk of death
of 50%, whereas a 20% treatment effect is non-significant in
a trial with 1000 patients per group with an untreated risk
of death of 10%.
Table 8. 1. The significance at the 95% level of confidence of various
clinical trials of treatments with different treatment effects on
patients with different absolute risks of death without treatment.
GROUP SIZE ABSOLUTE RISK RELATIVE RISK ODDS REDUCTION
(N) OF DEATH REDUCTION (95% CI)
100 10% 50% 0.47 (0.16-1.44)
100 50% 25% 0.59 (0.33-1.03)
500 10% 30% 0.68 (0.43-1.06)
500 50% 15% 0.74 (0.57-0.94)
1000 10% 20% 0.78 (0 .58-1.06)
1000 50% 10% 0.82 (0.69-0.98)
(2) Implications for Trials of Steroid Replacement
The finding that for a given level of illness severity, low
total plasma Cortisol concentrations are associated with an
increased mortality is important from the point of view of
clinical trials. Firstly, although neither the tissue avail¬
ability nor the tissue requirement for Cortisol during ill¬
ness is known, the greater than expected mortality might
possibly be due to the low concentrations of Cortisol.
Secondly, a trial of Cortisol replacement in patients with
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low Cortisol concentrations and a greater than expected
mortality will be attractive to participating clinicians.
Thirdly, the high absolute risk of death without treatment
means that a trial could be relatively small and yet still
have the power to exclude a moderate treatment effect.
If trial eligibility was confined to patients with an admis¬
sion plasma Cortisol concentration below the normal range
defined in this thesis for patients with APACHE II scores of
<16 and 16-24, and below 500 nmol/L in patients with APACHE
II scores >24, how many patients would have to be studied to
detect a 20% reduction in mortality? Of the patients stu¬
died in this thesis, 17 (7%) would be eligible. The mortal¬
ity amongst these patients was 77% (95% CI, 50-93). Assuming
the lower limit of mortality of 50%, a trial with 200 trea¬
ted cases and 200 controls would be reguired in order to
detect a 20% reduction in mortality with treatment [Treat¬
ment group: 80 deaths/200 vs Control group: 100 deaths/200.
Odds ratio = 0.67, 95% CI = 0.45 - 0.99 ] . If the mortality
among these patients was 77%, then the number reguired would
be reduced to 80 patients in each group [Treatment group: 50
deaths/80 vs Control group: 62 deaths/80. Odds ratio = 0.48,
95% CI = 0.24 - 0.97].
If the findings of this thesis were ignored and all ICU
patients were studied, a much larger trial would be neces¬
sary in order to detect a 20% reduction in mortality. Over¬
all mortality among the 260 patients in this study was 34%
(95% CI = 28 - 40). If we assume a mortality of 34%, then a
study with 500 patients in each group would be reguired to
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detect a 20% reduction in mortality at the 95% level of
confidence [Treatment group: 136 deaths/500 vs Control
group: 170 deaths/500. Odds ratio = 0.73, 95% CI = 0.55
0.95]. However, the overall benefit of steroid replacement
in all patients might well be less than in patients with low
Cortisol levels and a high mortality. If all patients were
treated, a trial with 2000 patients in each group would be
required in order to detect a 10% reduction in an untreated
mortality of 34%.
The above calculations illustrate the effect of the type of
patients studied on the sample size required. The disadvant¬
age of selecting the small proportion of high risk cases is
that they are few in number and acrual would therefore be
slow. For example, assuming 100% patient cooporation, a
trial with 80 high risk patients in each group would take 20
years to complete in the ICU in which this study was per¬
formed. However, a study of low risk patients with 2000
patients in each group would take 25 years to complete. Both
studies would, of course, need to be multi-centre. Acrual
into the high risk study would be increased by allowing
serial measurement of plasma Cortisol rather than a single
admission measurement, with entry into the trial when plasma
Cortisol fell below the above limits.
Patients with a plasma Cortisol response to a standard ACTH
stimulation test of less than 250 nmol/L also had a higher
than expected mortality in this study. The mortality among
the 25 patients with a Cortisol response of less than 250
nmol/L was 76% (95% CI = 55 - 91). In the 13 of these pa-
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tients who were suffering from septic shock, mortality was
100% (95% CI = 75 - 100). This may indicate minor adrenocor¬
tical impairment due to widespread organ failure. The high
mortality reflecting the widespread organ failure rather
than any insufficiency of Cortisol. However, as is illustra¬
ted above, because of the high mortality, clinically impor¬
tant insufficiency could be excluded by a trial of relative¬
ly small numbers of patients.
(3) Implications for Trials of Thyroid Hormone Replacement
Low concentrations of total thyroid hormones were not inde¬
pendently associated with a greater than expected mortality
when severity of illness was taken into account. This sug¬
gests that low total thyroid hormone concentrations do not
directly increase mortality. Moreover, those patients with
the lowest total thyroid hormone levels had the highest
metabolic rates. Total thyroid hormone levels give no infor¬
mation about tissue availability of thyroid hormone during
severe illness. However, these results do not support the
hypothesis that critically ill patients would benefit from
thyroid hormone replacement.
The two published controlled trials of thyroid hormone
replacement during critical illness in man involved 19
treated patients and 19 controls (Hesch et al, 1981; Brent
et al, 1986). There were 12 deaths in each group (relative
risk = 1.00, 95% CI = 0.62 - 1.63). The combined result of
these trials is consistent with a treatment effect somewhere
between a 40% improvment in survival and a 60% increase in
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mortality. From the point of view of further clincal trials
of thyroid hormone replacement during critical illness, the
results of this thesis provide no evidence that any particu¬
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Appendix
A Protocol for the Investigation of Adrenocortical
Function on an Intensive Care Unit
(1) Aims
(2) Methods
(a) Venepuncture and central line insertion.









The methodological problems of research involving critically ill pa¬
tients were discussed in Chapter 1. Interpretation of results is hin¬
dered by numerous confounding variables related to monitoring and treat¬
ment. The aim of this section of the thesis was to determine which of
the common ICU interventions alter plasma Cortisol levels. The purpose
being to develop a protocol for the performance of dynamic tests of
adrenocortical function in an ICU environment.
(2) Methods
(a) Venepuncture and Central Line Insertion
Ten patients were studied in order to determine whether peripheral
venepuncture alters plasma Cortisol concentration. A blood sample was
taken via a central venous line, and a 20 French Gauge cannula then
inserted into an antecubital fossa vein and a further sample taken
immediately following insertion of the cannula. Five patients were
sedated and ventilated and 5 were conscious, unsedated and self-venti-
255
lating.
Twelve patients were studied in order to determine whether the insertion
of a central venous line altered plasma Cortisol concentration. A triple
lumen central line was used in each case. All lines were inserted using
the Seldinger technique and a subclavicular approach after infiltration
of skin and underlying muscle with 5mls of 2% lignocaine. Samples were
taken by peripheral venepuncture immediately before the line was inser¬
ted and at 30 and 60 minutes after the procedure commenced. Seven pa¬
tients were sedated with intravenous propofol or midazolam and ventila¬
ted, and the remaining 5 were conscious, unsedated and self-ventilating.
(b) Intravenous Fluids and Blood Transfusion
Twenty four patients were investigated in order to determine the effects
of intravenous fluid administration and blood transfusion on plasma
Cortisol concentration. All intravenous fluids were stopped for 2 hours
prior to the study. A baseline blood sample was taken for plasma Corti¬
sol measurement and the specified intravenous fluid was given at a
uniform rate over 2 hours. Six patients were given 500 ml of 0.9% sal¬
ine, 6 were given 100 ml of 20% albumin, 6 were given 400 ml of whole
blood, and the remaining 6 were given 500 ml of full strength total
parenteral nutrition (1000 Kcal/1, 80% lipid). Six patients receiving
intravenous saline at a rate of 62.5 ml/hour were used as controls. In
the control patients fluids were not stopped prior to the study. All
infusions were started at lOOOh and were given via central venous lines
or antecubital fossa cannulae. Further plasma Cortisol measurements were
made 1, 2 and 4 hours after starting the infusion. No potentially
stressful procedures such as haemodialysis, physiotherapy or insertion
of arterial or venous lines were performed during this period. Relatives
of the patients were able to visit during the period and nurses were
able to perform all procedures felt to be necessary, including orophar¬
yngeal and tracheobronchial suction.
(c) Enteral Fluids
Twelve patients receiving enteral feeding were investigated. All pa¬
tients were fed via a fine bore nasogastric tube. Feeding was stopped at
midnight on the evening prior to the study. A baseline blood sample for
plasma Cortisol estimation was taken at 9 am. Fluid was then given via
the nasogastric tube. Six patients were given 500 ml of full strength
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enteral feed over 2 hours, and 6 were given 500 ml of water over the
same period. Further plasma Cortisol measurements were made 1, 2 and 4
hours after starting the infusion. The same restrictions on stressful
procedures as for the study of IV fluids were adopted for the 4 hours of
the study.
(d) Physiotherapy
Eight patients were investigated to determine the effect of chest phy¬
siotherapy on plasma Cortisol levels. Blood was taken for a baseline
Cortisol level immediately prior to physiotherapy. Each patient under¬
went the physiotherapy regimen which was clinically indicated at the
time. This included chest physiotherapy in all cases, and required
tracheobronchial suction in the ventilated patients. All patients were
investigated between 0900h and 1200h. Five patients were ventilated and
sedated and the remaining 3 were conscious, self ventilating and unseda-
ted. Physiotherapy lasted between 10 and 30 minutes. Further blood
samples were taken 30 minutes and 1 hour after physiotherapy was com¬
menced.
(e) Haemodialysis
Eight patients suffering from acute renal failure secondary to septic
shock were investigated. Blood was taken for Cortisol measurement
immediately prior to beginning dialysis and 30 minutes, 1 hour, 2 hours
and 4 hours after commencement of dialysis. In all cases dialysis was
performed using an automated haemodialysis machine and a right subcla¬
vian vein double lumen dialysis catheter. A bolus intravenous injection
of heparin 5000 units was given to all patients prior to dialysis. The
flow rates of blood to the dialysis machine varied between 100 and 500
ml/min. Dialysis sessions began between 0900h and llOOh. Patients were
used as their own controls, the protocol being repeated at the same time
the following day without dialysis. Blood pressure was recorded during
the dialysis and the control periods using measurements from a transdu¬
cer in either a radial or dorsalis pedis artery. No potentially stress¬
ful events, such as physiotherapy or the insertion of arterial or venous
lines, were allowed during the study period.
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(3) Results
Venepuncture and Central Line Insertion
The mean APACHE II score of the patients undergoing venepuncture was
16.8 (range 11 - 26). There was no significant difference between the
plasma Cortisol concentrations before and after insertion of a cannula
into an antecubital fossa vein in the 10 cases investigated. Mean [SD]
plasma Cortisol concentration from central line sampling was 873 [286]
nmol/L compared to 889 [301] nmol/L after insertion of the cannula.
The mean APACHE II score of the 12 patients undergoing central line
insertion was 17.4 (range 15-24). In 2 cases a single Cortisol measure¬
ment was unavailable. Central line insertion was associated with an
increase in plasma Cortisol concentration in 11 of the 12 patients
investigated [Fig Al, Table Al].
Table Al. Mean [SD] plasma Cortisol concentration following
central line insertion.
PLASMA CORTISOL CONCENTRATION [nmol/L].
TIME [mins] 0 30 60
SEDATED [N=7] 998 [211] 1071 [212] 1042 [201]
UNSEDATED [N=5] 823 [296] 906 [279] 1051 [284]
TOTAL [N=12] 911 [271] 989 [261] 1047 [246]
The overall increase in plasma Cortisol concentration between the basal
and 60 minute samples in sedated and unsedated patients combined was
significant [mean difference (MD) = 133 nmol/L, 95% CI = 19 - 247]. The
increase in plasma Cortisol concentration between the basal and 60
minute samples reached significance in unsedated patients [MD = 228
mol/L, 95% CI = 80 - 400]. In sedated patients the maximum mean plasma
Cortisol concentration was seen at 30 minutes, but the increase from
basal concentration was not significant [MD = 68 nmol/L, 90% CI = -12
145] .
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Intravenous Fluids and Blood Transfusion
The mean APACHE II score of the 24 patients studied was 21.2 (range 9
34). All Cortisol measurements were available. Plasma Cortisol concen¬
tration was not significantly altered during the intravenous saline
infusion [Fig A2, Table A2] . In 5 of the 6 cases investigated, plasma
Cortisol concentration fell following the saline infusion. The fall in
Cortisol concentration between 2 and 4 hours reached statistical signif¬
icance [MD = 210 nmol/L, 99% CI = 7 - 413]. The decrease in Cortisol
concentration was significantly greater than in the corresponding period
in control patients [MD = 160 nmol/L, 95% CI = 35 - 286]. There was no
significant change in plasma Cortisol concentration during or after
intravenous albumin infusion [Fig A2, Table A2].
Table A2. Mean [SD] plasma Cortisol concentration following
intravenous infusions of 0.9% saline and 20% albumin.
PLASMA CORTISOL CONCENTRATION [nmol/L]
TIME [hours] 0124
SALINE:
Mean [SD] 1087 [551] 1059 [549] 1128 [643] 918 [541]
ALBUMIN:
Mean [SD] 991 [381] 1023 [400] 1022 [362] 1119 [430]
There was an increase in plasma Cortisol concentration during the first
hour of the intravenous infusion of TPN in all patients studied [Fig A3,
Table A3]. This increase reached statistical significance [MD = 121
nmol/L, 95% CI = 28 - 214]. The Cortisol increase from basal to 1 hour
was significantly greater than the corresponding increase in control
patients [MD = 97 nmol/L, 95% CI = 2 - 193]. Plasma Cortisol levels fell
significantly between 1 and 4 hours after commencing the infusion [MD =
126 nmol/L, 95% CI = 33 - 298]. There was no significant change in
plasma Cortisol concentrations during or after blood transfusion [Fig
A3, Table A3] or in controls [Table A3].
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Table A3. Mean [SD] plasma Cortisol concentration following
infusions of total parenteral nutrition or blood or in controls.
PLASMA CORTISOL CONCENTRATION [nmol/L]
TIME [hours] 0124
TPN:
Mean [SD] 830 [373] 951 [394] 827 [296] 767 [301]
BLOOD:
Mean [SD] 1046 [444] 1008 [388] 1047 [454] 1003 [638]
CONTROLS:
Mean [SD] 975 [366] 999 [355] 986 [388] 938 [349]
Enteral Fluids
The mean APACHE II score of patients investigated was 14.2 (range 9
21). All Cortisol measurements were available. Plasma Cortisol concen¬
trations increased during infusions of full strength enteral feed in 5
of the 6 patients investigated [Figs A4, Table A4]. The increase reached
significance between the basal measurements and both the 1 hour [MD = 92
nmol/L, 95% CI = 3 - 180] and the 2 hour [MD = 154 nmol/L, 99% CI = 69 -
238] measurements. The fall in Cortisol concentration between 2 and 4
hours did not reach significance [MD = 110 nmol/L, 95% CI = -24 - 244].
Plasma Cortisol concentrations fell during and after the infusion of
enteral water in 4 of the 6 patients investigated [Fig A4, Table A4].
Table A4. Mean [SD] plasma Cortisol concentration following
infusion of full strength enteral feed or enteral water.
PLASMA CORTISOL CONCENTRATION [nmol/L]
TIME [hours] 0124
FEED:
MEAN [SD] 766 [281] 858 [225] 919 [302] 796 [250]
WATER:
MEAN [SD] 752 [188] 725 [239] 676 [182] 642 [138]
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Physiotherapy
The mean APACHE II score of patients studied was 17.4 (range 12 - 29). A
single Cortisol measurement was missing in 2 cases. There was a non¬
significant increase in plasma Cortisol concentration in response to
physiotherapy in 6 of the 8 patients studied [Fig A5, Table A5].







MEAN [SD] 1031 [510] 1099 [467] 1012 [494]
Haemodialysis
The mean APACHE II score of patients studied was 21.6 (range 16 - 34).
All Cortisol measurements were available. Mean duration of haemodialysis
was 126 minutes (range 46 - 243 mins). Plasma Cortisol concentration
increased after 30 minutes dialysis in 6 patients and after 1 hour in
all patients [Fig A6]. The difference in mean plasma Cortisol concentra¬
tions was significant at 1, 2 and 4 hours after commencement of dialy¬
sis [MD at 1 hour = 204 nmol/L (99% CI = 35 - 374), MD at 2 hours = 235
nmol/L (95% CI = 37 - 433), MD at 4 hours = 148 nmol/L (95% CI = 30 -
265), Table A6]. There was no change in the concentration of Cortisol in
the control group during the study period [Fig A7, Table A6].
Table A6. Mean [SD] plasma Cortisol concentration before, during and
after haemodialysis.
MEAN/SD PLASMA CORTISOL CONCENTRATION [nmol/L]
TIME [mins] 0 30 60 120 240
CASES 983 [235] 1064 [303] 1188 [318] 1218 [367] 1131 [276]
CONTROLS 1056 [216] 1039 [301] 1048 [298] 1015 [316] 983 [351]
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Mean arterial blood pressure was lower than the basal pressure after 1
hour of dialysis in all patients [Fig A8]. The mean level was signific¬
antly lower than baseline at 30, 60, 90, 120, 150 and 180 minutes after
commencement of dialysis [P < 0.01 at 60 and 90 mins, otherwise P <
0.05, Table A7]. Control measurements of MAP showed no significant
change over the 4 hour period [Fig A9, Table A7 ]. Absolute MAP was
lower in dialysis patients than controls from 30 to 180 minutes after
commencement of dialysis. There was a significant correlation between
the extent of the fall in MAP and the rise in plasma Cortisol concentra¬
tion 60 minutes after commencement of dialysis [r = 0.774, 95% CI
0.153 - 0.957].
Table A7. Mean [SD] mean arterial pressure during and after haemodia-
lysis and during control period.
MEAN ARTERIAL PRESSURE [mm Hg]
TIME [mins] 0 30 60 90 120 150 180 210 240
CASES 99[14] 93[15] 90[13] 92[15] 92[18] 92[16] 94[17] 98[16] 99[15]
CONTROLS 98[13] 97[13] 97[11] 98[11] 96[13] 96[11] 97[10] 97[11] 97[13]
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MISSING DATA IN CASES 3 AND 7.














FIG 4. PLASMA CORTISOL RESPONSE TO INFUSIONS































MISSING DATA IN CASES 2 AND 5.
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FIG 8. MEAN ARTERIAL PRESSURE DURING AND
AFTER HAEMODIALYSIS
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FIG 9. MEAN ARTERIAL PRESSURE DURING
HAEMODIALYSIS CONTROL PERIOD
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(5) Discussion
Venepuncture and Central Line Insertion
It is recommended that all forms of stress be avoided when measuring
plasma Cortisol concentration. Venepuncture is a "stressful" experience
for many patients, and has been shown to increase Cortisol concentra¬
tions for 1 to 2 hours (Van Cauter and Honinckx, 1985). No significant
effect was noted in this study, although only a small number of pa¬
tients were investigated, and blood was sampled within 1 or 2 minutes of
venepuncture. The intention was to investigate whether Cortisol measure¬
ments made following venepuncture would differ from those made at the
same time in the same patient via central venous access. No difference
was demonstrated. Repeated performance of stressful tasks reduces the
associated Cortisol response [Domanski, 1957], and it is possible that,
since the study patients had undergone numerous venepunctures in the
days immediately prior to being studied, the procedure was no longer
stressful. However, it is more likely that by sampling so soon after
venepuncture, a Cortisol stress response was missed. This is not a
problem for single measurements, but might be a source of bias in dyna¬
mic tests of adrenocortical function involving repeated blood sampling
over a period of time.
Central venous line insertion is a longer, more formal, and more painful
procedure than venepuncture, despite the use of local anaesthetic. The
line is secured using sutures, and the procedure takes at least 15
minutes. A consistent and significant rise in plasma Cortisol concentra¬
tion was seen following central line insertion. The response was greater
in unsedated than sedated patients. Sedation with benzodiazepines re¬
duces, but does not abolish, the Cortisol response to emotional and
surgical stress by limiting the ACTH response (Nilsson, 1990). The
Cortisol response to surgical procedures requiring general anaesthesia
is markedly reduced by also giving epidural anaesthesia (Nielsen et al,
1989), suggesting that neural mechanisms are involved in ACTH release
during surgery. Sedation will clearly reduce the conscious stress re¬
sponse, but will not abolish the neurally mediated nociceptive response.
Intravenous Fluids and Blood Transfusion
The majority of intensive care patients require intravenous hydration,
and rapid fluid replacement may sometimes be necessary. It is conceiv¬
able that rapid administration of crystaloids might reduce plasma corti-
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sol concentration for a short period by a process of dilution. Such an
effect might be more pronounced with concentrated albumin solution which
draws fluid into the vascular space. Albumin is also involved in the
protein binding of Cortisol.
Saline administration did not significantly alter plasma Cortisol con¬
centration during the infusion. A non-significant rise in Cortisol
concentration occurred, suggesting that dilution is not a problem at the
infusion rate studied. There was a significant fall in Cortisol concen¬
tration over the 2 hours following the infusion, which also occurred to
a non-significant extent in control cases. The reasons for this are
unclear, and any detailed analysis would require more cases. However,
despite the small number of patients studied, it can be concluded that
at a constant infusion rate of 250 ml/hour intravenous saline does not
significantly alter plasma Cortisol concentration during the infusion.
Infusion of neither albumin nor blood altered plasma Cortisol concen¬
tration. It is possible that by investigating only 6 patients a small
change might have been missed. The effect of blood transfusion might
vary depending upon the individual. In the event of a minor blood trans¬
fusion reaction, it is likely that the Cortisol concentration would
rise.
Nutrition
Infusion of TPN was associated with a significant rise in plasma Corti¬
sol concentration after 1 hour, followed by a fall. The initial rise
occurred in all patients. Eating increases Cortisol secretion (Follenius
et al, 1982), and in healthy patients, peaks in plasma Cortisol concen¬
tration, superimposed on the diurnal rhythm, occur after each meal. The
reasons for this response to food are unclear. There is no published
data on the Cortisol response to intravenous nutrition. This small
investigation suggests that the response is similar to that following
oral food intake. TPN infusions are not continuous, and are stopped for
at least 4 hours each day. It is possible, therefore, that they might
interfere with dynamic tests of adrenocortical function.
A significant proportion of ICU patients receive enteral nutrition. This
is frequently intermittent, and may alter Cortisol secretion. In pa¬
tients given enteral water there was no significant change in plasma
Cortisol secretion. In patients receiving enteral nutrition there was a
significant increase in plasma Cortisol concentration during the infu-
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sion, followed by a fall to pre-infusion levels 2 hours after the infu¬
sion had finished. Whether or not the increase in Cortisol concentra¬
tion is maintained during longer infusions of enteral nutrition was not
investigated.
Physiotherapy
Physiotherapy is carried out at least once daily on all ventilated and
the majority of non-ventilated ICU patients. The procedure requires
oropharyngeal and tracheobroncheal suction. Despite the unpleasant
nature of the procedure, no significant rise in Cortisol concentration
was detected in the patients investigated. The basal Cortisol concentra¬
tions were high, and given there significant intra-assay variation at
such levels, a Cortisol response to physiotherapy of up to 200 nmol/1
could easily have been missed.
Haemodialysis
Acute renal failure occurs in 30% of patients in the ICU. These patients
require regular haemodialysis which may interfere with adrenocortical
function. Previous research on this topic has been performed in other¬
wise healthy patients suffering from chronic renal failure. Dialysis
must remove significant amounts of free Cortisol, but does not remove
Cortisol binding globulin or albumin (Thysell et al, 1979). Concentra¬
tions of ACTH and Cortisol increase during dialysis, falling to normal
after 24 hours (Maher et al, 1965; Grekas et al, 1983). Adrenal respon¬
siveness to ACTH has been reported to be normal (Grekas et al, 1983;
Siamopoulos et al, 1988) and impaired (Mrinak et al, 1981) in chronic
renal failure. There are no published data on patients suffering from
acute renal failure.
Plasma Cortisol concentration increased in all patients studied during
dialysis, and levels remained high at 4 hours after commencement of
dialysis. The reasons for this response are unclear. Since plasma Corti¬
sol had increased within 30 minutes of commencing dialysis, it seems
unlikely that a reduction in urea concentration was responsible. Acute
reduction in blood pressure is associated with increased Cortisol con¬
centration (Grassier et al, 1990). In the patients studied haemodialysis
coincided with a significant fall in MAP. Blood pressure returned to
pre-dialysis levels after completion of dialysis. The hypotensive re¬
sponse to haemodialysis is well recognised in ICU patients, and often
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limits the rate of blood flow into the dialysis machine, and hence, the
length of dialysis. The extent of the fall in MAP correlated with the
increase in Cortisol concentration. This dose response effect suggests
that the hypotension may cause the Cortisol response.
(6) A Protocol for the Investigation of Adrenocortical Function During
Critical Illness
The results discussed above are based on investigation of small numbers
of patients in whom Cortisol concentrations were raised to a level where
there is considerable intra-assay variability. For the interventions
which did not appear to alter plasma Cortisol concentrations, a minor
Cortisol response cannot be excluded. However, it is likely that those
interventions which led to the greatest alteration in Cortisol concen¬
tration have been correctly identified. It is therefore possible to
define conditions for the investigation of adrenocortical function in
which some of the major confounding influences can be excluded:
1) Minor surgical procedures and the insertion of invasive monitoring
equipment, such as central and arterial lines, should be avoided during
tests of adrenocortical function and for 2 hours prior to the test.
2) Physiotherapy, including tracheobronchial suction, may be performed
before and during investigations.
3) The following intravenous fluid regimen will be permitted during
investigation: a) Saline infusions at rates equal to, or less than,
250ml per hour; b) Infusions of 20% albumin at rates equal to, or less
than, 50 ml per hour; c) Transfusion of cross-matched whole blood at
rates of equal to, or less than, 200ml per hour; d) Infusions of total
parenteral nutrition and enteral nutrition should be stopped 2 hours
prior to investigation and for the duration of the tests.
4) No investigations should be carried out during or in the 2 hours
following haemodialysis, although the timing of investigation need not
be influenced by the blood urea concentration.
It could be argued that most of the above recommendations are common
sense. However, the finding that intravenous fluids, blood and physio¬
therapy may be given during dynamic tests of adrenocortical function
without completely invalidating the results is important. A protocol
which excluded all such interventions would be very difficult to adhere
to in practice in studies of critically ill patients.
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